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ABSTRACT
AKR mice spontaneously develop lymphoid 
leukemia with a very high incidence (approx. 90%). The 
causative agent is a vertically transmitted oncogenic 
RNA virus. The thymuses represent the primary site of 
neoplastic transformation. The pathogenesis of the 
thymic lymphoma is unilateral in nature with malignant 
cells originating in only one of the two thymuses. 
Animals, although infected with the virus before birth, 
do not develop the lymphoma until they are 6-9 months 
of age. A study of cyclic nucleotide metabolism in 
normal, preneoplastic and neoplastic thymuses has been 
undertaken. C576J mice, a low leukemic strain, have 
been used as a parallel control series to obviate 
possible alterations in cyclic nucleotide metabolism 
that are age-dependent and not related to the develop­
ment of the lymphoma. The results show that:
(1) In the preleukemic period, basal adenylate 
cyclase activity and the responsiveness of 
the enzyme to agonist stimulation did not 
significantly change. Cyclic nucleotide 
phosphodiesterase activities, assayed at 
1 yM cyclic AMP and 100 yM cyclic AMP or 
cyclic GMP, increased progressively in the
v
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thymuses of AKR mice as the animals aged.
Enzyme activity assayed at 1 yM cyclic GMP 
did not significantly change. The cyclic AMP 
concentration in thymuses of AKR mice did not 
significantly alter in the preleukemic period.
The concentration of cyclic GMP was higher in 
thymuses of AKR mice >100 days when compared 
to animals <100 days of age. Results are 
presented which suggest that, during the 
preleukemic period, cyclic nucleotide 
metabolism is differentially regulated in the 
two thymuses; and
(2) Results obtained from established thymic 
lymphomas, when compared to AKR mice of a 
similar age not overtly showing tumour devel­
opment, reveal the neoplastic cells to have 
significantly higher basal adenylate cyclase 
activity and enhanced responsiveness to 
stimulation by PGE1, Gpp(NH)p and NaF. Cyclic 
nucleotide phosphodiesterase activities 
assayed at 1 yM cyclic AMP or cyclic GMP were 
significantly decreased in tumours, whilst 
enzyme activity assayed at 100 yM cyclic AMP 
or cyclic GMP was not significantly different.
The concentrations of cyclic AMP and cyclic GMP 
were significantly decreased in thymic lymphomas.
The results are discussed in relation to the 
possible role of cyclic nucleotides in the regulation 
of cellular proliferation. A hypothesis is presented
vii
which suggests that the failure of the thymus epithelium 
to produce a humoral factor which (via cyclic nucleotide- 
dependent mechanisms) modulates intrathymic differentia­
tion of thymocytes gives rise to a population of cells 
whose proliferative activity remains unimpaired but 
whose normal differentiation pathway is blocked. Such a 
cell population may be more susceptible to the oncogenic 
effect of the virus.
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CHAPTER ONE
THYMIC LYMPHOMA IN THE AKR MOUSE -  AN INTRODUCTION
1
21.1 Introduction
Cyclic adenosine 3',51-monophosphate (cyclic AMP) 
and cyclic guanosine 3 5 ' -monophosphate (cyclic GMP) 
function as 'second messengers' for a large number of 
primary stimuli (i.e. systemic and local hormones) in a 
variety of different cell types. They have been implicated 
in the control of many physiological processes, including 
cellular proliferation and differentiation (Whitfield et al 
1973; Berridge, 1975; Chlapowski et al., 1975; Pastan et al 
1975; Rasmussen et al., 1975; Byron, 1976; Coffino et al., 
1976; Whitfield et al., 1976a,b; Rasmussen and Goodman, 
1977; Whitfield et al., 1979; Whitfield, 1980). The 
possibility that cyclic nucleotides regulate proliferative 
activity in normal cells led to the speculation that 
derangements in cyclic nucleotide metabolism could result 
in, or contribute to, the uncontrolled proliferation that 
characterizes the neoplastic condition. Studies of cyclic 
nucleotide metabolism in human and animal tumours and in 
cultured neoplastic cell lines have been extensively 
reviewed (Criss, 1974; Ryan and Heidrick, 1974; Martin 
et al., 1976; Murad, 1976; Hunt and Martin, 1979; Tisdale, 
1979; DeRubertis and Craven, 1980a; Hunt and Martin, 1980) 
and are discussed in Chapter Three of this thesis.
Established tumours are composed of a very
3heterogeneous population of cells. They contain cells at 
various stages of differentiation, in differing phases of 
the cell cycle (Meistrich et al., 1977) and at different 
levels of oxygenation (Grdina et al., 1976). They also 
contain significant numbers of normal cells, these 
representing uninvolved host tissue, cells of the body's 
immune system (e.g. macrophages, lymphocytes, monocytes) 
that may or may not be functionally active in attempting to 
suppress tumour cell growth, and cells contained in the 
increased vasculature that is often induced by tumour cell 
products to supply oxygen and other nutrients to the 
neoplastic cells. Results obtained from functional, 
biochemical or immunological studies on such a diverse 
population of cells can be difficult to interpret. This is 
important in the study of cyclic nucleotide metabolism as 
different cell types can express:
(1) different receptors upon their surface, agonist 
binding to which may or may not affect intracellular 
cyclic nucleotide concentrations (Section 2.2);
(2) different 'basal' adenylate cyclase activities as 
measured in vitro (Section 2.2);
(3) different 'basal' guanylate cyclase activities 
and/or subcellular partitioning between soluble and 
particulate fractions (Section 2.3);
(4) different isoenzyme patterns of the cyclic nucleotide- 
dependent protein kinase enzymes (Section 2.4); and 
different molecular forms of the cyclic nucleotide 
phosphodiesterases and/or of the partitioning between 
soluble and particulate fractions (Section 2.5).
(5)
4Clearly it would be beneficial to separate the 
heterogeneous population of cells into more homogeneous 
subpopulations. Ideally such separation procedures 
(Meistrich et al., 1981) should:
(1) have a high resolution;
(2) preserve cell viability and function without 
perturbation;
(3) yield a high recovery; and
(4) be rapid and able to accommodate large numbers of cells.
The commonly used methods of bulk cell separation 
are based upon two physical properties of cells, namely 
their density and their sedimentation velocity. By their 
very nature it is inconceivable that separation procedures 
can 'function without perturbation'. When considering the 
intracellular concentrations of biochemical metabolites 
that are subject to rapid fluctuations, the usefulness of 
such separation procedures is extremely limited.
Many studies have made use of transplanted tumours 
and/or cultured cell lines. It should be appreciated that 
tumours that have been passaged many times tend to deviate 
progressively from the original tumour in a number of 
aspects (Metcalf, 1975a):
(1) There is often a progressive shortening in the 
doubling time of the tumour cell population, and 
hence in the interval between transplantation and 
death of recipients.
(2) There can be a progressive loss in the capacity of 
the tumour cells to exhibit specialized functions 
and to respond normally to specific regulators,
5e.g. hormones.
(3) There is a progressive failure to exhibit histocompati­
bility antigens on the cell surface, a situation that 
may allow tumour cell growth in non-syngeneic hosts.
(4) Karyotypic abnormalities increase in frequency in 
the tumour cells.
(5) It is possible for subclones of tumour cells to 
emerge which have a proliferative advantage over 
the original tumour cell population.
If experiments using transplanted tumour cells 
are to extend for months or years, and a comparison of the 
behaviour of the tumour cells is required, then it is 
advisable to store samples of the original tumour in 
liquid nitrogen and to re-initiate the passaged tumour at 
frequent intervals. It may be useful also to establish a 
standard response of the system(s) that the investigation 
is centred upon (for example, a dose response curve for 
cyclic nucleotide accumulation stimulated by a specific 
agonist under fixed experimental conditions).
The possible implications of cell culture 
techniques are too numerous to discuss in this introduction. 
As with passaged tumours, the use of cultured cell lines 
has some limitations. Both normal and neoplastic cells can 
change when continually cultured in vitro. They may lose 
specialized functions or adopt abnormal growth patterns 
and populations of variant cells may emerge which are 
either atypical of the original population or may even be 
mutations (Metcalf, 1975b). For these reasons, cells 
maintained in culture for long periods may be less likely
6to supply results valid for the in vivo situation. 
Therefore, primary culture techniques using cells taken 
directly from animals or patients in which observations 
are completed within a number of hours or days, may be 
more relevant to the biological system than tissue 
culture-adapted, continuously passaged cell lines. It 
should be appreciated, however, that cultured cell lines 
have proved to be invaluable as experimental systems, and 
it seems most probable that the aim of elucidating 
biological phenomenon will best be served by the 
complementary utilization of in vitro and in vivo 
techniques.
Acknowledging the advantages and disadvantages 
of the different systems described above (i.e. primary 
tumours, transplantable tumours and continuous cell lines), 
and taking into consideration that the vast majority of 
studies have been performed with established tumours or 
cultured cell lines, an investigation into the metabolism 
of cyclic nucleotides during the development of thymic 
lymphomas in AKR mice has been undertaken. This system has 
some advantages when compared to other animal tumour 
systems. The thymus, the primary site of neoplastic 
transformation, is a comparatively homogeneous organ with 
90% of its weight being made up of lymphocytes (Metcalf, 
1066a) . The tumour is caused by a vertically transmitted 
(i.e. from one generation to the next) oncogenic RNA virus 
Tie mice are infected with the virus before birth but do 
not develop the lymphoma until 6-9 months of age. This 
delay, from the time of infection to the emergence of
7lymphoma cells in the thymus, has been termed the 
'preleukemic period' (Metcalf, 1966a) as there may be 
changes occurring in the thymuses of the animal which 
are significant for the ultimate development of the 
tumour. Therefore, as Metcalf (1966a) notes:
'In AKR mice an almost unique opportunity is 
available for studying the progressive changes 
undergone in a tissue during carcinogenesis.
These mice develop leukemia in 9 out of 10 cases 
and they can be examined in great detail in the 
period before leukemia development with the 
assurance that some facet of the preleukemic 
state is being examined.'
Thus the AKR model allows for studies on a 
relatively homogeneous cell population in both the 
preneoplastic and neoplastic condition. The limitations 
are that there will be cells at various stages of 
differentiation towards mature T-lymphocytes (thymocytes) 
and cells in different phases of the cell cycle. It has 
been shown histologically that there are distinct preleukemic 
changes that occur in the pathogenesis of the tumour. These 
changes (discussed below) influenced the experimental design 
of this investigation and this serves to emphasise that 
biochemical studies upon tumour cells should be correlated, 
where possible, with the pathological development of the 
tumour, especially where such correlations may aid in the 
interpretation of results.
An historical account of the inbreeding that resulted 
in the AKR strain and some of the approaches that have
8made use of these mice to study lymphoma development has 
been presented by Furth (1978). It is interesting to note 
that Furth saw the creation of the strain as ' . . . merely 
a means to get leukemic mice . . . ' and in this respect 
the controlled inbreeding of mice may be thought of as a 
simple form of genetic engineering.
The viral etiology of the lymphoma has been 
extensively reviewed elsewhere (for example, Rich and 
Siegler, 1967; Kaplan, 1974; Gross, 1978).
1.2 Structure of the Thymuses
The thymuses develop as separate, bilaterally- 
paired organs from the embryonic pharynx. In the lower 
vertebrates and birds the paired organs lie on opposite 
sides of the body. In mammals they lie next to each other 
and their medial borders may touch or overlap. The 
anatomical relationship of the two thymuses is shown 
diagramatically in Figure 1.1. The close proximity of the 
two organs led early anatomists to regard them as a single, 
bi-lobed organ. This concept has persisted in the modern- 
day literature but as Siegler (1968) notes:
'If "the thymus" is a single organ consisting of 
two connecting parts like the brain then it should 
be so handled experimentally, and weighed, 
analysed and sectioned for histology as one. If, 
however, one is dealing with two paired organs, 
then experimental design would dictate that the 
two thymuses be separately weighed, sectioned or 
otherwise analysed.'
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FIGURE 1.1
ANATOMICAL RELATIONSHIP OF THE TWO THYMUSES IN MAMMALS 
(After Siegler, 1968).
9It will be shown below that treating the thymuses 
as separate, discrete entities is of the utmost importance 
in experimental leukemogenesis.
Each thymus has an outer, lymphocyte-rich cortex 
and an inner, medullary region. There are no parenchymatous, 
vascular, neural or lymphatic connections between the two 
organs (Siegler, 1968). In mice the thymus becomes lymphoid 
in late foetal life. The lymphoid cell precursors arising 
in the bone marrow 'seed' the thymus via the bloodstream. 
The organs show a rapid increase in size after birth and 
reach a maximum weight at 4-6 weeks of age. After this a 
characteristic weight loss (age-involution) occurs which 
proceeds rapidly for the first few months and then at a 
slower rate for the rest of the animal's life. At most 
ages the ratio of cortical to medullary tissue area is 
9:1, although in old age thymic atrophy tends to affect 
the lymphoid cortex more severely than the medullary 
region. The age-related involution (Figure 1.2) must be 
taken into consideration when planning a developmental 
study that utilizes biochemical assays. In very young 
animals there may be sufficient tissue to accomplish the 
desired experimental procedures within the sensitivity 
limits of the assays employed. However, with older mice, 
where there is a decrease in the amount of tissue 
available, there may be problems in acquiring equivalent 
information.
Cytological studies of the cortical lymphocytes of 
AKR mice (Metcalf, 1966a) reveal that there are three 
types of lymphocytes, this discrimination being made by

FIGURE 1.2
AGE-RELATED THYMIC INVOLUTION IN AKR MICE 
The animal on the left was 38 ± 7 days of age. 
Weight of the combined thymuses was 69 mg.
The animal on the right was 233 ± 7 days of age. 
Weight of combined thymuses was 35 mg.
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size. The large cells (approximately 1%) have a diameter 
of >11 y, the medium cells (approximately 10%) have 
diameters 7-11 yi and the small lymphocytes (approximately 
89%) have diameters <7 y. Using [3H]-thymidine labelling 
it has been established that there is a division sequence, 
with the large cells dividing to form medium cells and 
medium cells dividing to form small cells (Metcalf, 1966a). 
The cortical lymphoid cells exhibit intense mitotic activity, 
while lymphoid cells of the medullary region rarely exhibit 
mitoses. In the two month old AKR thymus the large cells 
divide every 6.8 hours and the medium cells every 8.2 hours 
(Metcalf and Wiadrowski, 1966). Most of the small cells 
appear to be non-dividing, as only 2% incorporate tritiated 
thymidine. The turnover of these small cells within the 
thymus is extremely rapid, with the vast majority being 
replaced every 3-4 days. It is believed that the small 
lymphocytes do not migrate from the thymus but die in situ 
(Metcalf, 1966a).
The thymuses are extremely sensitive to illness 
or stress of any type, exhibiting a rapid decrease in 
weight resulting from the destruction of small lymphocytes. 
These effects are mediated by the lymphocytolytic action of 
the adrenal corticosteroids. Reconstitution by regeneration 
of thymic lymphocytes restores thymic weight to normal. The 
thymuses react synchronously in both phases of this 
destruction-regeneration phenomenon.
It is recognised today that there are important 
functional and antigenic diversities between the lymphocytes 
within, or derived from, the thymuses and those lymphocytes
11
that are not processed by these organs. The thymuses play 
a critical role in the development and maintenance of the 
immune system and are recognised to have important 
endocrine functions. A discussion of these attributes is 
beyond the scope of this introduction. However, one of the 
features that has received much attention is the apparent 
lack of structural modifications in the thymic lymphocyte 
population following antigenic stimulation. Unlike the 
spleen and lymph nodes, germinal centres have been observed 
only exceptionally in the thymuses, as in the case of NZB 
mice developing autoimmune diseases (Burnet and Holmes,
1964) and in AKR mice during the preleukemic period 
(Metcalf, 1966a).
1.3 Pathogenesis of the Thymic Lymphoma
Although physiologically the thymuses function 
synchronously, in leukemogenesis each organ appears to act 
independently with the tumour originally developing in only 
one of the two organs (Figure 1.3). In the development of 
spontaneous tumours in AKR mice morphological changes may 
first be observed between 4-6 months of age (Siegler and 
Rich, 1963; Metcalf, 1966b; Siegler, 1968). One of the two 
organs loses its cortical lymphocytes, shrinks in size and 
takes on a distinct yellow-orange colour. Histologically 
the small thymus shows severe depletion of lymphocytes and 
a 'pulling together' of the epithelial-reticular network.
The opposite thymus at this time shows no change in weight 
or histological appearance. The neoplastic transformation 
occurs in the lymphocyte-depleted thymus, with cells indis­
tinguishable from lymphoma cells appearing within the organ.
PATHOGENESIS OF THE LYMPHOMA
NORMAL
THYMUSES
EARLY
BILATERAL
LYMPHOLYSIS
LATE
UNILATERAL
LYMPHOLYSIS
UNILATERAL
LYMPHOMA
/N -S /T U
UNILATERAL
LYMPHOMA
FIGURE 1.3
PATHOGENESIS OF THYMIC LYMPHOMA
(After Siegler, 1968)
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The distinct changes that occur in the preleukemic 
period have been described by Metcalf (1966a,b) as 
'medullary enlargement with cortical thinning' and 'cortical 
inversion'.1 The cumulative percentage incidence of these 
changes in AKR mice sacrificed at different ages is shown in 
Figure 1.4. It is evident that by six months of age, at which 
time very few of the mice have established thymic lymphomas, 
virtually all animals exhibit either medullary enlargement 
or cortical inversion.
That the thymuses represent the target organs in the 
development of the lymphoma and are the source of the lymphoma 
cells is suggested by the following:
(1) thymectomy ablates lymphoma development, with this 
ablation being overcome by thymic grafts (Metcalf, 
1966a,b); and,
(2) antigenic typing of neoplastic cells shows the 
presence of the T-lymphocyte-specific Thy-1 antigen 
(Della Porta et al., 1979).
The neoplastic cells proliferate and enlarge the 
involved organ. The tumour-bearing thymus is therefore 
initially smaller, then becomes equal in size and finally 
greatly outweighs the uninvolved organ, which can often 
remain free of neoplastic cells until late in the disease.
In the established lymphoma tumour cells spread rapidly to
1'Medullary enlargement with cortical thinning' - The thymus weight 
may be normal or slightly subnormal, but there is an absolute 
increase in the size of the medullary area. The cortex is thinner 
and there is a paucity of small lymphocytes.
'Cortical inversion' - The thymus is extremely atrophic and small 
lymphocytes are virtually absent from the cortex. Division between 
cortex and medullary regions is not distinct.
80
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40
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FIGURE 1.4
CUMULATIVE PERCENTAGE INCIDENCE OF DISTINCT 
MORPHOLOGICAL CHANGES OCCURRING IN THYMUSES OF 
AKR MICE DURING THE PRELEUKEMIC PERIOD 
(After Metcalf, 1966a,b).
Total number of animals used in this study was 
264. The shaded area represents the 'preleukemic1 
period of thymic lymphoma development.
Medullary enlargement with cortical thinning. 
Cortical inversion 
/\ Microscopic lymphoma 
Deaths from leukemia
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the opposite thymus and dissemination and metastasis of 
neoplastic cells to the mediastinum, lymph nodes, spleen, 
bone marrow, parenchymal organs and peripheral blood 
yields a generalized lymphoblastic leukemia that is 
characteristic of the advanced stages of the disease.
The pathology and pathogenesis of the various murine 
thymic lymphomas appears to be identical regardless of the 
means used to induce the tumour, i.e. spontaneous, 
chemically-induced, X-ray irradiation-induced, or virally- 
induced (McEndy et al., 1944; Carnes and Kaplan, 1956; 
Arnesen, 1958; Dunn et al., 1961; Wasi and Block, 1961; 
Rappaport and Baroni, 1962; Goodman and Block, 1963;
Siegler and Rich, 1962; Ito et al., 1964; Siegler et al., 
1964; Metcalf, 1966b; Siegler et al., 1966; Joshi and 
Frei, 1970).
In essence, then, not only does the AKR model 
allow studies of the preleukemic period but, by its 
unilateral nature, it also supplies ideal control tissue 
(i.e. the uninvolved organ) for comparisons of enzyme 
activities, biochemical metabolites, etc. As stated 
earlier, biochemical studies are limited by the 
sensitivities of the assays available. In the experiments 
reported in this thesis the intracellular levels of cyclic 
AMP and cyclic GMP and the activities of the cyclic 
nucleotide phosphodiesterase enzymes were estimated in 
thymuses, treating each organ as an independent entity.
The age-related thymic involution necessitated that the 
paired organs of a single animal be combined for the 
assay of basal adenylate cyclase activity and the response
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of the enzyme to stimulation by specific agonists.
C57BL/6J mice, a low leukemic strain (Staats, 1972), 
have been used as a parallel control series in an 
effort to obviate possible alterations in cyclic 
nucleotide metabolism that are dependent upon age 
and not related to the development of the lymphoma.
The gross appearance of animals with 
established thymic lymphomas are shown in Figures 1.5 
and 1.6 and described in the associated legends. A 
single cell suspension of a primary tumour when 
injected (approximately 106 cells/animal) subcutaneously 
into a syngeneic animal resulted in the development of a 
tumour and dissemination of cells from the site of 
injection to involve other organs (Figure 1.7 and 
associated legend). The histological appearance of 
normal and neoplastic thymus and metastases of lymphoma 
cells in spleen, lymph nodes and liver is shown in 
Figure 1.8.
1.4 Outline of Thesis
The information contained in this first chapter 
has attempted to introduce the model system that has been 
used to investigate potential alterations in cyclic 
nucleotide metabolism in the preleukemic period of thymic 
lymphoma development. Chapter Two reviews some of the 
information available on the enzymes involved in the 
synthesis, the degradation and the implementation of the 
actions of cyclic nucleotides, with emphasis on some of 
the more recent contributions. Chapter Three briefly 
reviews the status of cyclic nucleotides as regulators
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of cellular proliferation and studies of cyclic nucleotide 
metabolism in the preneoplastic and neoplastic state. 
Chapter Four describes the methods that have been used to 
estimate cyclic nucleotide levels and enzyme activities 
in the thymuses of AKR and C57BL/6J mice. Chapters Five, 
Six and Seven present the results obtained in normal, 
preneoplastic and neoplastic tissues. Chapter Eight is a 
general discussion of the results contained in this 
thesis and their relationship to previously published 
studies.

FIGURE 1.5
GROSS APPEARANCE OF AKR MOUSE WITH THYMIC AND
GENERALIZED LYMPHOID LEUKEMIA
This animal was 220 ± 7 days of age.
A Thymic lymphoma
B Enlarged inguinal lymph nodes
C Enlarged spleen
D Enlarged axillary lymph nodes

FIGURE 1.6
GROSS APPEARANCE OF AKR MOUSE WITH THYMIC AND
GENERALIZED LYMPHOID LEUKEMIA
This animal was 241 ± 15 days of age.
A Thymic lymphoma
B Enlarged liver
C Enlarged spleen
Axillary and inguinal lymph nodes (not arrowed) 
also show enlargement.

FIGURE 1.7
GROSS APPEARANCE OF AKR MOUSE BEARING A TRANSPLANTED 
LYMPHOMA
A Subcutaneous tumour
B Enlarged inguinal lymph nodes
C Enlarged axillary lymph nodes
D Enlarged spleen

FIGURE 1.8
PHOTOMICROGRAPHS OF NORMAL AND NEOPLASTIC THYMUS 
AND METASTASES OF LYMPHOMA CELLS IN INGUINAL LYMPH 
NODES, SPLEEN AND LIVER
Tissue from the animal shown in Figure 1.6 and from 
AKR mice 5-6 weeks of age was taken into 10% formol- 
saline fixative for hematoxylin and eosin staining 
and histological examination.
1.8A Normal thymus (x200)
C = Outer, lymphocyte-rich cortex.
M = Inner medullary region - lighter
staining, containing epithelial cells.
1.8B Normal thymus (x500)
The cortico-medullary junction.
1.8C Normal thymus (x800)
The thymic cortex in which large, medium 
and small thymocytes can be observed.

FIGURE 1.8 cont.
1.8D Thymic lymphoma (x500)
Tissue taken from the animal shown in Figure 1.6.
1.8E Thymic lymphoma (x800)
Note the preponderance of large and medium 
thymocytes in the tumour.
1.8F Thymic lymphoma (x800)
An area of the tumour showing cell death (small 
arrows) as evidenced by pycnotic nuclei.
1.8G Thymic lymphoma (x800)
An area of the tumour showing necrosis.
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FIGURE 1.8 cont.
1.8H Metastasis of lymphoma cells in inguinal 
lymph nodes (x 200)
1.81 Metastasis of lymphoma cells in the spleen (x800)
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FIGURE 1.8 cont.
1.8J 
1.8K
Infiltration of liver by lymphoma cells 
Infiltration of liver by lymphoma cells
(x200) 
(x800)
CHAPT ER TWO
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2.1 Mechanisms of Hormone Action
2.1.1 Introduction
The creation of different cell types each having 
a specific set of functions is an inherent feature of the 
evolution of multicellular from unicellular organisms.
The regulation and integration of the functions of the 
different cells is critical if the total mass of the 
organism is to be efficient and adaptable to changes in 
its external and internal environments. This is achieved 
by the coordinated interaction of the nervous and 
endocrine systems.
Hormones were classically defined by Starling 
and Bayliss (1902) as being chemical agents that are 
released from one set of cells to affect the functions 
of one or more different groups of cells, utilizing the 
bloodstream as a vector. An alternative definition proposed 
by Huxley (1935), which places less emphasis on the mode 
of transport and more emphasis on the biological function, 
regards hormones as being 'information-transferring 
molecules', the essential role of which is to transfer 
information from one set of cells to another for the 
benefit of the cell population as a whole. This latter 
definition allows for a more flexible interpretation of 
the word 'hormone' for it encompasses neurotransmitter 
substances released from nerve endings and therefore tends
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to emphasise the similarities rather than the differences 
in the modes of action of the nervous and endocrine 
systems. The definition may also be extended to include 
substances released from unicellular organisms, such 
substances possibly subserving a role similar to that of 
hormones in multicellular organisms, i.e. the transfer of 
information.
Using the classical definition, and analysing the 
modes of action, there seems to be at least two broad 
categories of hormones. The first, consisting of the 
majority of the polypeptide hormones, catecholamines and 
prostaglandins, are characterized by target cell responses 
that are usually:
(1) rapid and of a limited duration; and,
(2) the magnitude of the response at a given point in 
time is closely related to the amount of hormone 
present.
The second category, including the steroid 
hormones, thyroid hormone and growth hormone, effect their 
target cells in a different way. Cellular responses are 
usually:
(1) much less rapid than those due to hormones from the 
first category; and,
(2) changes may persist for long periods regardless of 
the prevailing hormone concentration.
This latter class has been variously referred to 
as maintenance, permissive or developmental hormones. It 
is important to appreciate that this classification, based 
upon duration of cellular response, is not strict in that
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hormones from category one can often have long-lasting 
effects and hormones from category two can have short­
term effects.
Mechanisms of hormone action have also been 
subdivided on the basis of the location of the specific 
hormone receptors. Steroid hormones enter their target 
cells and interact with specific receptors located in 
the cytosol. Some peptide hormones, catecholamines and 
prostaglandins interact with specific receptors that are 
located on or in the surface of their target cells. The 
demonstration that peptide hormones may, in fact, enter 
cells (Kolata, 1978) suggests that even this distinction 
may not be definitive. It is possible, however, that the 
location of peptide hormones inside cells may represent 
receptor-mediated endocytosis, a phenomenon that has 
been reviewed recently by Pastan and Willingham (1981) .
The discussion below will be restricted to those 
hormones whose initial interaction with a target cell is 
mediated via a specific cell membrane-bound receptor.
More specifically, it will be directed towards those 
hormones which are capable of causing an alteration in 
the concentration of intracellular cyclic nucleotides.
2.1.2 Cyclic nucleotides and hormone action
Adenosine 31,5'-monophosphate (cyclic AMP) was 
originally discovered by Sutherland and co-workers during 
an investigation of the hyperglycaemic action of adrenalin 
and glucagon. The progression of the experiments that 
resulted in the identification of cyclic AMP and the role 
of this compound in the stimulation of glycogenolysis in
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liver cells exposed to adrenalin and glucagon has been 
reviewed by Sutherland et al. (1968) and Sutherland (1971).
Since this first observation it has been demonstrated that 
several hormones are able to stimulate the intracellular 
accumulation of cyclic AMP in a variety of tissues (see 
Table 2.1) and that cyclic nucleotides have a broad 
spectrum of effects upon biological systems. It should be 
stressed that not all of the actions of a given hormone 
upon a particular target cell are necessarily mediated via 
a cyclic nucleotide-dependent process. It seems likely 
that the altered distribution of ions between extracellular 
and intracellular compartments and/or between intracellular 
subcompartments is intimately involved in the expression of 
the hormonal message. The importance of calcium ions in 
this respect and their interrelationships with the cyclic 
nucleotide systems has received much attention (Berridge, 
1975; Rasmussen et al., 1975; Rasmussen and Goodman, 1977; 
Bygrave, 1978; Berridge, 1980). Agonists whose interaction 
with receptors causes the mobilization of calcium in the 
cytosol of the cell appear to also share a common feature, 
in that receptor activation causes the breakdown of 
phosphatidylinositol (a quantitatively minor phospholipid) 
and a compensatory increase in the rate of its synthesis 
(Michell and Kirk, 1980) .
Extending the observations made on the stimulation 
of hepatic glycogenolysis by hormones, Sutherland 
instigated the second messenger hypothesis. In simple terms, 
the first messengers (the hormones themselves) travel from 
their cells of origin to the cells of their target tissue
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TABLE 2.1
SOME HORMONES WHICH STIMULATE CYCLIC AMP PRODUCTION
IN VARIOUS TISSUES1
Hormone Tissue in which it acts
Adrenalin Lung, brain, spleen, salivary gland, 
heart, aorta, diaphragm, skeletal 
muscle, liver, erythrocytes, fat 
cells, parathyroid gland, bone
Noradrenalin Fat cells, aorta, brain, hypophysis, 
salivary gland, melanocytes, 
erythrocytes
Prostaglandins Hypophysis, thyroid gland, lung, 
diaphragm, heart, aorta, skeletal 
muscle, spleen, platelets, kidney, 
corpus luteum, bone
Glucagon Heart, liver, platelets, fat cells
Parathyroid hormone Skeletal muscle, bone, kidney
Triodo-L-thyronine Heart, corpus luteum, spermatozoa
Vasopressin Kidney, urinary bladder, aorta
Thyroid-stimulating hormone Thyroid, fat cells
Luteinising hormone Fat cells, corpus luteum
Secretin Fat cells
Gonadotrophin Testes
Adrenocorticotropic hormone Adrenal cortex
Oxytocin Urinary bladder
1Adapted from Greengard (1978)
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and cause an alteration in the level of a second 
(intracellular) messenger. Sutherland (1968) devised 
four criteria which should be satisfied to conclude 
that the effect of a hormone upon a cellular process 
was a consequence of the hormone's effect upon the 
cyclic AMP system. These can be summarised as follows:
(1) Hormones that cause an elevation of cyclic AMP
in intact tissues should also stimulate adenylate 
cyclase in broken cell preparations.
(2) The levels of cyclic AMP in intact tissues should 
respond to hormonal stimulation with an 
appropriate dose-response relationship. The 
changes in cyclic AMP concentration should 
precede the physiological response under 
investigation.
(3) The action of hormones which stimulate adenylate 
cyclase activity should be potentiated by agents 
that inhibit the breakdown of cyclic AMP by the 
phosphodiesterase enzymes.
(4) It should be possible to mimic the action of the 
hormone by addition of exogenous cyclic AMP.
As Greengard (1978) comments it is unfortunate 
that a hypothesis, advanced to explain a specific case and 
then found to apply to certain other cases, is often 
assumed to be applicable in all situations. Initially, 
criteria established to validate the hypothesis are 
applied stringently but later testing becomes far from 
definitive and the hypothesis may be claimed to be 
applicable to situations in which the evidence is really
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very slight. This would appear to be true in the case of 
the second messenger hypothesis, for often all the 
criteria outlined above have not been established in 
systems in which cyclic AMP has been implicated as a 
second messenger. Recently several groups have 
re-evaluated some of these systems. These studies have 
involved the analysis of changes that occur in the 
occupancy of intracellular receptors for cyclic AMP, 
namely the receptor subunits of the dependent protein 
kinase enzymes (see Section 2.4), upon exposure of 
cells to low doses of hormones (Dufau et al., 1977;
Podesta et al., 1979; Sala et al., 1979). These studies 
suggested that changes in cellular functions could be 
mediated by small, possibly compartmentalized, 
elevations in the levels of cyclic nucleotides, such 
increases being undetectable by conventional assay 
methods. For further discussion see Earp and Steiner 
(1978) and Schimmer (1980).
The enzymes involved in the synthesis and 
degradation of cyclic nucleotides and in the mediation 
of their biological effects will now be considered.
2.2 Hormone-sensitive Adenylate Cyclase
[ATP pyrophosphate-lyase (cyclising) E.C. 4,6.1.1]
2.2.1 Introduction
Adenylate cyclase catalyses the conversion of
adenosine triphosphate (ATP) to cyclic adenosine 3',5'- 
monophosphate (cyclic AMP) (see Figure 2.1). It was 
first described in detail, and initially named adenyl 
cyclase, by Sutherland and his coworkers in 1962
5’-ATP 3’,5'-CYCLIC AMP PYROPHOSPHATE
FIGURE 2.1
REACTION CATALYSED BY ADENYLATE CYCLASE
24
(Klainer et al., 1962; Murad et al., 1962; Rail and 
Sutherland, 1962; Sutherland et al., 1962). Nearly 
two decades have elapsed and even though our 
understanding of this hormonally regulated enzyme 
has unquestionably increased, and although it is now 
possible to formulate various molecular models of 
enzyme activation, there still remain many unanswered 
questions. A comprehensive review of the vast literature 
relating to the adenylate cyclase complex is beyond the 
scope of this introduction. Studies prior to 1972 have 
been discussed by Perkins (1973). More recent reviews of 
the various components have been compiled by Tell et al.
(1978) , Ariens (1979) , Levitzki and Helmreich (1979) ,
Berridge (1980), Helmreich and Bakardjieva (1980),
Johnson et al. (1980), Lefkowitz and Hoffman (1980a,b),
Lefkowitz et al. (1980), Rodbell (1980), Ross and Gilman 
(1980) , Farfel et al. (1981a) and Limbird (1981) .
The enzyme is part of a complex regulatory 
system that mediates the actions, or at least some of 
the actions, of various polypeptide hormones, catecholamines, 
neurotransmitters and prostaglandins on their target cells. 
The current evidence suggests that the enzyme is structured 
within the lipid framework of the cell membrane, although 
it may be that the enzyme also exists and functions at 
intracellular sites (Flawia et al., 1981). The enzyme is 
found in almost all animal cells, with some erythrocytes 
and cultured cells being exceptions. When assayed in 
plasma membrane preparations the enzyme exhibits a 'basal' 
activity which varies according to the tissue and assay
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procedure used. This could represent:
(1) the true activity of the unperturbed enzyme;
(2) stimulation of the enzyme by ligands in the 
preparation itself, or in the ATP substrate; or,
(3) activation of the enzyme during the disruption 
of cell membrane structure.
This 'basal' activity can be increased by the 
addition of appropriate stimuli (e.g. hormones, hormone 
analogues, sodium fluoride, etc.). However, the extent 
of activation as assayed in broken cell preparations is 
usually less than that observed when the synthesis of 
cyclic AMP is studied in intact cells or tissues. The 
concentration of a hormone that is required to stimulate 
the enzyme is also frequently increased after homogeniza­
tion of the tissues (Ross and Gilman, 1980). Both these 
features presumably reflect the disruption of an 
organised system that functions optimally in an intact 
plasma membrane.
Recently, attention has focussed upon the 
inhibitory influence of various hormones and neuro­
transmitters upon adenylate cyclase systems (Cooper et al., 
1979; Jakobs and Schultz, 1980; Rather et al. , 1980;
Oron et al., 1980; Rodbell, 1980; Welton and Simiko, 1980; 
Woodcock et al., 1980; Garcia-Sainz et al., 1981). This 
receptor-mediated inhibition of cyclic AMP formation has 
been described for a-adrenergic and muscarinic cholinergic 
agonists in several tissues, for adenosine, some prosta­
glandins and nicotinic acid in fat cells, for opiates in 
neuronal cells, for ADP in platelets and angiotensin II
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in liver (see Section 2.2.6).
2.2.2 The two-component model of adenylate cyclase 
It is interesting to consider how the models 
that attempt to explain the structure and function of 
the adenylate cyclase complex have altered since the 
instigation of the hypothetical two-component system 
by Robison et al. (1967) (Figure 2.2). They used
indirect evidence to implicate at least two components: 
a receptor or regulatory component and a catalytic 
component. They based their conclusion on two important 
observations:
(1) hormonal regulation appeared to be highly 
selective; and
(2) hormonal sensitivity was readily lost under a 
variety of mildly stressful conditions, whilst 
basal catalytic activity was retained.
The model assumed the existence of two subunits 
that exhibited specific directional orientation. The 
receptor component was thought to be located at the cell 
membrane-extracellular fluid interface, whilst the 
catalytic moiety was orientated towards the cell membrane- 
intracellular fluid interface. The interaction of hormone 
with receptor was thought to produce an alteration in the 
latter, which in turn led to an activation of the 
catalytic unit, thus resulting in an enhanced production 
of cyclic AMP. The directional orientation was consistent 
with two independent lines of evidence:
(1) hormones bound to agarose beads could elicit 
normal responses in intact cells; and
INTRACELLULAREXTRACELLULAR
COMPARTMENT i MEMBRANE i COMPARTMENT
HORMONE
yclic AMP
FIGURE 2.2
HYPOTHETICAL, TWO-COMPONENT MODEL OF HORMONE-SENSITIVE 
ADENYLATE CYCLASE
R = Hormone receptor
C = Catalytic moiety of adenylate cyclase 
(Adapted from Perkins, 1973).
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(2) intracellular ATP represents the substrate for 
the enzyme reaction in intact cells and cyclic 
AMP accumulates within cells upon activation of 
the catalytic unit.
Hence the two-component model implied direct 
interaction between the receptor and catalytic moieties.
2.2.3 Multiple-component models of adenylate cyclase 
An alternative model was suggested (Hechter and 
Halkerston, 1964) that differed only in the implied 
existence of intermediates that coupled the receptor to 
the catalytic unit. Rodbell and co-workers (Birnbaumer 
et al. , 1970; Rodbell, 1971) expanded on this to formulate 
the hypothetical three-component model of the adenylate 
cyclase system (Figure 2.3). Their ideas were derived from 
kinetic analysis of the activation of adenylate cyclase, 
particularly in adipocyte membrane preparations. In these 
cells several hormones which bind to different receptor 
sites seem to compete for a fixed number of catalytic 
units. The model contains a hormone discriminator (i.e. a 
specific receptor), a transducer and an amplifier (i.e. the 
catalytic unit). Rodbell defined the term 'transducer' as 
being 'that element which couples events occurring at the 
discriminator to events taking place at the amplifier'. In 
essence the three-component model differs from the 
two-component model in that direct interaction between 
receptors and catalytic units is not required. At that time, 
then, it remained possible that:
(1) the adenylate cyclase system was a regulatory
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FIGURE 2.3
HYPOTHETICAL, THREE-COMPONENT MODEL OF HORMONE-SENSITIVE 
ADENYLATE CYCLASE 
R = Hormone receptor
C = Catalytic moiety of adenylate cyclase 
(Adapted from Perkins, 1973).
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enzyme with the receptor/discriminator being an 
allosteric site on a regulatory subunit and the 
transducer representing an alteration in 
enzyme conformation that resulted in an enhanced 
activity of the catalytic subunit; or 
(2) the receptor and catalytic moieties were
distinct entities, physically separated but 
capable of interaction within the framework of 
the plasma membrane.
It is clear now that receptors for hormones are 
individual proteins which are distinct from adenylate 
cyclase. The use of specific radioligand binding assays 
for hormone receptors has been a useful tool in this 
respect. Adenylate cyclase activity and radioligand 
binding can be physically separated by gel filtration 
(Limbird and Lefkowitz, 1977), sucrose-density centrifu­
gation (Haga et al., 1977) and affinity chromatography 
(Vauquelin et al., 1977; Caron et al., 1979). N-ethylmalei- 
mide, an agent which inactivates adenylate cyclase, did 
not destroy the ligand binding of avian erythrocytes 
(Schramm and Niam, 1970). Conversely, N,N-dicyclohexylcarbo- 
diimide inactivated binding sites for the B-adrenergic 
ligand iodohydroxybenzylpindolol at concentrations that did 
not inhibit the enzyme activity (Schramm, 1976). A genetic 
approach has shown that two clones of cultured cells that 
are phenotypically deficient in adenylate cyclase (HTC rat 
hepatoma and an S49 mouse lymphoma variant) both retain 
B-adrenergic receptors (Insel et al., 1976).
Hence, hormone binding and adenylate cyclase
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activity can be physically separated. The elegant studies 
of Orly, Schramm and co-workers (Orly and Schramm, 1976; 
Schramm et al., 1977; Schulster et al., 1978; Schramm,
1979) and Schwarzmeier and Gilman (1977) have added 
further support to the concept that receptors and 
adenylate cyclase are discrete entities. Recombination, 
and not separation, of receptor and catalytic units by 
cell-to-cell fusion or cell-to-membrane fusion formed 
the basis of the experiments. This work is summarized 
in Figure 2.4 and associated legend. Therefore, the 
central postulate of the 'mobile receptor' model of 
adenylate cyclase regulation (Cuatrecasas, 1974) has 
received considerable experimental support, in that 
hormone receptors and adenylate cyclase appear to be 
discrete entities which are capable of relatively free 
diffusion to allow interaction with other membrane 
components. As a caveat to that, however, studies with 
phospholipases have shown that hormonal activation of 
adenylate cyclase remains intact even after 85% of the 
membrane phospholipids have been digested and that loss 
of activity occurs when a fraction of the remaining 
phospholipid is hydrolysed. Rodbell (1980) suggests these 
findings could indicate a close proximity of receptors 
and catalytic units within the lipid framework of the 
membrane, possibly residing in selective domains of 
interacting phospholipids.
2.2.4 Guanine nucleotides and adenylate cyclase activation 
Having established that receptors and adenylate 
cyclase are separate proteins, the problem of why occupation
Heat or H eat or I NEM
TTE - FEY1 - HE Y1 - TFE
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FE - FETE - TE
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FIGURE 2.4
RECOMBINATION OF HORMONE RECEPTORS WITH THE CATALYTIC 
MOIETY OF ADENYLATE CYCLASE BY CELL-CELL FUSION EXPERIMENTS 
(Constructed from Orly and Schramm, 1976; Schramm et al., 
1977).
A TE
TTE
Y1
FE
NEM
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Turkey erythrocyte 
Treated turkey erythrocyte 
Mouse adrenal Y1 cells 
Friend erythroleukemic cells 
N-ethylmaleimide 
Sendai virus
Catalytic moiety of adenylate cyclase 
ß-adrenergic receptor
Basal adenylate cyclase activity of TE cells is stimulated by 
isoproterenol and NaF. Treatment of TE cells with heat or NEM 
destroys adenylate cyclase activity (TTE). Basal adenylate 
cyclase activity of Y1 and FE cells is not stimulated by 
isoproterenol. Fusion (Sendai virus) of TTE cells (containing 
ß-adrenergic receptors) with Y1 or FE cells (containing 
adenylate cyclase) produces hybrids (Yl-TTE, TTE-FE) in which 
enzyme activity can be stimulated by isoproterenol.
Friend erythroleukemic cells 
Treated Friend erythroleukemic cells 
Mouse adrenal Y1 cells 
Rat C6 glioma cells 
N-ethylmaleimide 
Sendai virus
Catalytic moiety of adenylate cyclase 
Prostaglandin E receptor
Basal adenylate cyclase activity of FE cells is stimulated by 
prostaglandin Ei and NaF. Treatment of FE cells with heat or NEM 
destroys adenylate cyclase activity. Basal adenylate cyclase 
activity of Y1 and C6 cells is not stimulated by prostaglandin Ei. 
Fusion (Sendai virus) of TFE (containing prostaglandin E receptors) 
with Y1 or C6 cells (containing adenylate cyclase) produces hybrids 
(Yl-TFE, C6-TFE) in which enzyme activity can be stimulated by 
prostaglandin Ex.
B FE 
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of the receptors by appropriate hormones leads to enhanced 
production of cyclic AMP has to be addressed. Several lines 
of evidence indicate that functional coupling of receptors 
and catalytic units involves interaction with guanine 
nucleotides:
(1) Membrane preparations from various cell types can 
be rendered virtually unresponsive to hormonal 
stimulation by removal of guanine nucleotides 
(Bimbaumer and Pohl, 1973? Bilezekian and Aurbach,
1974; Maguire et al., 1977).
(2) 5'-Guanylylimidodiphosphate [Gpp(NH)p], an analogue 
of GTP that is resistant to hydrolysis by cellular 
GTPase enzymes, very strongly activates cyclic AMP 
synthesis in membrane preparations. GTP itself 
produces a much smaller activation (Londos et al.,
1974; Schramm and Rodbell, 1975).
(3) Hormones can accelerate the rate of adenylate cyclase 
activation produced by Gpp(NH)p, but the maximal 
activity achieved is unaltered (Schramm and Rodbell,
1975).
(4) Enzyme activation by hydrolysis-resistant analogues 
of GTP is difficult to reverse, even with extensive 
washing of membrane preparations. Conversely, 
activation of the enzyme by hormone and GTP is 
readily reversible by washing or addition of hormone 
antagonists (Schramm and Rodbell, 1975; Lad et al.,
1977).
These lines of evidence led to the speculation that
hormone-receptor interaction causes activation of the adenylate
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cyclase enzyme by virtue of some interaction with a guanine 
nucleotide regulatory protein (Lad et al., 1977; Maguire 
et al. , 1977) . Initially the requirement for the presence 
of GTP as well as substrate for enzyme activation was 
established for glucagon stimulation in the plasma 
membrane preparations from rat liver (Rodbell et al., 1975); 
it has been found to be a general requirement for all types 
of cells that have been studied in detail (Ross and Gilman,
1980).
Cassel and Selinger proposed a two-state model 
for enzyme activation based upon their studies of the 
catecholamine-sensitive adenylate cyclase system of turkey 
erythrocyte membranes. They suggested that the GTP-liganded 
form of the enzyme is active and that hormone-receptor 
interactions increase the rate of formation of this active 
form. They were able to demonstrate an isoproterenol-stimulated 
GTPase activity in the membranes of these cells and proposed 
that hydrolysis of the bound GTP represented a 'turn off' 
mechanism returning the enzyme to an inactive state (Cassel 
and Selinger, 1976; Cassel and Selinger, 1977; Cassel, 1981).
It should be noted that hormone-stimulated GTPase activity 
has proven difficult to detect in other membrane preparations 
(Kaslow et al., 1979). This probably reflects a technical 
difficulty in that most cells have a very high 'background' 
of nonspecific nucleotide triphosphatase activity (Cassel 
and Selinger, 1976). The model proposed by Cassel and 
Selinger is generally consistent with a number of other 
studies relating to the role of guanine nucleotides in the 
regulation of adenylate cyclase activity.
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The above evidence implies the presence of a 
guanine nucleotide binding site on a regulatory protein. 
Strong evidence in favour of the existence of two 
distinct proteins, i.e. the regulatory component and a 
catalytic unit, has now been reported (Pfeuffer and 
Helmreich, 1975; Pfeuffer, 1977; Ross and Gilman, 1977;
Ross et al., 1978). Pfeuffer and co-workers made use of 
the affinity of the regulatory protein for GTP to 
resolve it from the catalyst by passing a Lubrol PX 
extract of pigeon erythrocyte membranes over a column of 
GTP-substituted agarose. Ross and Gilman and co-workers 
made use of the differing thermal stability of the two 
proteins and also performed some very elegant reconstitution 
studies, some of which are summarized in Figure 2.5 and 
associated legend. The reconstitution studies took 
advantage of the S49 lymphoma cell lines, which have been 
particularly useful for elucidating various facets of the 
hormonally regulated adenylate cyclase enzyme (for reviews 
see Johnson et al., 1980; Farfel et al. , 1981a).For a more 
detailed discussion of the molecular properties of the 
separated guanine nucleotide regulatory component see 
reviews by Johnson et al. (1980) and Ross and Gilman (1980).
Different authors use different terminology when discussing 
the properties of the nucleotide regulatory component. Ross 
and Gilman (1978) refer to it as the ' G/F protein' because 
it is necessary to confer guanine nucleotide and fluoride 
sensitivity upon the adenylate cyclase system. Pfeuffer 
(1979) has called it the 'G-protein' and Johnson et al.
(1978) use the term 'N-protein'. Future reference to this
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FIGURE 2.5
RECONSTITUTION OF HORMONE-SENSITIVE ADENYLATE CYCLASE 
ACTIVITY
(Constructed from Ross et al., 1978; Johnson et al., 
1980).
Wild S49 lymphoma cells contain adenylate cyclase activity 
that can be stimulated by a number of agonists. S49 eye“ 
cells demonstrate basal adenylate cyclase activity; none 
of the agents capable of stimulating basal activity in wild 
cells are effective in eye- cells, even though the cells 
contain ß-adrenergic receptors as shown by direct radioligand 
binding studies. Heat or N-ethylmaleimide treated (to destroy 
catalytic adenylate cyclase units) detergent extracts of wild 
S49 lymphoma cells when mixed with partially purified eye“ 
membranes reconstituted sensitivity to stimulation by 
isoproterenol and Gpp(NH)p. NEM or heat treatment of the eye” 
membranes prevented reconstitution, demonstrating that the 
eye” membranes contribute catalytic units. Protease treatment 
of detergent extracts of wild S49 lymphoma cells also 
prevented reconstitution, indicating the factor (s) responsible 
to be protein(s). Heat or NEM treated detergent extracts from 
mouse B82 cells and rat HTC cells similarly reconstituted 
hormone sensitive adenylate cyclase activity in eye“ membranes.
The results suggest that the eye“ membranes contribute
ß-adrenergic receptors and catalytic units, while the
detergent extracts contribute a coupling factor - the 'N-protein'.
Catalytic moiety of adenylate cyclase 
ß-adrenergic receptor
'N-protein'
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regulatory component in this thesis will use the terminology 
of Johnson et al. (1978), i.e. 'N-protein'. The N-activity
is associated with an elongated intrinsic membrane protein 
with a molecular weight of 126-130,000 daltons. The protein 
is oligomeric and contains at least one peptide subunit 
(Mr = 42,000) that serves as a specific substrate for 
ADP-ribosylation by cholera toxin. The latter is a protein 
excreted by Vibro cholerae and activates adenylate cyclase 
in virtually every animal cell or tissue exposed to it (for 
review see Gill, 1977).
2.2.5 Guanine nucleotides and hormone binding
Guanine nucleotides also affect the binding of 
agonists to their specific hormone receptors (Maguire et al., 
1976; Lad et al., 1977; Lin et al., 1977). The effects are 
agonist specific, with GTP, GDP and Gpp(NH)p shifting the 
dissociation constant (Kd) for binding to higher concentrations 
for ß-adrenergic agonists, but having no effect on antagonist 
binding (Maguire et al., 1976). This phenomenon has been 
studied in depth by Rodbell and co-workers for the glucagon- 
sensitive adenylate cyclase of liver membranes. Classically, 
the hormone binding event is thought to bring about a change 
in the receptor conformation that is favourable for hormone 
action. The relationship between binding and activation is 
complicated in the hormone-sensitive adenylate cyclase 
system because two ligands, the hormone and GTP, are required 
for action. By using labelled glucagon it was found that GTP, 
at concentrations required for enzyme activation in the 
presence of hormone, resulted in 90% of the receptors being 
converted to a form with a Kd higher than that required for
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activation of the enzyme, i.e. Kd > Kact. The remaining 
10% of receptors displayed kinetic properties that 
accommodate hormonal activation of the enzyme. Hence,
GTP exerts negative heterotropic effects on hormone 
binding in the glucagon-sensitive adenylate cyclase 
system (Lad et al., 1977). The effects of GTP could be 
mimicked by Gpp(NH)p and it was found that, although 
activation of the enzyme by this stable analogue was 
difficult to reverse, the effects upon hormone binding 
were rapidly reversible by dilution. These findings led 
Rodbell and co-workers to postulate that functionally 
(and possibly structurally) distinct guanine nucleotide 
regulatory sites are involved in the regulation of 
hormone binding and enzyme activity. This concept has 
more recently been expanded upon by Rodbell (1980) in 
an attempt to implicate GTP-regulatory proteins in other 
membrane transduction systems involving surface receptors, 
apart from those controlling adenylate cyclase activity. 
This will be discussed in greater depth in Section 2.2.6.
The N-protein may also play a role in the 
agonist-induced desensitization that has been observed in 
many different hormone-sensitive adenylate cyclase systems 
(Tell et al., 1978; Lefkowitz et al., 1980; Tiggle, 1980). 
This phenomenon, known variously as desensitization, 
tachyphylaxis, tolerance, refractoriness or subsensitivity 
is characterized by a diminished response either during, 
or subsequent to, the initial action of an agonist. 
Therefore, exposure of cells to an agonist that causes an 
increased accumulation of cyclic AMP often reduces the
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responsiveness to a second exposure of the agonist 
(Remold-0'Donnell, 1974; Clark et al., 1975; Mickey 
et al., 1975; Su et al., 1980). The desensitization 
process probably occurs by different mechanisms in 
different cell types, and may also involve a number 
of components in the same cell system. One such 
mechanism involving the concomitant loss of hormone 
receptors, i.e. a 'down regulation' of receptor 
number, has received considerable attention. Shear 
et al. (1976) demonstrated that 'wild-type' S49 
lymphoma cells exhibit isoproterenol-induced desensiti­
zation associated with a reduction in the number of 
ß-adrenergic receptors. This down-regulation of receptor 
number was not seen with cyc~ cells, a mutant line of S49 
lymphoma cells which functionally lacks N-protein in its 
adenylate cyclase system. This implies that a regulatory 
component that is absent in cyc~ cells is necessary for 
desensitization. Other workers have postulated that the 
formation of a high-affinity state of the hormone 
receptor is involved in the process (Maguire et al.,
1977). Interestingly, the ß-adrenergic receptors of eye 
and unc membranes (guanine nucleotide regulation is 
partially defective in unc membranes) appear unable to 
exhibit a high affinity state and both mutant lines 
fail to show down-regulation of receptor number (Johnson 
et al., 1980).
2.2.6 Interrelationships between the components of
hormone-sensitive adenylate cyclase
The limitations of the systems that have been
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used to study hormone-sensitive adenylate cyclase are 
functions of the properties of the enzyme itself. It 
appears to consist exclusively of intrinsic membrane 
proteins, the proper integration of which into a 
membrane is essential for hormonal regulation. Hence, 
the individual proteins can be separated and assayed 
as independent entities but hormonal stimulation is only 
observed in intact membranes. The proteins of the enzyme 
complex are scarce, probably none existing in a 
concentration greater than 10 pmols/mg membrane protein. 
Finally, the proteins are quite labile in detergent 
solutions and dissociation probably enhances the unstable 
nature of the proteins during further manipulation. Despite 
these problems it is now clear that the system is composed 
of at least three proteins:
(1) a catalytic protein that is relatively inactive 
and displays none of the regulatory properties 
described above;
(2) the N-protein that mediates the actions of 
various regulatory ligands and is essential 
for the transduction of events occurring at 
the receptor level to the catalyst; and
(3) the hormone receptor itself.
It is useful to present pictorial models in an 
attempt to explain how the activity of the adenylate 
cyclase enzyme is controlled. The status of any of these 
models is somewhat tenuous because the field is rapidly 
evolving. However, I have decided to use two of the most 
current examples for illustrative purposes. The first of
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these is that of Lefkowitz and Hoffman (1980a) which 
specifically addresses itself to the ß-adrenergic 
responsive enzyme (see Figure 2.6). Interaction of 
a hormone agonist with its specific receptor results 
in the initial formation of a lower affinity, freely 
reversible complex. Agonists induce a conformational 
change in the receptor such that a ternary complex 
between the agonist, receptor and N-protein results.
This complex has been described as a 'high-affinity' 
state. The formation of this complex is thought to be 
associated with the loss of tightly bound GDP from 
the nucleotide regulatory protein and a facilitation 
of the binding of GTP. This interaction destabilises 
the ternary complex, freeing the nucleotide regulatory 
component which is now associated with GTP. In this 
state the N-protein activates the catalytic unit, 
resulting in an enhanced production of cyclic AMP. 
Cleavage of the GTP, by a GTPase activity, to GDP 
returns the system to its baseline state. Lefkowitz 
and Hoffman therefore see the activation of adenylate 
cyclase as several interlocking cycles of activation 
and deactivation.
As stated in Section 2.2.1, receptor-mediated 
inhibition of adenylate cyclase has received considerable 
attention recently. The inhibitory effects produced by 
various ligands share some common characteristics:
(1) Agonists reduce adenylate cyclase activity
without an apparent lag phase, and antagonists 
(where available) block the inhibitory effects 
rapidly.
H -R -N INACTIVEACTIVE
RECEPTOR REGULATORY CATALYTIC
CYCLE CYCLE CYCLE
FIGURE 2.6
HORMONE-SENSITIVE ADENYLATE CYCLASE 
(Adapted from Lefkowitz and Hoffman, 1980a). 
Refer to text for discussion.
•
H = Hormone 
R = Receptor 
N = 'N-protein'
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(2) Inhibition of both basal and hormonally-stimulated 
activity is seen to approximately the same extent, 
i.e. 20-60%.
(3) In most of the systems which have been studied,
GTP is necessary for hormone-induced inhibition.
The involvement of guanine nucleotides in this 
inhibition is complex and awaits further 
elucidation (Jakobs and Schultz, 1980).
(4) In most reports, though not all (Garcia-Sainz 
et al., 1981), sodium ions are required for the 
demonstration of hormone-induced adenylate 
cyclase inhibition. In fat cells, liver and 
heart preparations the sodium ions activate 
the enzyme in the presence of GTP and the 
inhibitory hormones counteract this sodium 
activation. The effective ion concentration 
range is 20-200 mM. The high concentrations,
as with the high concentrations of hormones 
required for activation, may reflect the 
disturbance of membrane integrity produced by 
cell disruption.
Jakobs and Schultz (1980) speculate that the 
inhibitory hormones and neurotransmitters may inhibit 
the adenylate cyclase activity by stimulation of the 
GTPase which was suggested by Cassel and co-workers 
(1976) to be the terminating step in cyclase activation. 
However, this assumes a basal, unstimulated activity of 
the enzyme in vivo, an assumption that may not be valid
(as discussed in Section 2.2.1). Alternatively, there
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may be a separate, unidentified guanine nucleotide 
regulatory protein that is responsible for mediating 
hormone-induced inhibition. Rodbell (1980) favours 
this latter interpretation and Figure 2.7 shows a 
theoretical 'dual regulation' model of an adenylate 
cyclase enzyme by stimulatory and inhibitory hormones 
and neurotransmitters.
The role of sodium ions remains unclear. It 
is interesting to speculate that, should the sodium- 
sensitive component face the intracellular compartment, 
then hormone binding may be coupled with an influx of 
sodium ions from the extracellular fluid. This could 
raise the local ion concentration to a level similar 
to that necessary for inhibition in vitro.
The second model that I will discuss is that 
of Rodbell (1980), because it attempts to explain 
enzyme inhibition as well as activation, and also makes 
use of recent speculations as to the organization of 
hormone receptors and guanine nucleotide binding proteins 
within the structure of the plasma membrane. As stated in 
Section 2.2.5, Rodbell and co-workers favour the concept 
of functionally, and possibly structurally, distinct 
guanine nucleotide regulatory sites. It has been suggested 
that at least two types of N unit exist functionally, one 
(Ns) mediating stimulation and the other (Ni) mediating 
inhibition of the adenylate cyclase enzyme. Rodbell 
proposes that receptors (R) and N units normally exist 
independently of the catalytic units, as aggregates or 
oligomers of an RN complex. In this state R is said to
STIMULATING AGENTS INHIBITORY AGENTS
ß - Adrenergic, 
Glucagon,
ACTH, Adenosine
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—  Opiates, 
Cholinergic, 
Adenosine
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FIGURE 2.7
THEORETICAL MODEL OF DUAL REGULATION OF ADENYLATE 
CYCLASE BY STIMULATORY AND INHIBITORY HORMONES AND 
NEUROTRANSMITTERS 
(Adapted from Rodbell, 1980).
The model depicts two classes of receptors; one (Rs) 
mediates hormone effects through stimulatory 
nucleotide regulatory units (Ns) and the other (Ri) 
mediates inhibitory effects through linkage with 
inhibitory nucleotide regulatory units (Ni).
C = Catalytic moiety of adenylate cyclase
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inhibit interaction of the N unit with GTP. The binding 
of agonist to receptor somehow relieves this inhibitory 
influence, resulting in enhanced interaction of N with 
GTP. The breakdown of the oligomeric complex occurs, 
yielding monomeric RN complexes. In this state 
interaction with the catalytic moiety takes place 
forming the holoenzyme (RNC) complex. Depending upon 
the type of R and N unit that interact with the catalytic 
unit, formation of cyclic AMP can be either enhanced or 
suppressed.
The basis for the postulate that R and N units 
exist, in the unstimulated state, as oligomeric units 
resulted from experiments using the technique of target 
size analysis. This technique, based upon inactivation by 
ionizing radiation, was first applied to the adenylate 
cyclase system by Houslay et al. (1977) to test possible
interactions of regulatory proteins with the catalyst in 
its membrane environment. Rodbell (1979, 1980) used 
hepatocyte, adipocyte and turkey erythrocyte membranes to 
investigate changes in target size under a number of 
different conditions. The catalytic unit when free from 
interaction with other components of the system 
preferentially utilizes manganese-ATP (Mn-ATP) as a 
substrate. Combination with N confers upon C the potential 
to utilize the natural substrate magnesium-ATP (Mg-ATP). 
Therefore the minimal size active unit (i.e. C alone) is 
obtained by supplying Mn-ATP and no other regulatory 
ligands. The size was found to increase significantly by 
preactivation with guanine nucleotides or fluoride ions,
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and this theoretically represents the NsC complex. 
Activation with hormone and GTP, which theoretically 
produces the holoenzyme complex (RNsC) similarly 
produced an increment in the target size. By 
manipulations such as these and utilization of 
labelled glucagon in binding studies, Rodbell and 
co-workers were able to deduce that the RNs structure 
in hepatocyte membranes has a molecular weight of 
6-13 x 105 daltons, this being 3-6 times the estimated 
size of the RNs unit associated with the holoenzyme 
complex. This suggested that RNs units normally reside 
as an oligomeric complex. In adipocyte membranes the 
RNs unit for catecholamine and ACTH receptors is 
reported to be 13 x 105 daltons with the RNi unit for 
adenosine receptors being significantly larger (i.e.
RNi > 13 x 105). Rodbell states that ’although target 
analysis cannot give the structure and composition of 
the target, it can be inferred from the size differences 
that the stimulatory and inhibitory processes reflect 
different structures that are complexes of RN units 
comprising the holoenzyme'. Obvious care must be taken 
when interpreting such results, especially as the turkey 
erythrocyte catecholamine-sensitive system does not 
demonstrate oligomeric RN structures (Rodbell, 1980).
Figure 2.8 and associated legend represents a 
schematic adaptation of Rodbell's 'disaggregation­
coupling' model for hormone and GTP effects on the 
adenylate cyclase enzyme. As the interaction of R with 
N restrains interaction with GTP, cells devoid of
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FIGURE 2.8
DISAGGREGATION-COUPLING MODEL OF ADENYLATE CYCLASE 
ACTIVATION
(Adapted from Rodbell, 1980).
Rodbell (1980) suggests that hormone receptors and 
'N-protein' units exist as oligomeric complexes 
within cell membranes. For illustrative purposes a 
tetrameric structure is depicted in panel A. The RN 
oligomeric complex is stated to exist in two 
configurations: an unoccupied structure (as shown in
panel A) which favours binding of hormones but not 
GTP, and a hormone-induced structure (as in panel B) 
which favours reaction of GTP with the 'N-protein'. 
Reaction with GTP results in a dispersion of the 
oligomer to monomers (panel C). The negative hetero­
tropic effects of GTP upon hormone binding are 
suggested to occur in this monomeric state. The 
monomeric units are capable of interacting with the 
catalytic moieties (C) to form the holoenzyme 
complex RNC (as in panel D) that converts Mg-ATP to 
cyclic AMP.
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receptors should display a high reactivity to GTP. Lin 
et_al. (1979) have reported that a strain of HeLa cells 
deficient in 3-adrenergic receptors do display high 
reactivity to GTP. Enrichment of these cells with 
receptors results in a requirement for catecholamines 
to restore the level of activity seen with GTP alone in 
the receptor-deficient cells.
The hormone-sensitive adenylate cyclase enzyme 
is a very complex system. That alterations in the normal 
regulatory processes do occur in preneoplastic and 
neoplastic cells is evident from the literature and will 
be discussed in Chapter Three. The S49 lymphoma cell lines 
(Johnson et al., 1980) that have been extensively used in 
research into the adenylate cyclase system confirm that 
deletions do occur in the neoplastic condition and show 
how these may be elucidated.
A great deal of information relating to the 
properties and interactions of hormone receptors, 
guanine nucleotide regulatory units and adenylate cyclase 
has been collected, and yet Ross and Gilman (1980) state 
that 'the study of the biochemistry of adenylate cyclase 
is just beginning'. Some of the unanswered questions that 
they pose are:
(1) Is it possible to quantitate the kinetics 
and the thermo-dynamics of the multiple 
ligand/protein interactions?
(2) What is the mechanism of action of fluoride 
ions on the guanine nucleotide regulatory
unit?
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(3) What are the mechanisms involved in the 
long term hormonal regulation of adenylate 
cyclase (e.g. desensitization of target 
cells)?
(4) How is the synthesis and stoichiometry of 
receptors, N units and catalytic units 
coordinated?
2.3 Guanylate Cyclase [GTP pyrophosphate-lyase
(cyclising) E.C. 4.6.1.2]
2.3.1 Introduction
Guanylate cyclase catalyses the conversion of 
guanosine triphosphate (GTP) to cyclic guanosine 3 5 ' -mono­
phosphate (cyclic GMP) (see Figure 2.9). Cyclic GMP was 
initially identified as a naturally occurring constituent of 
rat urine (Ashman et al., 1963) and was subsequently 
detected in animal tissues (Goldberg et al., 1969; Ishikawa 
et al. , 1969). A specific enzyme catalysing the biosynthesis 
of this compound was demonstrated by Hardman and Sutherland 
(1969), Ishikawa et al. (1969) and White and Aurbach (1969). 
George et al. (1970) observed that acetylcholine, a
neurotransmitter that produces effects upon cardiac 
metabolism and function that are opposite to those produced 
by noradrenaline, could promote a rapid accumulation of 
cyclic GMP and a suppression of cardiac contractility. 
Coupled to other observations, which suggested that the 
levels of cyclic GMP in tissues could be elevated by agents 
which acted in an antagonistic fashion to those promoting 
cyclic AMP accumulation, Goldberg and co-workers (1975)
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FIGURE 2.9
REACTION CATALYSED BY GUANYLATE CYCLASE
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proposed the 'Yin Yang hypothesis'. Yin Yang, an ancient 
oriental concept/ symbolizes a dualism between opposing 
natural forces that, under appropriate conditions, may 
mutually interact. The hypothesis therefore saw cyclic 
AMP and cyclic GMP as biological effectors capable of 
regulating cellular functions in a bidirectional fashion, 
and placed emphasis on their relative, rather than their 
absolute, concentrations. Considerable effort has been 
expended in attempts to validate this hypothesis and 
although applicable in specific cases, the concept of 
dualism does not appear to be universal (Murad et al., 
1979) .
2.3.2 Distribution and basic properties
Early studies of guanylate cyclase that 
established the basic properties of the enzyme have 
been reviewed by Goldberg et al. (1973), Kimura and
Murad (1975a,b) and Goldberg and Haddox (1977). These 
properties can be summarized:
(1) All organisms, from bacteria to mammals, exhibit 
guanylate cyclase activity. In lower forms of 
life sea urchin sperm has provided a good source 
of the enzyme, although sea urchin eggs and 
vertebrate sperm exhibit little, if any, enzyme 
activity. The highest activities in mammalian 
tissues are found in the rod outer segment of 
the retina, in the lung and in the small 
intestinal mucosa.
(2) Guanylate cyclase activity is found in both
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soluble and particulate fractions of homogenized 
mammalian tissues, in contrast to lower forms 
where the enzyme is essentially particulate.1 
The distribution of enzyme activity between 
soluble and particulate forms is species, tissue 
and cell specific. It ranges from 90% particulate 
in rat small intestine (Ishikawa et al., 1969) 
and fibroblast cultures (Wallach and Pastan, 1976) 
to 80% soluble in rat lung and liver (Kimura and 
Murad, 1974; Chrisman et al., 1975) and platelet 
preparations (Glass et al., 1977). Separation of 
tissues into component cell types has shown 
marked differences in guanylate cyclase distribution 
between those different types (Goridis et al., 1974; 
Helwig et al., 1975). Subfractionation of particulate 
preparations has localized guanylate cyclase activity 
in plasma membrane and microsomal fractions of liver 
(Kimura and Murad, 1975d),in purified rat liver 
nuclei (Earp et al., 1977) and nuclei from calf 
uterus (Siegel et al., 1976).
(3) Incubation with non-ionic detergents, e.g. Triton 
X-100 or Lubrol PX, enhances the activity of the 
particulate form (300-1200%) to a greater extent 
than the soluble form (50-100%). Therefore, when 
the latent (i.e. expressable in the presence of 
detergent) activity is considered most cells have 
a preponderance of the particulate enzyme. As the
■^Soluble activity is usually assessed in the supernate of a 
105,000 x g centrifugation, with the particulate activity 
representing the resuspended pellet from that centrifugation.
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activity of the soluble fraction is also enhanced 
this detergent effect appears to be more than a 
simple solubilization phenomenon. The mechanism 
of detergent activation is unknown (Murad et al.,
1979) .
(4) The divalent cation requirement for the enzyme's 
catalytic activity is best fulfilled by manganese 
(Mn2 + ). Magnesium (Mg2+) and calcium (Ca2+) only 
support a fraction of the activity seen with 
optimal Mn2+ concentrations.
(5) Soluble and particulate forms can be distinguished
by differences in their biochemical and immunological 
properties:
(a) Detailed kinetic analysis (Kimura and Murad, 
1974; Chrisman et al., 1975) reveals that the 
soluble form exhibits classical Michaelis-Menten 
kinetics with respect to Mn2+-GTP, whilst the 
particulate form exhibits positive cooperativity.
(b) Gel filtration (Kimura and Murad, 1974;
Chrisman et al., 1975) and sucrose gradient 
centrifugation (Neer and Sukiennik, 1975) reveal 
that the soluble and particulate forms are of 
different molecular size, with the soluble form 
generally having a lower molecular weight.
(c) The soluble form is not inhibited by high 
concentrations of Mn2+, is more sensitive to 
inhibition by ATP and is usually stimulated, 
rather than inhibited, by millimolar concentrations * 
of Ca2+. Exceptions to these generalizations do
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exist; for example, the particulate enzyme from 
intestinal mucosa is activated by Ca2+ (Murad 
et al., 1978).
(d) Antibodies, both polyclonal (Garbers, 1978; 
Nakane and Deguichi, 1980) and monoclonal (Lewicki 
et al., 1980) have been raised against guanylate 
cyclase enzymes. Garbers (1978) demonstrated that 
antibodies generated to the particulate activity 
of sea urchin sperm inhibited the particulate, 
but not the soluble, forms of the enzyme from a 
variety of rat tissues. The availability of 
monoclonal antibodies should provide both low and 
high affinity sera useful to study the tissue 
distribution of the enzymes by immunocytochemical 
techniques and in the preparation of affinity 
columns to aid large scale enzyme purification 
procedures.
The observations summarized above do not rule 
out the existence of a single type of catalytic unit.
The association of additional subunits and/or some form 
of proteolytic cleavage could confer the distinctive 
molecular size, kinetic and immunological properties of 
the soluble and particulate enzymes. The apparent 
multiplicity of forms will best be clarified by detailed 
kinetic studies on purified proteins. The particulate 
enzyme from sea urchin sperm (Garbers, 1978) and the 
soluble enzymes from rat liver (Tsai et al. , 1978; 
Braughler et al., 1979) and rat lung (Garbers, 1979;
Lewicki et al., 1980) have been purified. Interestingly,
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the purified particulate enzyme from sea urchin sperm 
demonstrated classical Michaelis-Menten kinetics with 
respect to Mn2+-GTP, as opposed to the positive 
cooperativity seen in crude preparations. The purified 
enzymes should also prove useful in the elucidation of 
the mechanism of guanylate cyclase activation.
Inhibitors of guanylate cyclase activity have 
been derived from the balsam pear or bitter melon 
(Momordica charantia) (Vesely et al. , 1977a; Claflin et al., 
1978; Takemoto et_al., 1979; Takemoto et al., 1980) and 
garlic (Allium sativum) (Dhillon et al., 1981). The 
preparation from the balsam pear inhibited basal guanylate 
cyclase and the activation of the enzyme by nitroso 
chemical carcinogens (see Section 2.3.4.2). It blocked the 
growth of an undifferentiated prostate adenocarcinoma 
in vitro and inhibited basal and concanavalin A-stimulated 
[3H]-thymidine incorporation into splenic lymphocytes. 
Partial purification by Takemoto et al. (1980) has shown
the cytotoxic and guanylate cyclase inhibitory activities 
to coelute as a single, trypsin-sensitive peak from a 
Sephadex G-200 column. The aqueous extract from garlic 
inhibited the guanylate cyclase activity from liver and 
hepatoma cytosols, membranes and from triton-solubilized 
membrane preparations. A 5-fold purification showed the 
factor to have a molecular weight of 8,800 daltons and to 
be heat- and trypsin-stable. It decreased the growth of 
two poorly differentiated Morris hepatomas and returned 
to normal the blood pressure and heart rate of hypertensive 
rats. The physiological significance of guanylate cyclase
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inhibitors and, indeed, the demonstration of their 
presence in mammalian tissues has yet to be reported.
2.3.3 Altered activity and subcellular distribution 
in physiological and pathological conditions
The acute regulation of guanylate cyclase is
discussed in Section 2.3.4. Alterations in the total
enzyme concentration and in the partitioning between
soluble and particulate compartments have also been
observed. Several studies have analysed the total
homogenate and soluble and particulate enzyme activities
of rat liver in the normal adult, the foetus, in
regenerating liver following partial hepatectomy and in
the neoplastic state (Kimura and Murad, 1975c; Goridis
and Reutter, 1975; Koide et al., 1978). Regenerating
liver shows no alteration in total homogenate activity
but an increase in the particulate to soluble ratio;
this increase is cycloheximide-sensitive. Foetal liver
and a number of hepatoma cell lines similarly show an
increased particulate to soluble ratio. There are several
other reports (e.g. Criss et al., 1976a; Frattola et al.,
1976; DeRubertis and Craven, 1977) of altered enzyme
activities and subcellular distribution in the neoplastic
condition and these are discussed in more detail in
Section 3.4. Other examples include:
(1) In foetal and early post-natal rat heart the 
soluble activity is increased compared to adult 
values (Vesely et al., 1976).
(2) Following unilateral nephrectomy the soluble 
activity of the contralateral kidney increases
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and precedes any apparent renal hypertrophy 
(Scholondorff and Weber, 1976).
(3) Early in testicular maturation both soluble 
and particulate activities are elevated.
Increased soluble guanylate cyclase activity 
is observed in the abdominal testes following 
bilateral cryptorchidism. Unilateral 
cryptorchidism produces a similar increase in 
soluble activity in the abdominal testis when 
compared to the remaining scrotal testis (Earp 
et al., 1980).
(4) Dystrophic and denervated muscle also exhibit 
increased soluble guanylate cyclase activity 
(Novom and Lewinstein, 1977; Blosser and Appel,
1978) .
Therefore, in normal and abnormal cell growth 
and in differentiation there are changes in total 
guanylate cyclase and/or alterations in subcellular 
distribution. The data is often conflicting. For example, 
transplantable hepatomas, ethionine-induced hepatomas 
and renal tumours in rats (Criss et al. , 1976a; Criss 
et al., 1976b; Murad, 1976; DeRubertis and Craven, 1977) 
demonstrate increased particulate to soluble ratios 
whilst human renal adenocarcinomas (Kim et al., 1977) 
show the opposite. Clearly, care must be taken when 
attempting to generalize and the cause and effect 
relationships of the observed alterations remain to be
established.
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2.3.4 Acute regulation of enzyme activity
2.3.4.1 Hormones and guanylate cyclase activity
There has been a natural tendency to search 
for analogies in the synthesis, degradation and modes 
of action of the cyclic nucleotides. Hormones and 
other agents that cause cyclic AMP accumulation in 
intact tissues can often be shown to activate 
adenylate cyclase in broken cells. In contrast, 
although a number of hormones can cause elevation of 
cyclic GMP levels in intact tissues, there are few 
convincing, reproducible reports of hormonal effects 
upon guanylate cyclase activity in cell free 
preparations. This supports the concept that hormonal 
activation of the enzyme in vivo is an event 
relatively distal to the initial hormone-receptor 
interaction (Murad et al., 1978; Murad et al. , 1979).
It has been suggested that early reports of direct 
hormonal stimulation by secretin and pancreozymin 
(Amer, 1974; Howell and Montague, 1974; Thompson et al., 
1974a)were probably due to bile salt contamination of 
crude hormone preparations, these salts having detergent­
like actions (Ichihara et al., 1977). The review by 
Goldberg and Haddox (1977) contains a very detailed 
account of tissue specific, positive and negative 
effectors of the steady state level of cellular cyclic 
GMP.
Schultz et al. (1973) demonstrated that
stimulation of cyclic GMP accumulation in isolated vas 
deferens by acetylcholine was dependent upon the presence
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of calcium ions. The effects of divalent cations and 
nucleotides upon the kinetic analysis of the soluble 
and particulate enzyme activities are complex. Some 
observations can be summarized:
(1) soluble guanylate cyclase activity assayed in 
the presence of suboptimal, but physiological, 
concentrations of Mn2+ can be enhanced by 
millimolar concentrations of Ca2+ and Mg2 +
(Kimura and Murad, 1974; Chrisman et al., 1975);
(2) a crude preparation of the particulate enzyme is 
inhibited by millimolar Ca2+, but purified 
microsomal guanylate cyclase is unaffected (Kimura 
and Murad, 1975d); and
(3) physiological concentrations of ATP can inhibit 
both soluble and particulate forms of the enzyme
(Kimura and Murad, 1974; Chrisman et al., 1975). 
Alterations in the distribution of calcium 
ions, at both the cellular and subcellular levels, and 
of intracellular nucleotide pools might, therefore, act 
as effectors for hormonal regulation of guanylate cyclase 
activity in vivo.
2.3.4.2 Non-humoral activation of guanylate cyclase 
A variety of agents can increase cyclic GMP 
levels in tissues and stimulate guanylate cyclase 
activity in cell free systems. These include sodium 
azide, nitric oxide, nitroprusside, nitrosamines, 
nitrosureas (Kimura et al., 1975; Arnold et al., 1977; 
Vesely et al., 1977b;Murad et al., 1978; DeRubertis
and Craven, 1979; Murad et al., 1979; DeRubertis and
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Craven, 1980) , Superoxide dismutase and hydroxyl radicals 
(Mittal and Murad, 1977; Yoshikawa and Kuriyama, 1980), 
unsaturated fatty acids (Wallach and Pastan, 1976), 
prostaglandin endoperoxides and fatty acid hydroperoxides 
(Graff et al., 1978). It has been suggested (Murad et al., 
1978; Murad et al., 1979) that these compounds share a 
common pathway of enzyme activation via the formation of 
oxidising free radicals. The activating species may be 
nitric oxide in the case of nitro and nitroso compounds 
or, under appropriate conditions, the hydroxyl radical. 
The mechanism by which free radicals activate guanylate 
cyclase is at present unclear. Murad et al. (1979)
speculate that this free radical activation may mediate 
the effects of hormones on enzyme activity in vivo. They 
also propose that guanylate cyclase may function as a 
monitor of the redox state and/or of the extent of free 
radical production within cells. If this is so, the 
increased production of cyclic GMP could serve as a 
negative feedback regulator, readjusting the cellular 
redox state and rate of free radical production that, if 
left unchecked, could result in the oxidation of protein 
and lipid constituents of the cell. This hypothesis views 
cyclic GMP not as a primary mediator of hormone action 
but as a mechanism to 'turn off' some events induced by 
the hormone. At present there is no evidence for or 
against this 'negative feedback hypothesis'. The precise 
events that occur between hormone-receptor interaction 
and guanylate cyclase activation are still unknown.
54
2.4 Cyclic Nucleotide-dependent Protein Kinases
(E.C.2.7.1.37)
2.4.1 Introduction
The cyclic nucleotides produced by the activation 
of the cyclase enzymes have one of at least three possible 
fates within the cell:
(1) They can exert their physiological effect, 
this being mediated by the interaction of 
the cyclic nucleotides with their dependent 
protein kinase enzymes and subsequent 
phosphorylation of specific substrates 
within the cell. Although it has not been 
demonstrated unequivocally in all systems 
(particularly for cyclic GMP) that the 
protein kinases are the sole mediators of 
cyclic nucleotide action, the evidence for 
alternative mediators is meagre.
(2) They can be degraded to the respective
5'-nucleotides by the cyclic nucleotide 
phosphodiesterase enzymes (Section 2.5).
(3) They can be transported to the extracellular 
compartment.
The latter process has received comparatively little 
attention in the literature and most of the reports 
available focus their attention on the export of cyclic 
AMP from cells. This has been shown to occur in avian 
erythrocytes, mammalian and rat reticulocytes and a 
variety of cultured mammalian cells via an active process 
that, while dependent upon the availability of intracellular
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cyclic AMP, is not directly coupled to the activities 
of the enzymes of cyclic AMP metabolism (Davoren and 
Sutherland, 1963; Rindler et al., 1978; Brunton and 
Mayer, 1979; Brunton and Buss, 1980). Whether the 
mechanism of extrusion applies in vivo has not been 
clearly defined. However, cyclic AMP can be detected 
in perfusates of isolated mammalian organs and 
application of hormones known to cause increased 
intracellular levels of cyclic AMP can increase the 
concentration of the cyclic nucleotide in the 
extracellular fluid of animals (Broadus et al., 1971).
This export from the intracellular compartment is 
presumably the source of the cyclic nucleotides found 
in plasma, cerebrospinal fluid and urine (Broadus, 1977).
The extruded nucleotides therefore appear to be stable. 
Whether they subserve any physiological function is 
unknown. Brunton and Buss (1980) speculate on a possible 
vasoactive role for extracellular cyclic AMP. Interestingly, 
it has been reported that some cultured mammalian cells 
exhibit receptors for cyclic AMP on the exterior surface of 
their plasma membranes (Wen et al., 1979). Therefore, 
exportation could serve the dual function of lowering 
intracellular levels of cyclic nucleotides and providing a 
source in the intracellular compartment that could exert 
physiological actions via membrane bound receptors.
Intracellular functions regulated by cyclic 
nucleotides appear to be mediated solely by the activation 
of the dependent protein kinase enzymes. The phosphorylation- 
dephosphorylation of specific proteins is now recognised
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as a reversible covalent modification that serves to 
exert a regulatory influence upon a cellular process, 
that influence usually being of a limited duration.
The state of phosphorylation of a protein is controlled 
by the activities of two classes of enzymes; the 
specific protein kinases and the phospho-protein 
phosphatases.
Protein kinase
Protein + nATP^ ► Protein-Pn + nADP
Phosphoprotein Phosphatase
Protein-Pn + nH2Q ~^~" »Prntpin + nPi
Krebs and Beavo (1979) have classified the 
protein kinases in terms of their regulation by specific 
agents. Hence there are:
(1) cyclic AMP-dependent protein kinases;
(2) cyclic GMP-dependent protein kinases;
(3) calcium ion-dependent protein kinases;
(4) double stranded RNA-dependent protein 
kinase; and
(5) nonspecified or messenger-independent 
protein kinases.
The following discussion will be limited to the 
protein kinase enzymes whose activities are regulated by 
their interaction with cyclic nucleotides.
2.4.2 Cyclic AMP-dependent protein kinases
2.4.2.1 Introduction
Cyclic AMP-dependent protein kinase (cyclic 
AMP-PK) was initially discovered in rabbit skeletal muscle 
(Walsh et al., 1968). Since this finding there has been a
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continuously expanding literature on the role of this 
enzyme in the mediation of the effects of cyclic AMP 
in a number of different systems (for reviews see 
Langan, 1973; Nimmo and Cohen, 1977; Corbin and Lincoln,
1978; Earp and Steiner, 1978; Krebs and Beavo, 1979;
Glass and Krebs, 1980).
2.4.2.2 Distribution, subunit structure and activation 
The holoenzyme complex contains two types of 
subunit: a regulatory subunit (R), which binds cyclic
AMP and a catalytic subunit (C), which contains the 
active site. Early studies using gel filtration, sucrose 
density gradient centrifugation and ion-exchange chroma­
tography reported the resolution of multiple molecular forms 
of the enzyme. Some of these forms are now known to be 
artifacts of the systems employed and the consensus indicates 
that there are two major classes of soluble cyclic AMP-PK 
present in mammalian tissues. These two isoenzymes can be 
separated by chromatography on DEAE-cellulose and are 
referred to as the Type I and Type II forms (Reimann, 
et al. , 1971; Corbin et al., 1975; Hofmann et al., 1975).
The distribution of enzyme activity between the two 
elution peaks has been examined in a number of mammalian 
tissues and it is known that:
(1) the proportions of Type I and II forms in
a given tissue vary widely between different 
mammalian species;
(2) the proportions of the two forms vary from 
tissue to tissue in a given species; and
(3) the proportion of the two forms can vary 
from cell to cell within the same organ.
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Each isoenzyme has a tetrameric subunit structure 
consisting of 2 regulatory and 2 catalytic units. The 
forms differ in the characteristics of their R subunits 
(R^R2) whilst the catalytic moiety appears to be identical 
in structure and function (Sugden et al., 1976; Bechtel 
et al. , 1977; Corbin and Keely, 1977). The mechanism of 
enzyme activation has been summarized as:
R2C2 + 2cAMPI« " — >R2 (cAMP) 2 + 2C
inactive
holoenzyme
complex
active
catalytic
subunit
by Nimmo and Cohen (1977) and by Krebs and Beavo (1979) 
or as:
r 2C2 + 4cAMP^r~r_i__  =^R2 (cAMP) 4 + 2C
M.W.190,000 M.W.110,000 M.W.40,000
by Corbin and Lincoln (1978; source of molecular weight 
estimates) and Glass and Krebs (1980). The latter 
representation resulted from a re-evaluation of the 
stoichiometry of the binding of cyclic AMP to the R subunit 
of cyclic AMP-PK which indicated that 2 mol, and not 1 mol, 
of cyclic AMP are bound to the monomer at equilibrium. 
Binding of cyclic AMP to the R subunits is followed by 
dissociation of R and C which results in the C subunit 
being 'freed' from the inhibitory constraints imposed by 
R and able to phosphorylate specific amino acid sequences 
in the protein substrates of the enzyme. The physical and 
functional characteristics of the subunits of cyclic AMP-PK 
have been extensively reviewed (Rubin and Rosen,1975;
Nimmo and Cohen, 1977).
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2.4.2.3 Structural determinants of substrate specificity 
Early studies of the amino acid sequences of 
phosphorylation sites in substrates of cyclic AMP-PK 
revealed no apparent similarities. This led to the 
assumption that a particular three-dimensional configura­
tion was necessary within the substrates for phosphoryla­
tion by the enzymes (Cohen et al., 1975). However, the 
observations that the enzymes would also phosphorylate 
small peptides and that denaturation of certain proteins 
enhanced their susceptibility to phosphorylation argued 
against the requirement for a specific substrate configura­
tion (Daile and Carnegie, 1974; Bylund and Krebs, 1975;
Humble et al., 1975). These lines of evidence suggested 
that the primary structure of the protein is important in 
the determination of specificity. Earp and Steiner (1978) 
note that, as denaturation of certain proteins allows 
phosphorylation that does not occur in the native state, 
it appears likely that primary and tertiary protein 
structure are important in determining the specificity of 
protein phosphorylation by cyclic AMP-PK. This is further 
supported by the observation that synthetic peptide 
substrates of phosphorylation site sequences do not always 
exhibit the kinetic characteristics of the native substrate, 
hence implicating higher orders of structure (Kemp et al., 
1976; Kemp, 1979).
The importance of basic amino acid residues in the 
determination of specificity was suggested by studies of the 
phosphorylation of genetic variants of 3-casein (Kemp et al.,
1975) and has been supported by the use of synthetic peptide
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substrates corresponding to sequences around naturally 
occurring substrate phosphorylation sites (Kemp et al.,
1976; Kemp et al., 1977; Kemp, 1979). Arginine residues 
appear especially important in this respect. Sequence 
analysis of a number of phosphorylation sites has shown 
them to contain multiple basic residues near to, and on 
the aminoterminal side of, those sites (Williams, 1976).
Two main patterns of primary sequence have been observed 
in the enzyme's natural substrates:
(1) Arg-Arg-X-Ser(P), and
(2) Lys-Arg-X-X-Ser(P).
The use of synthetic peptide sequences has also 
been useful, in that:
(1) they showed that serine residues appear to be much 
better phosphate acceptors than threonine residues;
(2) they showed that the presence of a basic residue 
on the carboxyterminal side of the phosphorylated 
serine is deleterious to the catalysis by cyclic 
AMP-PK;
(3) they have provided tools for inhibition of the 
activity of cyclic AMP-PK;
(4) they have allowed studies of the kinetics of the 
enzyme-catalysed reaction; and
(5) they may be used in studies of the active site 
of the enzyme itself.
2.4.2.4 Autophosphorylation
Erlichman et al. (1974) reported that the cyclic
AMP-PK of bovine cardiac muscle catalysed the phosphorylation 
of its own regulatory subunit. This autophosphorylation has
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been shown to be a property associated with the Type II 
isoenzyme from various tissues and species (Maeno et al., 
1974; Rosen et al., 1975; Walter et al., 1977). It has 
been reported to occur in both soluble and membrane bound 
forms of the enzyme (Rubin et al. , 1979). Autophosphory­
lation of Type I kinase is normally undetectable (Hofmann 
et al. , 1975). However, Steinberg et al. (1977) reported
that the regulatory subunit of Type I kinase in an S49 
mouse lymphoma cell line was predominantly in the 
phosphorylated form in the intact cell. The enzyme 
catalysing this phosphorylation was not characterized.
The autophosphorylation of the R subunit occurs 
in the undissociated holoenzyme (Rangel-Aldao and Rosen, 
1976a; Todhunter and Purich, 1977). A phosphoprotein 
phosphatase enzyme that acts on the free phosphorylated 
form of Type II regulatory subunit but poorly on the 
phosphorylated holoenzyme has been reported (Chan et al., 
1975). The autophosphorylation of Type II kinase alters 
its sensitivity to cyclic AMP (Erlichman et al., 1974) 
such that dissociation is favoured (Rangel-Aldao and 
Rosen, 1976b, 1977). The phosphorylated holoenzyme has a 
lower dissociation constant for cyclic AMP than does the 
dephosphorylated form and phosphorylated Type II regulatory 
subunits have a reduced rate of reassociation with free 
catalytic units in the presence or absence of cyclic AMP.
The biological significance of the autophosphory­
lation of Type II kinase is poorly understood because no 
studies have assessed the phosphorylated state of the enzyme 
in vivo.
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2.4.2.5 Protein modulation
Tissues have been shown to contain a heat-stable 
protein inhibitor of cyclic AMP-PK. Purification to 
homogeneity has been achieved for the inhibitor from 
skeletal muscle, brain and heart (Demaille et al., 1977;
Weber and Rosen, 1977; Demaille et al., 1978). The protein 
is a potent inhibitor of the catalytic subunit of the 
kinase enzyme, exhibiting competitive inhibition with 
respect to protein substrates. The role of the inhibitor 
in vivo is still unclear. Muscle, a tissue in which the 
inhibitor is relatively abundant, only contains the 
inhibitor in concentrations such that, at most, 20% of the 
cyclic AMP-PK could be blocked (Walsh and Ashby, 1973). 
Therefore, although the inhibitor might serve to inhibit 
free catalytic subunits under basal conditions and thereby 
prevent activation at ’low' concentrations of cyclic AMP 
(Beavo et al., 1974) its function at 'higher' concentrations 
of cyclic AMP is unknown. It has been reported that the 
concentrations of the inhibitor can change under different 
physiological conditions (Walsh and Ashby, 1973; Kuo, 1975; 
Costa, 1977). Despite the uncertainty as to the physiological 
role of this protein it has served as a useful tool for 
distinguishing cyclic AMP-PK activity from other protein 
kinases (Traugh et al., 1974). Two other inhibitory proteins 
have been reported, one from rat testis that is also 
inhibitory to cyclic AMP-phosphodiesterase (Beale et al., 
1977), and another from brain that inhibits the action of 
several classes of protein kinases, including cyclic GMP-PK 
(Szmigielski et al., 1977) .
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2.4.2.6 Criteria to establish protein phosphorylation by 
cyclic AMP-PK
As Sutherland attempted to establish criteria that 
had to be fulfilled to allow the conclusion that the action 
of a hormone was mediated by its effects upon the cyclic 
nucleotide system, Krebs (1972) suggested a set of criteria 
that should be satisfied before an effect mediated by cyclic 
AMP could be said to involve phosphorylation of a protein 
by cyclic AMP-PK. These criteria were modified by Nimmo and 
Cohen (1977) and have been further updated by Krebs and 
Beavo (1979). They can be paraphrased as follows. There must 
be:
(1) An in vitro demonstration that a protein substrate 
can be phosphorylated in a stoichiometric fashion 
and at a significant rate by an appropriate protein 
kinase enzyme, and dephosphorylated by a phosphoprotein 
phosphatase.
(2) A correlation between the altered functional properties 
of the protein and the degree of phosphorylation of 
that protein.
(3) A demonstration that the phosphorylation-dephosphorylation 
of the protein can occur in vivo, or in an intact cell 
system, with the associated alteration in function.
(4) A correlation of cellular levels of the enzymes 
catalysing the phosphorylation-dephosphorylation with 
the extent of the phosphorylation of the protein.
The criteria outlined can be applied to a protein 
that exhibits multiple phosphorylation sites, although under 
these circumstances the significance of each site must be 
examined separately. Krebs and Beavo (1979) suggest that,
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associated with these criteria, the investigators must use 
a considerable amount of judgement. Obviously, the enzymes 
shown to catalyse the phosphorylation-dephosphorylation of 
a protein must be present in the cell type and, probably 
more importantly, the subcellular compartment in which the 
protein resides (Earp and Steiner, 1978).
2.4.3 Cyclic GMP-dependent protein kinase
2.4.3.1 Introduction
The presence of a protein kinase that was distinct 
from cyclic AMP-PK and that was preferentially activated by 
cyclic GMP was initially discovered in arthropods (Kuo and 
Greengard, 1970; Kuo et al., 1971). The presence of this 
cyclic GMP-PK in mammalian tissues was subsequently 
demonstrated (Kuo, 1974) . The properties and regulation of 
this enzyme are not understood as fully as those of cyclic 
AMP-PK. This is probably a consequence of the more restricted 
tissue distribution and concentration and, initially, the 
unavailability of a homogenous preparation of the enzyme.
Such preparations have been obtained from bovine lung 
(Gill et al., 1976) and heart (Flockerzi et al., 1978).
It still remains unclear whether all physiological actions 
of cyclic GMP are mediated by activation of the cyclic GMP-PK. 
Chromatography on DEAE-cellulose of extracts from several rat 
tissues reveals two peaks of cyclic GMP binding activity.
Peak 1 is without cyclic GMP-PK activity whilst peak 2 has 
both binding and cyclic GMP-PK activities (Lincoln et al., 1976).
For reviews on the properties of cyclic GMP-PK see 
Corbin and Lincoln (1978) , Kuo et al. (1978a,b) , Gill and
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McCune (1979) and Glass and Krebs (1980).
2.4.3.2 Distribution, subunit structure and activation
From the tissues that have been examined, the lung, 
the cerebellum, the femoral artery and lymph node lymphocytes 
of mice are the sources of highest cyclic GMP-PK activity.
In these tissues the activity is comparable to, or may 
exceed, cyclic AMP-PK activity. In most tissues, however, 
the cyclic GMP-PK activity is only some 5-20% of that 
observed for cyclic AMP-PK. As the lung and cerebellum have 
high concentrations of cyclic GMP, in comparison to other 
tissues studied, there appears to be a correlation between 
cyclic GMP content and cyclic GMP-PK activity in these 
tissues. At the subcellular level the majority of the 
cyclic GMP-PK activity is associated with the soluble 
fraction (Kuo et al., 1978a).
Early studies on the mechanism of activation of 
cyclic GMP-PK utilized partially purified enzyme preparations 
and were suggestive of an activation process analogous to 
that of the cyclic AMP-PK enzyme (Miyamoto et al., 1973;
Kuo et al., 1976b. However, it was observed that:
(1) at low concentrations of cyclic GMP, that fully 
activated the enzyme, dissociation of the kinase 
enzyme could not be observed (Kuo et al., 1978a); 
and
(2) a cyclic GMP-regulatory unit has not consistently 
been recovered after activation (Kuo et al., 1978b).
It has been reported that the homogeneous enzyme 
preparations of bovine lung and heart do not exhibit 
dissociation into subunits upon cyclic GMP activation.
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The lung enzyme is comprised of only one type of subunit 
that displays cyclic GMP binding and protein kinase activity 
(Lincoln et al., 1977). The mechanism of activation is 
therefore different from that of the cyclic AMP-PK and can 
be depicted as:
E2+ 2cGMP^—  — ^ E2 (cyclic GMP)2
inactive active
Therefore the native enzyme is a dimeric structure 
of only one type of subunit.
2.4.3.3 Structural determinants of substrate specificity 
Little is known about the structural determinants 
for cyclic GMP-PK activity. At present few reports on the 
amino acid sequences of phosphorylated sites in the 
endogenous substrates of the enzyme are available (see 
Section 2.4.4) and so the synthetic peptides discussed in 
Section 2.4.2.3 have been utilized as substrates. The 
information from these synthetic substrates, summarized 
from the review by Glass and Krebs (1980), is as follows:
(1) The pyruvate kinase sequence peptide and a sequence 
from the a-subunit of phosphorylase kinase are both 
phosphorylated by cyclic GMP-PK. Kinetic analysis 
reveals that they are relatively poor substrates 
for cyclic GMP-PK when compared to cyclic AMP-PK.
(2) Threonine residues do not substitute well for serine 
residues in the synthetic peptide substrates.
(3) The optimal spatial arrangement of basic residues 
on the aminoterminal side of the phosphorylation 
site is similar for both kinases.
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(4) Pure substrates that cyclic GMP-PK phosphorylates 
more efficiently than cyclic AMP-PK include: the 
sequence Arg-Lys-Arg-Ser-Arg-Lys-Glu and analogues 
of this peptide, which represents a fragment of 
histone H2B; a carboxyterminal chymotryptic 
fragment of histone Hi (Zeilig et al., 1981) and 
the free regulatory subunit of Type I cyclic AMP-PK 
(Geahlen and Krebs 1980a,b; Geahlen et al., 1981; 
Hashimoto et al., 1981).
2.4.3.4 Autophosphorylation
The purified preparation of cyclic GMP-PK from 
bovine lung undergoes autophosphorylation. The reaction 
is intramolecular, involving 2 mol of phosphate per mol 
of holoenzyme. The phosphorylation sites have not been 
identified. As with the autophosphorylation of the Type II 
cyclic AMP-PK regulatory subunits the physiological 
significance of this phenomenon remains unclear. Cyclic 
GMP is reported to inhibit, and cyclic AMP and histone to 
enhance, the autophosphorylation (de Jonge and Rosen, 1977; 
Lincoln et al., 1978).
2.4.3.5 Protein modulation
The heat stable protein inhibitor of cyclic AMP-PK 
activity has been discussed in Section 2.4.2.5. Investigations 
using crude preparations of this inhibitory protein from 
various sources were observed to stimulate cyclic GMP-PK 
isolated from lobster tail muscle (Donnelly et al., 1973) 
and cyclic GMP-PK enzymes from mammalian sources. An absolute 
requirement for this stimulatory modulator for the expression
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of maximal cyclic GMP-PK activity and for maximal stimulation 
by cyclic GMP has been suggested (Kuo et al., 1978b). Kuo 
and co-workers (1976a,c) were able to separate the inhibitory 
and stimulatory modulators present in crude mammalian 
preparations by Sephadex G-100 gel filtration. When crude 
preparations of lobster muscle were chromatographed in a 
similar fashion the two activities co-eluted in a single 
peak. These studies suggested that:
(1) Crude mammalian preparations of protein modulators 
represent a mixture of inhibitory and stimulatory 
activities that reside in separate proteins.
(2) The proportions of stimulatory and inhibitory 
modulators are tissue dependent. Skeletal muscle 
contains almost exclusively inhibitory modulator 
whilst the small intestine contains almost 
exclusively stimulatory modulator. Most other 
tissues examined have comparable amounts of the 
two activities.
In contrast to the inhibitory modulator that 
exerts its action by directly interacting with the 
catalytic subunit of cyclic AMP-PK (Demaille et al.,
1977) the stimulatory modulator exerts its effect by 
interaction with the substrates to be phosphorylated.
The action increases the rate of substrate phosphoryla­
tion and does not alter the specific phosphorylation 
sites. These effects are seen predominantly using histones 
as substrates (Yamamoto et al. , 1977; Shoji et al., 1978).
As with the inhibitory modulator of cyclic AMP-PK the 
physiological function of this stimulatory protein is as 
yet unknown.
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2.4.4 Summary
Should the cyclic nucleotide-dependent protein 
kinases be the sole mediators by which cyclic AMP and 
cyclic GMP exert their intracellular actions, then their 
importance to any study relating to the metabolism of 
cyclic nucleotides is obvious. Where the techniques and 
expertise required to construct a meaningful investigation 
are available the ultimate goals of such investigations 
should be the elucidation of the specific substrates 
available for phosphorylation and the alteration in cellular 
process(es) that is(are) a consequence of the altered 
phosphorylated state of the protein. To realize these goals 
further studies must address major challenges that remain to 
be surmounted:
(1) The sequence analysis of some phosphorylation sites 
within the endogenous protein substrates still have 
to be determined, this being especially so for cyclic 
GMP-PK (see below).
(2) The molecular structures of the kinases and, in 
particular, the active sites of the enzymes have to 
be clarified (Hixson and Krebs, 1979; Zoller and 
Taylor, 1979; Hixson and Krebs, 1981). Specific 
inhibitors for use in vivo would be very powerful 
tools in the further understanding of the role of 
cyclic nucleotides in cellular regulation.
(3) What is the physiological significance of the 
autophosphorylation of Type II cyclic AMP-PK and 
cyclic GMP-PK and of the protein modulators of 
the enzymes' activities?
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(4) The integration of a coordinated, short-term
hormonal response involving the cyclic nucleotide 
system must involve positive (on) and negative 
(off) components. The activation of cyclases 
produces increased intracellular concentrations 
of cyclic nucleotides which activate the dependent 
protein kinases, resulting in the phosphorylation 
of 'target' proteins. The effects are terminated 
by the degradation of cyclic nucleotides by 
phosphodiesterases and/or extrusion from the cell 
and the dephosphorylation of the target proteins 
by phosphoprotein phosphatase enzymes. The 
possibility of hormonal regulation of the activity 
of the latter class of enzymes has received little 
attention (Lee et al., 1980), although they 
represent the key to the termination of a short-term 
response. Subcellular compartmentalization of the 
enzymes could make the coordination of these events 
possible.
Finally some recent work that has involved the 
collaboration of Greengard's and Cohen's laboratories 
highlights some current directions in the study of cyclic 
nucleotide dependent protein kinases (Aswad and Greengard, 
1981a,b; Aitken et al., 1981). Despite the diversity of 
functions proposed for cyclic GMP there still exists no 
system in which a detailed role has been firmly 
established. The search for specific substrates for 
cyclic GMP-PK has involved the incubation of crude 
systems (whole cells, membranes or unfractionated cytosols)
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under phosphorylating conditions and subsequent attempts 
to isolate proteins whose phosphorylation is specifically 
stimulated by low concentrations of cyclic GMP but not 
by equivalent concentrations of cyclic AMP. One such 
protein, isolated from the cytosol of rabbit cerebellum, 
has been reported by Schlichter et al. (1978) and termed
the 'G-substrate'. Recent work on this protein can be 
summarized as:
(1) The 'G-substrate* from rabbit cerebellum has been 
purified to apparent homogeneity as judged by 
sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis and is a monomeric, heat- and 
acid-stable protein of 23,000 daltons.
(2) Detailed kinetic studies on the phosphorylation of 
the purified 'G-substrate' by homogeneous preparations 
of cyclic GMP-PK from bovine lung and the catalytic 
subunit of cyclic AMP-PK from bovine heart reveal 
that both enzymes catalyse the phosphorylation of
2.0-2.1 mol of 32P/mol of 'G-substrate'. The 
simultaneous presence of both enzymes caused only 
a slight increase in the amount of incorporation 
(2.4 mol 32P/mol substrate) indicating that both 
enzymes phosphorylate the same sites, which are 
threonine residues. Kinetic analysis (Table 2.2) 
suggests that there is a high degree of specificity 
towards the cyclic GMP-PK that is based upon 
selective substrate binding rather than catalytic 
efficacy.
(3) The isolation and availability of 'G-substrate' in
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TABLE 2.2
KINETIC CONSTANTS FOR PHOSPHORYLATION OF G-SUBSTRATE BY 
CYCLIC GMP-DEPENDENT AND CYCLIC AMP-DEPENDENT PROTEIN KINASES
Protein kinase Km Vmax
(yM) (ymol/min/mg)
Cyclic GMP-PK 0.21 2.2
Cyclic AMP-PK 5.8 2.3
After Aswad and Greengard (1981b)
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a homogeneous form has provided a unique opportunity 
to determine the amino acid sequences of the 
phosphorylation sites in this cyclic GMP-PK- 
specific endogenous substrate. Over a 26 amino acid 
sequence surrounding the two phosphorylated threonine 
residues, 18 of the amino acids were found to be 
identical and 4 of the remaining 8 positions 
represented conservative substitutions (i.e. the two 
amino acids found at a particular site, though 
different, were from the same basic, acidic or 
neutral class). This sequence homology is suggestive 
of an internal gene duplication. Comparison of the 
sequences to the sequence around serine-32 in histone 
H2B shows the characteristic clustering of lysine and 
arginine residues on the aminoterminal side of the 
phosphorylated residues, supporting earlier findings 
reviewed in Sections 2.4.2.3 and 2.4.3.3 regarding 
the importance of basic residues as structural 
determinants of substrate specificity.
The results of these recent studies will allow the 
production of synthetic peptide sequences against which it 
may be possible to raise specific antibodies. These would 
be useful in the elucidation of the cellular and subcellular 
localization of this protein and hopefully provide some 
insight into its physiological role.
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2.5 Cyclic Nucleotide Phosphodiesterases (E.C.3.1.4.17)
2.5.1 Introduction
The irreversible enzymatic hydrolysis of cyclic 
nucleotides, the only known catabolic pathway, is catalysed 
by the phosphodiesterases. The presence in extracts of 
brain, heart and liver of an enzyme capable of destroying 
the biological activity of cyclic AMP was recognised by 
Sutherland and Rail (1958). Partial purification of this 
activity from dog heart revealed the reaction product to 
be 5'-adenosine monophosphate (5'-AMP). Activation by Mg2+ 
and inhibition by caffeine was also reported. Subsequent 
identification of the phosphodiesterase enzyme from a 
variety of tissues (Drummond and Perrott-Yee, 1961; Butcher 
and Sutherland, 1962; Nair, 1966; Cheung, 1967) indicated 
apparent Km values for cyclic AMP of approximately 10“4 M, 
this being at least two orders of magnitude higher than 
tissue cyclic AMP levels. These observations, which showed 
the enzyme to have a very low affinity for its substrate, 
led to the questioning of the importance of the enzyme in 
the control of cyclic nucleotide levels. For this reason, 
investigations tended to focus upon the enzyme (adenylate 
cyclase) which catalyses the synthesis of cyclic AMP as 
the prime regulatory site in cyclic AMP metabolism (see 
Section 2.2).
The development of sensitive assays led to the 
recognition of an enzyme activity with a much higher 
affinity for cyclic AMP and ultimately to an appreciation 
of the critical role that the enzymes subserve in the 
control of intracellular cyclic nucleotide concentration.
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The active extrusion of cyclic AMP from cells was discussed 
in Section 2.4.1. It should be appreciated that, even 
though the extrusion phenomenon exists, in cultured cells, 
at least, the hydrolysis of cyclic nucleotides by the 
phosphodiesterase enzymes represents the major factor in 
the control of total nucleotide turnover (Barber and 
Butcher, 1981). It is interesting to note that, although 
much emphasis has been placed upon the physiological 
importance of the high affinity enzymes, a theoretical 
analysis of the functioning of high and low affinity 
enzymes in the regulation of the concentration of cyclic 
AMP in cells also indicates a role for the latter form 
(Fell, 1980).
2.5.2 Multiple forms of phosphodiesterase
It is now clear that most cells contain multiple 
forms of phosphodiesterase activity with different affinities 
for their substrates. These conclusions are based partly on 
the non-linearity of Lineweaver-Burk or Hofstee-Eadie plots 
of kinetic data obtained from studies of tissue homogenates 
or partially purified enzyme preparations (Brooker et al., 
1968; Beavo et al., 1970; Huang and Kemp, 1971; Thompson and 
Appleman, 1971a; Weiss et al., 1972). The anomalous kinetic 
data could also be explained by a single enzyme exhibiting 
negative co-operativity (Russell et al., 1972) but 
corroborative evidence for multiple molecular forms of cyclic 
nucleotide phosphodiesterase came from the physical separation 
of enzyme species. This was first achieved by Thompson and 
Appleman (1971a,b) for the enzymes from a variety of tissues, 
using gel filtration techniques. A range of methods have now
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been applied to separate the multiple phosphodiesterase 
forms. These include gel filtration (e.g. Thompson and 
Appleman, 1971b; Ball et al., 1980; Onali et al., 1981), 
starch gel electrophoresis (e.g. Monn and Christiansen, 
1971), anion exchange chromatography (e.g. Russell et al., 
1973; Wells et al., 1975; Ball et al., 1980; Onali et al., 
1981), polyacrylamide gel electrophoresis (e.g. Uzunov 
and Weiss, 1977; Hait and Weiss, 1979), sucrose density 
gradient centrifugation (e.g. Thompson et al., 1973;
Epstein et al., 1977; Pledger et al., 1979; Ayad and 
Tobia, 1980) and isoelectric focussing (e.g. Pledger 
et al., 1974).
The multiple enzyme forms of mammalian tissues 
demonstrate characteristic substrate affinities, kinetic 
behaviour, molecular sizes and sensitivities to inhibitors 
and activators. These properties have been extensively 
reviewed (Appleman et al., 1973; Amer and Kreighbaum, 1975; 
Appleman and Terasaki, 1975; Weiss, 1975; Chasin and 
Harris, 1976; Weiss and Hait, 1977; Wells and Hardman,
1977; Amer, 1978; Gain and Appleman, 1978; Stefanovitch, 
1978; Strada and Thompson, 1978; Thompson and Strada, 1978; 
Weiss and Levin, 1978; Stoclet, 1979).
The terminology most frequently used to describe 
the different forms is that of Russell et al. (1973) .
DEAE-cellulose chromatography of liver extracts prepared 
by homogenization, sonication and centrifugation showed 
the presence of three active peaks, referred to as DI, DII 
and Dill (reflecting the order of elution from the column 
by a salt gradient). The first peak (DI) is a soluble
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enzyme with a high affinity (low Km) for cyclic GMP 
and a low affinity (high Km) for cyclic AMP. This 
has been referred to as a cyclic GMP phosphodiesterase 
(Gain and Appleman, 1978) and is activated by Ca2+ plus 
a protein factor (see Section 2.5.3). The second peak 
(DII), also a soluble enzyme, has a low affinity for 
both cyclic AMP and cyclic GMP. This has been referred 
to as a cyclic nucleotide phosphodiesterase; the 
hydrolysis of cyclic AMP by this form can be stimulated 
by cyclic GMP (Gain and Appleman, 1978). The third peak 
(Dill) is associated with the particulate fraction of 
the cell and has a high affinity for cyclic AMP.
Referred to as a cyclic AMP phosphodiesterase, this form 
exhibits negative co-operativity with respect to its 
substrate (Gain and Appleman, 1978).
It is important to appreciate that although 
kinetically distinct forms of phosphodiesterase can be 
obtained from a variety of mammalian tissues, using a range 
of different techniques, the properties and regulation of 
these forms will not always be similar to those described 
above for rat liver. Analysis of rat and bovine heart 
activities, separated by DEAE cellulose chromatography, 
showed some similarities to the liver enzymes (Russell 
et al., 1973) but also notable differences (Appleman and 
Terasaki, 1975; Terasaki and Appleman, 1975; Ho et al., 
1976). The v?ork of Thompson et al. (1976 , 1980a,b) on
the characterization of phosphodiesterase enzymes in 
human peripheral blood lymphocytes and monocytes is also 
illustrative. The mononuclear leukocytes contain cyclic AMP
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phosphodiesterase enzymes that differ from those of other 
mammalian tissues. They exhibit soluble, low molecular 
weight, high affinity forms but are devoid of higher 
molecular weight, low affinity enzymes and also cyclic 
GMP phosphodiesterase activity. In contrast to human 
lymphocytes, the murine cells contain both cyclic AMP 
and cyclic GMP phosphodiesterase activities (Hait and 
Weiss, 1977; Weiss and Winchurch, 1978; Hait and Weiss,
1979) .
Pichard and Cheung (1976), and more recently 
Ayad and Tobia (1980) , have suggested that the different 
forms of phosphodiesterase activity may be interconvertible. 
In the former study, extracts of rat liver and human 
platelets displayed three peaks of phosphodiesterase 
activity separable in a continuous sucrose density 
gradient. Any one of these three forms, upon recentrifu­
gation on the gradient, could generate the other two, 
implying that the multiple forms represent different 
aggregated states of the enzyme. The equilibrium between 
the different forms could be altered in vitro by enzyme 
concentration and dibutyryl cyclic AMP. The phosphodiesterase 
activity and apparent Km values were also affected by 
enzyme concentration. Association/dissociation affected the 
hydrolysis of cyclic AMP and cyclic GMP in an opposite 
manner, suggesting that the cyclic AMP and cyclic GMP 
phosphodiesterases are probably separate. It was 
hypothesised that, as dibutyryl cyclic AMP induced a shift 
towards the dissociated form which was more active towards
cyclic AMP, a self-regulating mechanism to rapidly hydrolyse
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cyclic AMP after adenylate cyclase activation may exist.
Whether the different forms of phosphodiesterase 
enzymes are discrete entities or represent interconvertible 
forms due to aggregation/disaggregation is at present 
unclear. It is apparent from the literature that different 
tissues display multiple phosphodiesterase activities which 
can be separated by a variety of techniques. The use of 
several separation procedures and enzyme classifications 
often makes it difficult to compare and interpret results 
from different laboratories. It would seem, therefore, that 
the kinetic complexity and modes of regulation of the 
phosphodiesterases will best be elucidated by the use of 
highly purified preparations of the enzymes (e.g. Klee 
et al. , 1979; Morrill et al., 1979; La Porte et al., 1979; 
Sharma et al., 1980).
2.5.3 Regulation of cyclic nucleotide phosphodiesterase 
by calmodulin
Kakiuchi and Yamazaki (1970) first reported that 
phosphodiesterase activity was regulated by micromolar 
concentrations of free Ca2 + . The Ca2+-dependent enzyme 
was stimulated by a heat stable trypsin-sensitive factor 
that corresponded to the protein activator of phosphodiesterase 
first reported by Cheung (1970). This factor has been variously 
referred to as protein activator, modulator protein, Ca2+- 
dependent regulator protein (CDR) or troponin C-like protein. 
These titles have now been superseded by the term calmodulin 
(Cheung, 1980; Means and Dedman, 1980).
In most tissues studied thus far, calmodulin is a 
potential regulator of the rate of cyclic nucleotide
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degradation by its action on cyclic nucleotide 
phosphodiesterases (Wells and Hardman, 1977; Wolff and 
Brostrom, 1979; Wang and Waisman, 1979). The Ca2+- 
dependent interaction of calmodulin with a variety of 
enzyme systems appears to involve at least two stages. 
Calmodulin (CaM) initially binds Ca2 + :
CaM + nCa2^ ^ =" » CaM-Ca 2+^ — ► CaM*C.a 2 +n n
The binding of calcium is accompanied by a 
conformational change and calmodulin in this altered 
state interacts with an enzyme which may be inactive 
or partially active. This interaction results in 
activation of the enzyme:
CaM*Ca 2+ + En* ^  » CaM^a 2 + - Enz^~ ► CaM?Ca 2 + <Enz*n n ^ n
A recent study (Huang et al., 1981) suggests that 
the mechanism of activation of cyclic nucleotide 
phosphodiesterase requires the binding of 4 Ca2+ to each 
calmodulin molecule.
The DI form (soluble, high affinity for cyclic 
GMP, low affinity for cyclic AMP) of the enzyme appears to 
require calmodulin to express maximal activity (Appleman 
and Terasaki, 1975; Kakiuchi et al., 1975). The Dill form 
(particulate, high affinity for cyclic AMP) has been 
considered to be independent of calmodulin (Kakiuchi et al., 
1975; Wolff and Bronstrom, 1979; Klee et al., 1980).
However, Smoake et al. (1981) have reported the presence
of a calmodulin-dependent, high affinity cyclic AMP 
phosphodiesterase in membranes of hamster liver. These
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membranes, prepared by differential centrifugation and 
continuous sucrose gradient centrifugation, contain cyclic 
AMP phosphodiesterase activity and calmodulin. The enzyme 
activity was reduced by ethylene glycol bis (ß-amino- 
ethylether) N,N'-tetraacetic acid (EGTA, a chelator of 
Ca2 + ions) or LaCl3 (La3+ acts as a competitive inhibitor 
of Ca2 + ). Solubilization of the enzyme with Triton X-100 
and chromatography on DEAE cellulose to remove endogenous 
calmodulin resulted in an enzyme that could be stimulated 
by exogenous calmodulin, this activation being blocked by 
EGTA. Clearly a more definitive classification of the forms 
of phosphodiesterase that are sensitive to calmodulin 
activation coupled with their tissue and subcellular 
localization and substrate specificities is required.
The activation of the enzyme is a reversible 
process, occurring in two stages as outlined above. A Ca2+- 
dependent, Mg2+-independent complex between calmodulin and 
phosphodiesterase has been demonstrated by gel filtration 
experiments (Teshima and Kakiuchi, 1974; Lin et al., 1975). 
In the absence of calmodulin, highly purified enzymes 
exhibit a low level of activity towards both cyclic GMP and 
cyclic AMP and the kinetics are often non-linear (Ho et al., 
1977; Klee et al., 1979; LaPorte et al., 1979; Morrill 
et al., 1979). With saturating concentrations of calmodulin 
the kinetics of hydrolysis become linear and the Vmax is 
increased 6-15 fold, depending upon assay conditions and 
enzyme preparation. The apparent Km values are either 
slightly decreased or unchanged (Klee et al., 1979;
Morrill et al., 1979).
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The regulation of phosphodiesterase activity by 
Ca2+*calmodulin, and also the effects of Ca2+♦calmodulin 
upon adenylate cyclase activity (for reviews see Wolff 
and Bronstrom, 1979; Klee et al. , 1980), serves to 
re-emphasise the intimate relationship between cyclic 
nucleotide metabolism and intracellular calcium ion 
distribution in the control of cellular processes.
2.5.4 Hormonal control of phosphodiesterase activity
The recognition of multiple molecular species of 
phosphodiesterase with differing sensitivities to a variety 
of agents greatly enhanced the probability that they would 
be active participants in the regulation of biological 
processes. Phosphodiesterase activity and subcellular 
distribution can be altered in a number of different 
physiological and pathological conditions (e.g. Takemoto 
et al., 1979; Nagasaka and Hidaka, 1980; Sharma and 
Bhalla, 1980; Smoake and Solomon, 1981). Alterations in 
neoplastic tissues are discussed in more detail in 
Section 3.5. The hormonal regulation of phosphodiesterase 
activity has been extensively reviewed (Appleman et al., 
1973; Wells and Hardman, 1977; Strada and Thompson, 1978; 
Thompson and Strada, 1978). Current understanding of the 
regulatory systems implies that there are at least two 
major control mechanisms. One, which can be termed 'short­
term activation', involves the stimulation of the activity 
of pre-existing enzyme molecules and does not require 
protein synthesis. The second, which can be termed 'long­
term induction', requires new RNA and protein synthesis.
No attempt has been made to compile an exhaustive survey
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of the available literature relating to hormonal effects 
upon phosphodiesterase activity. Recent studies are used 
to illustrate 'short-term activation' and 'long-term 
induction'. Clearly, in light of the previous discussion, 
when studying the effect of an agent upon enzyme activity 
it is advisable to separate the multiple forms in order 
to determine the specificity, or otherwise, of that agent.
2.5.4.1 'Short-term activation'
The activation by insulin of cyclic nucleotide 
phosphodiesterase represents the most comprehensively 
studied system. Insulin effects have been reported for 
liver and adipose tissue, skeletal muscle and cells in 
culture (Thompson and Strada, 1978). Early, unsuccessful 
attempts to demonstrate an effect of insulin (reviewed by 
Appleman et al., 1973) were principally due to an inability 
to analyse the high affinity cyclic AMP phosphodiesterase 
activity (i.e. the Dill form). Loten and Sneyd (1970) and 
Loten (1970) first reported that insulin increased the 
activity of this enzyme. In these studies insulin increased 
the Vmax, having no effect upon the Km. These effects were 
localised to a particulate high affinity enzyme by 
differential centrifugation and discontinuous sucrose- 
gradient centrifugation (Manganiello and Vaughan, 1973; 
Sakai et al., 1974; Zinman and Hollenberg, 1974). The 
recent work of Marchmont and Houslay (1980a,b,c; 1981a,b) 
has thus far provided the most convincing explanation of 
the mechanism by which insulin causes this activation of 
phosphodiesterase activity. These studies can be
summarized:
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(1) The cyclic AMP phosphodiesterase activity of 
purified rat liver plasma membranes can be 
divided into a high Km (low affinity) 'intrinsic' 
enzyme exhibiting normal Michaelis-Menten kinetics 
and a low Km (high affinity) 'peripheral' enzyme 
demonstrating negative cooperativity with respect 
to its substrate.1 * The low Km enzyme was distinct 
from cytosolic forms and bound with a high affinity 
to a protein site on the plasma membrane.
(2) Incubation of membranes with insulin, cyclic AMP 
and Mg2+-ATP together resulted in a doubling of 
phosphodiesterase activity. This activation was 
only obtained when all three constituents were 
present in the preincubation and when native 
insulin was used. It was maximal within three 
minutes and confined to the peripheral enzyme 
which could be solubilized from the membranes by 
high ionic strength treatments in a 2.5-fold 
activated state.
(3) Dose response curves for insulin's activation 
indicated a Ka of 1.4 x IO“10 M. The dependence 
upon cyclic AMP exhibited a Ka of 1.6 x 10”6 M, 
indicating that at basal cyclic AMP levels
(3-5 x 10“7 M) little, if any, insulin activation 
could be achieved. Elevation of cyclic AMP levels 
(to 2-4 x 10~6 M) by glucagon would facilitate the 
activation by insulin.
1 ' Intrinsic' implies binding to membranes through extensive
hydrophobic interactions, whilst 'peripheral' implies
binding predominantly by electrostatic interactions.
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(4) The dependence upon both cyclic AMP and Mg2+-ATP 
indicated the involvement of a cyclic AMP-dependent 
phosphorylation. Addition of the specific protein 
inhibitor (see Section 2.4) of cyclic AMP-PK 
prevented activation of the phosphodiesterase in a 
dose-dependent manner.
(5) Preincubation of membranes with insulin, cyclic AMP 
and [3 2P]-ATP, followed by polyacrylamide gel 
electrophoresis of the peripheral proteins, resulted 
in three distinct peaks of radioactivity, with the 
major peak co-migrating with the peripheral 
phosphodiesterase activity. 32P-incorporation could 
be inhibited by omission of insulin or cyclic AMP
or by the addition of the protein kinase inhibitor.
The dose response curves for 32P-incorporation 
yielded Ka’s for insulin and cyclic AMP that were 
identical to the Ka values for phosphodiesterase 
activation.
These findings await confirmation by other 
laboratories. However, it is interesting to note that 
Ball et al. (1980) obtained a rapid activation of one
form of phosphodiesterase activity in myoblasts exposed 
to dibutytyl cyclic AMP. This activation could be 
demonstrated in cell free extracts, was dependent upon 
both cyclic AMP and ATP and was inhibited by the protein 
kinase inhibitor. Sharma et al. (1980) reported that the
highly purified, calmodulin-dependent phosphodiesterase 
enzyme from bovine brain is a substrate for the catalytic 
subunit of cyclic AMP-PK. This phosphorylation was specific
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because two cyclic nucleotide-independent kinases did not 
catalyse incorporation of 32P.
2.5.4.2 'Long-term induction*
Persistent exposure of some cell types to 
adenylate cyclase agonists, agents that inhibit 
phosphodiesterase activity or exogenous cyclic AMP (i.e. 
conditions that elevate endogenous cyclic AMP levels) 
causes an induction of phosphodiesterase activity that 
is dependent upon new RNA and protein synthesis (D'Armiento 
et al. , 1972; Uzunov et al., 1973; Russell and Pastan, 1974; 
Schwartz and Passonneau, 1974; Oleshansky and Neff, 1975; 
Browning et al., 1976; Ross et al., 1977; Duttagupta et al., 
1978; Ball et al., 1980). Cyclic AMP-dependent protein 
kinase has been implicated in this process (Bourne et al., 
1973). The studies of Schwartz and Costa (1980a,b) and 
Onali et al. (1981) are illustrative of the postulated 
sequence of events responsible for enzyme induction. 
Continuous exposure of C6 glioma cells to isoproterenol 
resulted in a ß-adrenergic receptor-mediated activation 
of adenylate cyclase and a rapid increase in intracellular 
cyclic AMP levels. Soluble cyclic AMP-dependent protein 
kinase (type II in C6 glioma cells) is activated and a 
translocation of catalytic subunits to the nucleus occurs, 
this being maximal after 45-60 minutes. There follows a 
delayed (3-4 hour) increase in cyclic AMP phosphodiesterase 
activity. This induced activity, limited to the soluble 
fraction, could be reproduced by incubating cells with 
8-bromo cyclic AMP but not 8-bromo cyclic GMP. DEAE 
Sephacel chromatography of a 100,000 x g supernate resolved
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two peaks of cyclic nucleotide phosphodiesterase 
activity in these cells. The first, hydrolysing both 
cyclic AMP and cyclic GMP, was sensitive to 
Ca2+*calmodulin whilst the second was specific for 
cyclic AMP and Ca2+*calmodulin insensitive. Isoproterenol 
selectively increased the specific activity of this 
second peak.
It is not clear whether all cell types exhibiting 
induced enzyme activity utilize the sequence of events 
described above. A careful dissection of the systems 
involved is required. These studies emphasise that the 
multiple forms of phosphodiesterase can be independently 
regulated. More studies are needed on the possible 'short­
term activation' and 'long-term induction' control of the 
cyclic GMP and cyclic nucleotide phosphodiesterases (i.e. 
types DI and DII).
CHAPTER THREE
CYCLIC NUCLEOTIDE METABOLISM IN NEOPLASTIC CELLS
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3.1 Cyclic Nucleotides and Cellular Proliferation
In 196 8 Biirk observed that exogenous cyclic AMP 
or inhibition of phosphodiesterase activity slowed the 
growth of a baby hamster kidney (BHK) cell line. BHK cells 
transformed by polyoma virus were also found to have a 
lower basal adenylate cyclase activity when compared to 
untransformed cells. Ryan and Heidrick (1968) also 
observed inhibition of cell division by exogenous cyclic AMP 
in HeLa and Strain L cells, with the inhibition being 
reversible upon removal of the cyclic AMP. These early 
studies provided the impetus that has resulted in a vast 
literature attempting to equate the intracellular levels 
of cyclic nucleotides with the growth rate or growth state 
of a variety of different cell types. This highly contro­
versial premise has been extensively reviewed (Whitfield 
et al. , 1973; Ryan and Heidrick, 1974; Chlapowski et al., 
1975; Pastan et al., 1975; Friedman et al., 1976;
Whitfield et al., 1976 a,b; Rebhun, 1977; Whitfield et al., 
1979; Hunt and Martin, 1980; Whitfield, 1980) and is 
considered only briefly here to demonstrate the existence 
of generalizations suggesting that aberrant cyclic 
nucleotide metabolism may be involved in the generation 
and/or maintenance of the neoplastic state.
A large proportion of the many studies of cyclic 
nucleotides in cultured cells have taken advantage of 
continuous cell lines (for example, fibroblasts, Chinese
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hamster ovary cells, HeLa cells) that are highly adapted 
to in vitro tissue culture conditions. This practice, 
which makes extrapolation of data to the physiological 
state difficult, has continued despite strong criticism 
(Hayflick, 1975). The growth pattern of these cells in 
culture is characterized by an exponential phase followed 
by cessation of growth in a monolayer.
The hypothesis that basal levels of cyclic AMP 
are involved in the regulation of cell growth and its 
normal cessation was based upon reports which suggested 
that the growth rates of cultured cells were inversely 
proportional to the intracellular cyclic AMP concentration, 
and that so-called 'contact-inhibited' cells contained 
elevated cyclic AMP levels when compared to similar, but 
growing cells (Heidrick and Ryan, 1971; Otten et al., 1971; 
Froehlich and Rachmeler, 1972; Otten et al., 1972; Anderson 
et al. , 1973; Rudland et al., 1974a).1 Other reports 
suggested that it was the depletion of serum factors by the 
cells which signalled the increase in cyclic AMP and not 
'contact'- or 'density'-dependent inhibition of cell growth 
(Sheppard, 1972; Siefart and Paul, 1972; Kran et al., 1973; 
Oey et al., 1974) . Haslam and Goldstein (1974) reported 
cyclic AMP levels to decrease from the time of subculturing 
till density dependant cessation of growth in two strains 
of human skin fibroblasts. Burstin et al. (1974) and Oey
et al. (1974) have shown that cyclic AMP levels fall when
3T3 fibroblasts become density restricted or when various
Growth is used in the sense of proliferation as opposed to an increase 
in cell size.
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strains of SV-40 transformed 3T3 cells become confluent. 
Clearly these results are anomalous.
Several studies have shown that cells released 
from quiescence (e.g. by the addition of fresh serum) 
undergo an immediate fall in cyclic AMP concentration 
(Otten et al., 1972; Sheppard, 1972; Oey et al., 1974;
Rudland et al., 1974b; Moens et al., 1975). Whether this 
is a prerequisite for the reinitiation of cell growth, 
and whether the temporal relationship between alterations 
in nucleotide concentration and initiation of DNA synthesis 
is correct, remains uncertain (Friedman, 1976).
The levels of cyclic nucleotides during the 
progression of the cell cycle have also been extensively 
studied (e.g. Sheppard and Prescott, 1972; Millis et al., 
1972; Russell and Stambrook, 1975; Costa et al., 1976a;
Costa et al., 1978) . The phases of the cell cycle referred 
to are those defined by Howard and Pelc (1953) shown 
schematically in Figure 3.1. Cell synchronization is 
usually achieved by thymidine blockade of DNA synthesis 
or by shaking cells in mitosis from the substratum. The 
cyclic nucleotide concentration profiles obtained as cells 
pass through the Gi, S and G2 phases to mitosis vary from 
one report to another. This could result from different 
methods used to synchronize cell populations, the different 
cell types used or the different culture conditions employed. 
Cyclic AMP levels have been consistently observed to be 
lowest when the cells are in mitosis. In contrast to these 
cell cycle fluctuations observed in cultured cell lines, 
no changes in the intracellular levels of cyclic AMP or
THE CELL CYCLE
FIGURE 3.1
DIAGRAMMATIC REPRESENTATION OF THE CELL CYCLE 
(After Howard and Pelc, 1953).
M = Mitosis 
S = DNA synthetic phase 
Gx = Gap 1 
G^  = Gap 2
G0 = A resting, non cycling population which can 
readily be recruited into Gx
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cyclic GMP were observed in sea urchin or amphibian eggs 
from fertilization through to cleavage (Pays-de Schütter 
et al. , 1975; Rebhun, 1977). These observations suggest 
that changes in intracellular cyclic nucleotides are not 
a prerequisite for proliferation in all cell types.
Further evidence in support of this statement comes from 
the work of Tomkins and coworkers using mutant cell lines 
derived from S49 lymphoma cells (Bourne et al., 1975; 
Coffino et al., 1975; Daniel et al., 1975; Coffino et al., 
1976). A mutant line was isolated that contained no cyclic 
AMP binding sites and no detectable cyclic AMP-dependent 
protein kinase activity. As cyclic AMP is without its 
effector systems it should theoretically have no effects 
on this cell line. Elevation of endogenous cyclic AMP or 
application of exogenous cyclic AMP did not affect the 
growth rate of these cells whilst the parental cell line 
responded to these treatments with a slowing of growth 
rate. Both parental and mutant lines had similar cell 
cycle characteristics in the absence of artificially- 
induced changes in cyclic AMP, suggesting that, in this 
cell type at least, the timing of the cell cycle is not 
determined by intrinsic changes in cyclic AMP metabolism.
Effects of exogenously added cyclic AMP on the 
growth of cultured cells has been studied in detail 
(reviewed in Ryan and Heidrick, 1974; Chlapowski et al., 
1975; Pastan et al., 1975). Cyclic AMP itself does not 
readily enter cells and the dibutyryl and monobutyryl 
derivatives have frequently been used in such studies. 
These derivatives are metabolised by cells and butyrate,
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5'-AMP and adenosine have all been observed as products.
It is possible that effects of these agents upon cellular 
functions have been ascribed to cyclic AMP (Prasad and 
Sinha, 1976) because of poorly controlled studies.
Numerically the reports which suggest that exogenous 
cyclic AMP or its derivatives inhibit cellular prolifera­
tion are more prevalent than observations to the contrary. 
However, the addition of moderate concentrations of the 
nucleotide or its derivatives has been shown to facilitate 
growth of some cell types (e.g. MacManus and Whitfield,
1970; Filosa et al., 1975; Short et al., 1975; Green, 1978; 
Raff et al., 1978; Marcelo, 1979; Nishimune et al., 1981).
The recent work of Brtfnstad and Christoffersen (1980) may 
provide a partial explanation for these discrepancies.
Using primary cultures of rat hepatocytes isolated and 
seeded after partial hepatectomy they observed that 
isoprenaline, a ß-adrenergic agonist that increases cyclic 
AMP accumulation in these cells, exerted biphasic actions 
on DNA synthesis that were dependent upon the concentration 
of the agonist. At low concentrations (10~10 - 10-8 M) the 
incorporation of thymidine into DNA was stimulated, at 
intermediate concentrations (10“7 - 10-6 M) there was no 
effect and at higher concentrations (>10~6 M) there was a 
significant inhibition. Glucagon (4 x 10""11 - 10“ 7 M) also 
stimulated thymidine incorporation into DNA, as did dibutyryl 
cyclic AMP (10 ~ 9 - 10 5 M). Clearly, in view of these 
results, early studies that often used millimolar 
concentrations of exogenous cyclic AMP should be treated
with some caution.
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Several studies have shown cyclic GMP levels 
to fall as cells become quiescent, either as a result of 
serum restriction or density-dependent inhibition. The 
converse to this has also been reported (Rudland et al., 
1974a,b; Seifart and Rudland, 1974a,b; Moens et al. , 1975).
Therefore, the results of studies on the role of 
cyclic nucleotides in cellular proliferation, as discussed 
briefly above and reviewed extensively elsewhere, are 
often found to be contradictory. However, generalizations 
may frequently be cited in the literature. As Goldberg 
(1980) comments:
The first decade of work was predicated on the 
'second messenger' concept developed by 
Sutherland and his colleagues. It was natural, 
therefore, for investigations during this 
period to focus on correlating changes in the 
levels of cyclic AMP and cyclic GMP with the 
proliferative status of the cell and also on 
the effects of exogenous cyclic nucleotides 
(usually analogues) to promote or inhibit 
proliferation or differentiation. The results 
of these experiments have been far from 
uniform but the conclusion from a very 
significant number is that increased cyclic 
AMP is generally associated with inhibitory 
and increased cyclic GMP with stimulatory 
influences on cell proliferation.
This approach, and the potentially misleading 
assertions that have evolved from it, is today recognised 
as an oversimplification of a highly complex regulatory 
system, the basis of which still remains elusive. However 
the literature continues to expand with positive and 
negative reports of cyclic nucleotide fluctuations being 
related to growth rate, growth state and cell cycle 
progression (e.g. Ahn et al., 1978; Richman et al., 1980;
Knightbridge and Ralph, 1981; Oleinick et al., 1981).
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The association most frequently quoted in the 
literature is one between enhanced proliferation and 
decreased intracellular cyclic AMP and/or increased 
cyclic GMP. This prompted the study of cyclic nucleotide 
levels and the activities of the related enzymes in 
tumour cells. The results of these studies are now 
discussed in detail.
3.2 Intracellular Concentrations of Cyclic Nucleotides
in Tumour Cells
The concentrations of cyclic AMP and cyclic GMP 
in established tumours, transplanted tumours and cultured 
neoplastic cell lines of both human and animal origin have 
frequently been reported in the literature. A summary of 
some of the available data is presented in Table 3.1 where 
a classification has been made based upon the organ of 
origin. The correct, or most appropriate, way to express 
results is a matter of some controversy and often makes 
the literature difficult to interpret. Several 
alternatives are available including 'per unit wet weight', 
'per unit protein', 'per unit DNA' or 'per unit RNA'.
Minton et al. (1976) propose that the use of wet weight,
to express the tissue concentrations in terms of fluid, 
represents the most valid method. The use of 'per unit 
DNA' seems inappropriate as tumour cellularity may be 
markedly altered when compared to that of normal tissue. 
Theoretically, the use of 'per unit protein' also seems 
inappropriate as tumour cell protein content may be 
different from that in normal cells. However, most 
reports have expressed cyclic nucleotide concentrations
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in terms of 'per unit wet weight' or 'per unit protein' 
and qualitatively, at least, there seems to be no 
difference between these two methods (Hickie et al.,
1974; DeRubertis and Craven, 1976) although exceptions 
are apparent (Rillema et al. , 1978). Rung et al. (1977) 
studied cyclic nucleotide concentrations in normal, 
dysplastic and neoplastic human mammary tissue and 
observed that the cyclic AMP and cyclic GMP concentrations 
are elevated in neoplasia if results are expressed 'per 
unit wet weight' or 'per unit protein'. By microscopic 
observation of the tissues they observed an increased 
cellularity in the tumour such that if results are 
expressed on a 'per cell' basis the concentration of both 
nucleotides are lower in the neoplastic tissue. This 
method seems less justified than expressing results in a 
way that indicates an actual concentration.
This problem of correct expression of results 
not only applies to the tissue concentrations of the 
cyclic nucleotides but also to the enzymes involved in 
their metabolism. This can best be highlighted if the 
results of Rillema et al. (1978) are considered. The
concentrations of cyclic AMP and cyclic GMP and the 
activities of the respective cyclase and phosphodies­
terase enzymes were assessed in 9,1O-dimethyl-1,2-benz­
anthracene-induced mammary tumours in rats and in normal 
mammary tissue. Cyclic AMP levels were elevated in 
tumours if expressed 'per unit protein, RNA or wet 
weight' but unaltered if expressed 'per unit DNA'.
Cyclic GMP levels were lower in tumours if expressed
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'per unit protein or DNA' but unaltered if expressed 
'per unit RNA or wet weight'. Adenylate cyclase 
activity was elevated irrespective of the method 
chosen to express results. Guanylate cyclase activity 
was unaltered except when expressed 'per unit DNA' 
where there was a 50% decrease in tumour tissue. The 
phosphodiesterase activities, expressed 'per unit RNA 
or wet weight', were elevated in tumours whilst on 
the basis of 'per unit DNA or protein' the activities 
were similar to, or less than, control tissue. Clearly 
caution must be exercised before making any quantitative 
judgement on the concentration of a cyclic nucleotide 
or the activity of an enzyme, especially when the 
result is only expressed in one way. It is probably 
best, where possible, to utilize both 'per unit wet 
weight' and 'per unit protein' measurements. These 
problems will be compounded when the tumour of interest 
represents a very heterogeneous mixture of cell types 
such as that found in human breast carcinomas.
A further problem exists in that tissues or 
cells must be rapidly obtained so that the enzymes that 
synthesize and degrade the compounds to be measured can 
be irreversibly inactivated. This is discussed in more 
detail in Section 4.2.3, but is especially applicable 
to human tissues obtained at surgery and renders 
results obtained from such studies difficult, and 
possibly misleading, in their interpretation.
As can be observed from Table 3.1, the 
concentrations of both cyclic AMP and cyclic GMP in
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tumours can be decreased, unaltered or increased when 
compared to control values. Where possible a comparison 
has been made between tumour tissue and control tissue 
obtained from animals that do not bear the primary or 
transplanted tumour. This is especially relevant to 
transplantable hepatomas where so-called 'uninvolved' 
tissue from the organ of the same animal often exhibits 
an altered cyclic nucleotide concentration when compared 
to normal tissues from non-tumour bearers (e.g. DeRubertis 
and Craven, 1976).
Leukemic cells, in general, have lower cyclic AMP 
concentrations than control cells (Carpentieri et al.,
1980a;Peracchi et al., 1980) although elevated levels have 
been reported (Masaracchia and Walsh, 1976; Polgar et al., 
1977). Such anomalies remain to be resolved. It is 
important to appreciate that biochemical observations on 
cells such as chronic lymphocytic leukemic lymphocytes 
(which are of B-lymphocyte origin) almost invariably, and 
incorrectly, rely on the use of human peripheral blood 
lymphocytes (a mixed lymphocyte population) as control 
material. The use of 'pure' B-lymphocyte preparations 
isolated from blood may provide more suitable controls, 
however, these will still consist of varying proportions 
of cells differing in function and immunological type.
The likelihood of obtaining, in sufficient numbers to 
allow biochemical analysis, immature B-lymphocytes at a 
similar stage of differentiation seems at the present 
time remote (Tisdale and Thomson, 1980). It has been 
shown recently that purification procedures applied to
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lymphocytes can cause marked changes in the intracellular 
concentrations of cyclic nucleotides, hence making the 
use of such purified populations invalid in the context 
of this discussion (Goffstein et al., 1980).
Transplantable Morris hepatomas have proved to 
be very convenient for experimental manipulation and as 
such have been studied in some detail. As can be seen 
from Table 3.1 cyclic nucleotide levels may be decreased, 
normal or increased when compared to normal liver tissue. 
Although attempts have been made to correlate intracellular 
concentrations of cyclic nucleotides with the growth rate 
of the hepatomas (i.e. slow, medium and rapidly growing 
cell lines are available) few general conclusions can be 
made (Hunt and Martin, 1980). It is interesting to note 
that induced hepatomas, using a range of carcinogens in a 
number of different laboratories, are characterized as 
having high concentrations of cyclic AMP and cyclic GMP 
(Chayoth et al., 1972, 1973; DeRubertis and Craven, 1976, 
1977; Boyd et al., 1978a,b; Br^nstad et al., 1978). The 
reason for this discrepancy between transplantable Morris 
hepatomas and chemically-induced hepatomas is unclear.
Rat mammary tumours induced by 7,12-dimethylbenz- 
anthracene are seen to have low levels of cyclic AMP 
(Cohen and Chan, 1975; Matusik and Hilf, 1976; Lee, 1980). 
Cohen and Chan (1975) reported elevated levels of cyclic 
AMP in cultured mammary adenocarcinoma cells. Whether this 
results from the cellular heterogeneity of the tumour cell 
population in vivo or the fact that the cells were
cultured in vitro is not clear. In contrast to rat models
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human mammary tumours are characterized by having high 
levels of cyclic AMP and cyclic GMP (Minton et al., 1974; 
Guerinot et al. , 1977; Kling et al. , 1977; Feller et al. , 
1979). Once again, this discrepancy remains to be resolved.
It has been suggested that the relative concen­
trations of the two nucleotides are more important than 
their independent absolute levels. An increased cyclic 
GMP to cyclic AMP ratio, supposedly characteristic of 
rapid cell proliferation, has been observed in some 
systems (e.g. Goldberg et al., 1975; DeRubertis et al.,
1976; Shima et al., 1976) whilst the converse has also 
been reported (e.g. DeRubertis et al., 1976; Hickie 
et al. , 1977; Stowe et al. , 1977).
The study of cyclic nucleotide concentrations 
in established tumours would seem to be of little value 
if nothing is known about the status of the cyclic- 
nucleotide-dependent protein kinase enzymes. Before dis­
cussing the studies of enzymes involved in the metabolism 
of cyclic nucleotides it must be stated that the 
information supplied in Table 3.1 suggests that any 
relationship between cyclic nucleotides and growth of 
established tumours in vivo must be more complex than a 
simple one between intracellular concentration and rate 
of proliferation.
3.3 Adenylate Cyclase Activity and Responses to
Agonists in Tumour Cells
The possible aberrations in the regulation of 
cyclic nucleotide metabolism both in 'normal' and neoplastic 
cells exhibiting alterations in specific functions are
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multiple and complex. In this and subsequent sections a 
theoretical discussion precedes a presentation of the 
literature available on the altered properties and 
activities of specific enzymes in tumour cells. The 
regulation of the hormone-sensitive adenylate cyclase 
enzyme could be abnormal for several reasons:
(1) The number of receptor sites for specific agonists 
may be sub- or supranormal. These receptors may 
show changes in their affinities and/or 
specificities.
(2) The production and/or expression of receptors 
that are not normally associated with, or 
detectable upon, the specific cell type may 
result in responses to 'inappropriate' agonists.
If these so-called 'ectopic' receptors are 
synthesized and expressed because of tumour- 
associated abnormalities in the transcription 
and translation of genetic information they are 
analogous to the production of 'ectopic' hormones 
and other proteins by neoplastic cells (Rees, 1976; 
Ellison, 1980; Todaro and Delarco, 1980).
(3) The ability of receptors to interact with 'N'-units 
may be impaired or enhanced.
(4) The total number of 'N'-units within the membrane 
and the ability of these to interact with receptors 
and the catalytic moiety of adenylate cyclase may 
be abnormal. The characteristics of 'N'-units 
(i.e. Ns, Ni) associated with specific receptors 
may change.
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(5) The GTPase activity, thought to represent a 
'turn-off' mechanism for activated adenylate 
cyclase may be sub- or supranormal.
(6) The total number of catalytic units and their 
ability to interact with 'N' and substrate 
may be altered. Changes in intracellular 
pools of nucleotide triphosphates could have 
effects on both 'N' and catalytic units.
Table 3.2 presents some of the available 
reports on the 'basal' activity of the adenylate cyclase 
enzyme in tumour cells. It is seen that the activity of 
the enzyme may be subnormal, normal or supranormal when 
compared to control cells. This serves to rule out a 
universal correlation between adenylate cyclase activity 
and the rate of tumour growth. Human leukemic cells have 
been reported to have subnormal basal activity (Polgar 
et al. , 1973; Sheppard et al., 1977; Mendelsohn and 
Nordberg, 1979; Peracchi et al., 1980; Carpentieri et al., 
1981) while mouse thymic lymphoma is said to exhibit 
supranormal activity (Kemp and Duquesnoy, 1974; Kemp 
et al. , 1975) . Solid tumours show no consistent 
patterns of altered basal activity. No study has clearly 
defined the cause of the abnormal 'basal' activities 
observed in tumour cells. It would seem appropriate 
that future studies focus attention on the activity of 
the GTPase and the amount of the 'N-protein' present in 
membrane preparations from neoplastic cells in an attempt 
to draw a correlation between these factors and basal 
adenylate cyclase activity.
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The effects of agonists on the accumulation of 
cyclic AMP in intact cells, or the activity of adenylate 
cyclase in broken cell preparations, from tumours may be 
subnormal, normal or supranormal when compared to control 
cells. Table 3.3 presents some information on altered 
responsiveness of the adenylate cyclase complex in 
tumour cells. As a general rule anaplastic malignant 
tumours appear more likely to exhibit alterations in the 
response of the enzyme to specific agonists than are more 
differentiated malignancies. Benign tumours can often show 
normal responses.
Hepatomas show a decreased responsiveness to 
glucagon stimulation in intact tissues or broken cell 
preparations (e.g. Christoffersen et al. , 1972; Lacombe 
et al. , 1976 ; Boyd et al., 1978a; Mirrel et al., 1978).
In certain instances this decreased response has been 
shown to be due to a decrease in the total binding 
capacity of the cells (Criss and Morris, 1976; Mirrel 
et al. , 1978; Pezzino et al., 1979) . However, Klein 
et al. (1974) reported that the binding of glucagon was
normal in the Morris hepatoma cell lines 9121 and 3924A, 
these lines still exhibiting decreased responsiveness to 
glucagon. The study of Pezzino et al. (1979) analysed the
binding of both glucagon and insulin to plasma membranes 
prepared from Morris hepatoma cell lines of varying growth 
rates. The total binding of both hormones was lower in 
hepatoma membranes when compared to control liver membrane 
preparations. The binding of 125I-glucagon in hepatomas
was greatest in the slowest growing tumour (42% of control)
110
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and lowest in the fastest growing hepatoma (1% of 
control). Although glucagon binding tended to decrease 
with increasing growth rate there was no statistically 
significant correlation between the two parameters. 
125I-insulin binding was greatest in the slow (57% 
of control) and lowest in the fast growing tumours 
(10% of control). There was a significant positive 
correlation between the decrease in insulin binding and 
the increase in growth rate.
Increased adrenergic stimulation of adenylate 
cyclase has been reported in hepatomas (e.g. Christoffersen 
et al., 1972; Boyd et al., 1974, 1978a; Christoffersen 
and Berg, 1975; Br^nstad et al. , 1978) whilst the converse 
has also been reported (Emmelot and Bos, 1971; Okamura and 
Teryama, 1976). The latter study suggested that the 
binding of epinephrine was normal despite the decreased 
response. Lacombe et al. (1976) observed an interesting
qualitative change in the adrenergic receptors of 
Zajdela hepatomas in rats. The receptors of normal liver 
displayed B2 characteristics while those of the tumour 
exhibited ßx characteristics.
The responses of hepatomas to PGE^  ^ have been 
reported to be subnormal (Okamura and Teryama, 1977) or 
supranormal (Hickie et al., 1975a; Brtfnstad et al., 1978). 
The subnormal response was associated with a loss of 
PGE1 binding. The reasons for the anomalous reports in 
the literature are unclear. Little, if any, emphasis 
has been placed upon the interpretation of responses of 
the enzyme to sodium fluoride and Gpp(NH)p. As both these
116
agents are thought to activate the enzyme via the 'N' 
protein it would be interesting to see if the responses 
to these agonists correlated with observed alterations 
in basal activity.
Leukemic cells show a depressed responsiveness 
to g-adrenergic agonists (e.g. Polgar et al., 1973, 1977; 
Kemp and Dequesnoy, 1974; Kemp et al., 1975). In human 
chronic lymphocytic leukemia this has been associated 
with a decrease in the number of available binding sites 
(Sheppard et al., 1977) . Decreased responses to a range of 
prostaglandins have also been reported (Polgar et al., 
1973, 1977; Mendelsohn and Nordberg, 1979; Carpentieri 
et al., 1981) .
The enzyme from rat adrenocortical carcinoma 494 
was observed to respond to inappropriate agonists via 
’ectopic' receptors (Schorr and Ney, 1971; Schorr et al., 
1971). Adenylate cyclase from normal adrenocortical tissue 
is stimulated by adrenocorticotrophic hormone (ACTH) and 
PGE^ The enzyme from the tumour was also stimulated by 
epinephrine, norepinephrine, thyroid-stimulating hormone 
(TSH), follicle-stimulating hormone (FSH) and leutinizing 
hormone (LH). No response was obtained for glucagon, 
vasopressin, parathyroid hormone or thyrocalcitonin. The 
stimulation of the tumour enzyme by adrenergic agonists 
was confirmed by Brush et al. (1974). Williams et al.
(1977), using [3H]-dihydroalprenolol, demonstrated the 
presence of B-adrenergic binding sites in the tumour cell 
membranes. These observations on the rat model have been 
confirmed using tissue from human adrenocortical adenomas
117
and carcinomas (Matsukura et al. , 1980). Adrenocortical 
tumours have also been found in some cases to be resistant 
to ACTH and PGE1 stimulation. This resistance has been 
characterized as a loss of binding capacity or an 
alteration in the binding affinity for ACTH and as a loss 
of binding capacity for PGE1 (Saez et al. , 1975; Tell 
et al. , 1978). Cikes (1978), in attempting to explain the 
appearance of 'ectopic' receptors, has postulated that the 
quantitative and qualitative changes observed are the 
results of 'retrogenic expression'. This implies that 
the tumour cells are demonstrating properties that are 
characteristic of certain developmental stages of the 
normal parental cells. At present there is little evidence 
either for or against this hypothesis.
The study of Boonyaviroj and Gutman (1977) on a 
human pheochromocytoma is of interest in that normal 
tissue from the adrenal medulla responded to PGEX with a 
decrease in the intracellular level of cyclic AMP, whilst 
in the tumour PGE1 stimulated the accumulation of cyclic 
AMP. Many of the clinical symptoms that are associated 
with this tumour result from the hypersecretion of 
catecholamines. Cyclic AMP has been implicated as an 
intracellular mediator of this release process. It may be 
speculated that in normal cells the PGE^  ^ receptors are 
associated with Ni units that mediate inhibition of the 
adenylate cyclase enzyme but in tumour cells the receptors 
have become associated with Ns units which mediate 
stimulation of the enzyme. This might contribute to the 
hypersecretion of catecholamines. This tumour has also
118
been shown to respond to glucagon, ACTH and TSH via 
'ectopic' receptors (Dexter and Allen, 1970; Schorr 
et al., 1972).
The work of Piot and Jacquemin (1980) on a 
spontaneous murine thyroid tumour also demonstrates 
alteration in the hormone-sensitive enzyme system.
TSH had no effect upon cyclic AMP accumulation in 
intact tissues, but was shown to stimulate the enzyme 
in broken cell preparations. In the absence of added 
GTP the stimulation produced by TSH in normal and 
tumour homogenates was similar. Addition of Gpp(NH)p 
and TSH together resulted in a much greater increase 
in the activity of the enzyme in normal tissue. The 
tumour enzyme exhibited smaller responses to both NaF 
and Gpp(NH)p. Taken together these observations suggest 
that not only is there a defect in the mechanism that 
couples events at the receptor level to the catalytic 
units, but also that there is probably a decreased 
amount of the 'N'-protein in membranes of tumour cells.
In intact cells receptors and 'N' units may be physically 
separate. Disruption of the system by homogenization might 
allow reassociation.
The TSH-responsiveness of adenylate cyclase in 
thyroid tumours has been extensively studied. Results 
are often anomalous and it should be noted that the 
responses of the enzymes from different patients or 
animals can be very heterogeneous. Toccafondi et al.
(1979) reported that the TSH responses of human thyroid 
adenomas could be subnormal, normal or supranormal.
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Sand et al. (1976) and Thomas-Morvan (1978) reported
adenomas as having normal responses, whilst DeRubertis 
et al. (1972) and Abe et al. (1981) have reported
enhanced responses. In undifferentiated thyroid carcinomas 
the response to TSH is frequently absent (DeRubertis 
et al. , 1972 ; Abe et al., 1977 , 1981 ; Origazzi et al.,
1977; Thomas-Morvan, 1978). This results from the lack of 
a high affinity receptor in the membranes of undifferen­
tiated carcinomas (Abe et al., 1977, 1981). Differentiated 
thyroid carcinomas can often show normal responses to 
TSH (Abe et al., 1977, 1981; Origazzi et al., 1977). The 
presence of a high affinity receptor has been demonstrated 
in membranes of these tumours (Ischikawa et al., 1976; Abe 
et al., 1981).
The work discussed above lends support to the 
initial statement that the possible aberrations in cyclic 
nucleotide metabolism in tumour cells are multiple and 
complex. Though no simple relationship exists between 
adenylate cyclase activity and the rate of tumour growth, 
the alterations in cell surface receptors and responsive­
ness of the enzyme will have consequences for the normal 
control of cellular metabolism and, perhaps, ultimately 
the integrated functioning of the organism as a whole.
3.4 Guanylate Cyclase Activity, Subcellular
Distribution and Responses to Agonists in 
Tumour Cells
Several possible alterations in the regulation 
of guanylate cyclase activity could occur in tumour cells: 
(1) The total amount of the enzyme may change. This 
could result in an alteration in the expression
120
of basal activity.
(2) Mechanisms responsible for modulation of basal 
activity in vivo could be altered.
(3) Subcellular partitioning between soluble and 
particulate forms of the enzyme may change.
Examples of these possibilities have been 
reported in the literature. Table 3.4 presents some 
observations on the basal activity of the enzymes from 
tumour cells compared to normal control cells. It 
should be stressed that these are results obtained from 
whole homogenates of tissues. Different separation 
protocols utilized to divide total homogenate activity 
into soluble and particulate forms makes comparison of 
results obtained from different laboratories difficult.
The total homogenate activity of tumours can be decreased 
or increased. One report failed to detect enzyme activity 
in three Morris hepatoma cell lines (Goridis and Reutter, 
1975). There is no correlation between guanylate cyclase 
activity and the growth rate of Morris hepatomas. 
Chemically-induced hepatomas exhibit an increase in enzyme 
activity (DeRubertis and Craven, 1977; Boyd et al., 1978b). 
Human renal adenocarcinoma and transplantable and hereditary 
rat renal tumours show decreased total homogenate activity 
(Criss et al., 1976b; Kim et al., 1977; Eker et al., 1979). 
Decreased activity has been reported in leukemic cells by 
Peracchi et al. (1980) whilst Carpentieri et al. (1981)
observed the converse. Different types of brain tumours 
can exhibit either increased or decreased enzyme activity 
(Frattola et al., 1976; Kumakura et al., 1977). From these
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observations it can be stated categorically that the 
neoplastic condition is not invariably associated with 
an increase in guanylate cyclase activity.
It has been suggested that the subcellular 
distribution of the enzyme is of more importance than 
its total activity. An increase in the particulate:soluble 
ratio is seen in foetal and regenerating rat liver (Goridis 
and Reutter, 1975; Kimura and Murad, 1975c). An increased 
ratio has also been observed in a number of Morris hepatoma 
cell lines (Goridis and Reutter, 1975; Kimura and Murad,
1975c; Criss et al., 1976a; Hickie et al., 1977), in 
chemically-induced hepatomas (DeRubertis and Craven, 1977; 
Boyd et al., 1978b) and in transplantable rat kidney tumour 
cell lines (Criss et al., 1976b). These observations indicate 
a possible relationship between an increased particulate: 
soluble ratio and high growth rates. However, in human renal 
adenocarcinoma a decrease in the particulate:soluble ratio 
is apparent (Kim et al., 1977). This anomaly remains 
unresolved, though clearly future studies should aim at 
substantiating or disproving this premise.
Altered responses of the enzyme in broken cell 
preparations and of cyclic GMP accumulation in intact 
tissues have been reported in tumours. Morris hepatoma 
and rat kidney tumour cell lines are unresponsive to 
azide stimulation (Criss et al., 1976a,b). The enzymes 
from ethionine-induced hepatomas exhibited a decreased 
response to azide, hydroxylamine and nitrite in broken 
cells. Carbamylcholine produced a three-fold elevation 
of cyclic GMP in slices of normal liver but had no effect
124
on the hepatoma (DeRubertis and Craven, 1977). The enzyme 
from human renal adenocarcinoma had a decreased response 
to azide (Kim et al., 1977). Intact human leukemic 
leucocytes showed no response to carbamylcholine or 
serotonin (Peracchi et al., 1980) whilst the enzyme in 
broken cell preparations was insensitive to azide and 
dehydroascorbic acid (Carpentieri et al. , 1981) . Carbamy1- 
choline failed to increase cyclic GMP in intact fragments 
of a spontaneous murine thyroid tumour (Piot and Jacquemin, 
1980). As the exact mechanisms responsible for activation 
of the enzyme in vivo under normal physiological conditions 
are still unknown (see Section 2.3) it is not possible to 
supply reasons for the apparent lack of responsiveness in 
the neoplastic state. Another interesting observation is 
that a range of chemical carcinogens are capable of 
stimulating guanylate cyclase activity, both in broken 
cell preparations and in intact tissues (DeRubertis and 
Craven, 1980a,b). However, the functional significance of 
the activation of the guanylate cyclase-cyclic GMP system 
by these compounds remains unclear.
3.5 Cyclic Nucleotide-dependent Protein Kinases
in Tumour Cells
The intracellular binding sites and activities of 
dependent protein kinases are of paramount importance as 
these are the systems by which cyclic nucleotides affect 
cellular processes. It is unfortunate that these enzymes 
have been studied infrequently in tumour cells. Some 
possible alterations in the functioning and regulation of 
these enzymes are outlined below:
125
(1) The total amount of the kinases may alter.
In the case of cyclic AMP-PK this could be 
associated with a specific effect upon either 
of the isoenzymes or a generalized effect on 
both.
(2) The ability of the regulatory subunits of 
cyclic AMP-PK, or of cyclic GMP-PK, to bind 
their respective cyclic nucleotides may be 
sub- or supranormal.
(3) Interaction of the kinases with ATP and their 
'target' substrates may be impaired or enhanced.
The expression of the protein substrates of the 
enzymes could be abnormal in pathological 
conditions.
(4) The levels of the inhibitory and stimulatory 
modulators of kinase activity may change, as 
may the systems involved in the translocation of 
kinases from the cytosolic to the nuclear 
compartment of the cell.
Alterations in protein kinase activity have been 
described as a function of cell growth rate, stage of 
differentiation and phase of the cell cycle. Lee et al. 
(1976) reported that testes from foetal and two-day old 
rats contained only Type I cyclic AMP-PK. Type II activity 
increased progressively with testicular maturation and 
differentiation and was maximal at twenty-five days, this 
coinciding with the expression of maximal capacity for 
spermatogenesis and steroidogenesis. Haddox et al. (1979)
similarly found the ratio of protein kinase Type I:Type II
126
to be elevated in the hearts of young mice compared 
to adult values. Gharrett et al. (1976) noted that
SV40 transformation of 3T3 cells resulted in the 
appearance of Type I cyclic AMP-PK which was absent 
in normal cytosol. In synchronized populations of 
Chinese hamster ovary cells Type I cyclic AMP-PK is 
elevated during mitosis and relatively depressed 
during the G1 and S phases of the cycle. Conversely 
Type II activity is low during mitosis and increases 
at the G1~S border (Costa et al. , 1976a,b; Costa et al., 
1978). Stimulation of mitogenesis in human lymphocytes 
has been correlated with activation of Type I cyclic 
AMP-PK (Byus et al., 1977) , whilst an increase in the 
activity of Type II cyclic AMP-PK has been identified as 
an early event in the cyclic AMP- or ovariectomy-induced 
arrest of growth in rat mammary carcinomas (Cho-Chung 
et al. , 1978; Shafie et al., 1979; Cho-Chung et al., 1980; 
Bodwin et al., 1981). Taken together these observations 
suggest that the emergence or dominance of Type I cyclic 
AMP-PK may be associated with active cell growth, cell 
transformation or an early stage of differentiation 
(Russell, 1978). However, DeRubertis and Craven (1980b) 
observed that the Type I cyclic AMP-PK activity did not 
vary as a function of proliferative activity or stage of 
differentiation in colonic epithelium of rats. The 
proportion of Type I activity in proliferating cells 
from the lower crypts was not significantly different 
from that of normal surface cells. Exposure of the 
epithelium to the carcinogen 1,2-dimethylhydrazine
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increased the proportion of Type I activity in both 
superficial and crypt cells, but an enhanced rate of 
DNA synthesis in the lower crypt cells was not 
associated with Type I activity in excess of that 
observed in surface cells. This suggests that any 
relationship between Type I kinase and proliferative 
activity may not be universal.
These studies emphasise the importance of 
separating the different isoenzymes of cyclic AMP-PK. 
Table 3.5 summarizes some of the reports available on 
cyclic nucleotide dependent protein kinases in tumour 
cells and it is apparent that resolution of the 
different enzymes has been accomplished in only a few 
cases. The work of Eppenburger et al. (1977, 1980) and
Handschin and Eppenburger (1979) on human mammary 
tumours tends to support the hypothesis that Type I 
kinase may be associated with proliferative activity in 
that the ratio of Type I:Type II was increased in tumour 
tissue compared to control. Similarly Fossenberg et al. 
(1978) have reported an increase in the Type I:Type II 
ratio in human renal cell carcinomas, with the general 
properties of the enzymes being similar in normal and 
tumour tissue. Tisdale and Thomson (1980), however, 
reported that in 'control' lymphocytes Type I activity 
exceeded Type II activity whilst in leukemic cells the 
isoenzyme activity ratio was reversed. D<z$skeland et al. 
(1978) have shown that the Type II isoenzyme is the 
dominant form in chemically-induced carcinomas of the 
uterus in mice and that the elution profile from a
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DEAE-cellulose column and general properties of the 
enzymes are similar for tumour and normal epithelial 
cytosols.
Goldberg et al. (1975) found the binding of
both cyclic AMP and cyclic GMP to be decreased in a 
variety of Morris hepatoma cell lines. In the 4 cell 
lines found to have decreased binding for cyclic GMP 
the levels of the nucleotide were supranormal. Shoji 
et al. (1978) studied one of these cell lines (3924A)
further and reported the basal kinase activity to be 
increased. They suggested that the activity of cyclic 
GMP-PK and its stimulatory modulator was enhanced 
relative to cyclic AMP-PK and its inhibitory modulator. 
These results seem anomalous. The study of Shoji et al. 
(1978) is the only one to have assessed the levels of 
the protein modulators.
Granner (1972, 1974) and Mackenzie and 
Stellwagen (1974) studying the HTC hepatoma cell line 
reported a decrease in binding, and activation, of 
protein kinase by cyclic AMP. This was associated with 
the absence of a high affinity binding site in these 
cells. This observation is interesting in relation to 
the recent work of Malkinson and Butley (1981). Using 
8-azidoadenosine cyclic 3',5!-[32P]-monophosphate, a 
specific photoaffinity analog of cyclic AMP, they 
examined the binding capacity of R^ and R subunits 
from extracts of normal neonatal and adult mouse lung 
and urethane-induced lung adenomas. The ability of R 
to bind the analog was similar in all tissues examined,
132
while the binding by R was dependent upon both 
developmental stage and neoplastic state. Analysis 
of the binding indicated R to have both high and 
low affinity sites. R subunits from the tumour 
exhibited only low affinity sites while neonatal 
R showed greatly reduced binding to both sites.
The significance of these observations to tumour cell 
growth or function remain unclear but studies of this 
nature indicate that changes in the properties and 
activities of the isoenzymes in neoplastic cells may 
be subtle and undetectable by gross analysis.
Human adrenocortical tumours (Riou et al., 1977) 
have been shown to exhibit subnormal, normal or supra- 
normal basal and cyclic AMP-stimulated activities. The 
subnormal response of one tumour was associated with the 
loss of Type II kinase and the inability of cyclic AMP 
to stimulate Type I. Shanker et al. (1979) and Shanker
and Sharma (1980) have demonstrated abnormal cyclic AMP-PK 
in rat adrenocortical carcinoma 494. These enzymes, 
designated as 1autophosphorylating cyclic AMP-binding 
protein kinase 85 and 134' (AUT-PK 85,134), bind cyclic 
AMP and autophosphorylate but do not phosphorylate the 
exogenous substrates histone, casein, phosphorylase b 
or polysomes in the absence or presence of cyclic AMP.
As yet no physiological significance has been 
attributed to these enzymes and a definitive demonstra­
tion of their total absence in normal tissue is 
required.
Future studies making use of the improved
133
technology which is now available should focus their 
attention on the separation of the isoenzymes of 
cyclic AMP-PK to more clearly define possible lesions 
in their regulation. More studies on cyclic GMP-PK 
are required.
3.6 Cyclic Nucleotide Phosphodiesterases in
Tumour Cells
Some of the possible alterations in cyclic 
nucleotide phosphodiesterases of tumour cells are 
listed below:
(1) There may be an alteration in the 'total' amount
of enzyme activity as assayed in tissue homogenates. 
This could result from the selective alteration of 
any one of the multiple enzyme forms or may 
represent a generalized response of all forms 
present.
(2) There could be an alteration in the distinct 
kinetic properties, substrate affinities, etc. 
of the multiple forms and/or a shift in the 
subcellular partitioning between soluble and 
particulate fractions.
(3) The regulation of specific forms of the enzyme 
by the processes of 'short-term activation' and 
'long-term induction' may be abnormal. If 
ultimately it is shown that all cell types 
require the activation of cyclic nucleotide- 
dependent protein kinases, and in the case of 
'long-term induction' translocation of the 
kinase to the nucleus (see Section 2.5), for
134
this regulation then the presence of functional 
kinase enzymes would be a prerequisite.
(4) Alterations in the levels of calmodulin
and the subcellular distribution of calcium 
ions could alter the activity of the Ca2+* 
calmodulin responsive form of the enzyme.
Table 3.6 summarizes some of the availaable 
information on the activities of cyclic AMP and cyclic 
GMP phosphodiesterase enzymes in tumours. As stressed 
previously, the different techniques used to separate 
the multiple forms of the enzymes makes the comparison 
of results from one laboratory to another difficult.
This is further compounded by the large range of 
substrate concentrations that are used in the assay of 
phosphodiesterase activity. For these reasons the 
observations summarized in the Table represent 'total' 
homogenate activities. Future studies should endeavour 
to separate the different species of the enzymes in an 
effort to pinpoint alterations in specific forms that 
cause the changes in 'total' enzyme activity.
In leukemic cells the activities of cyclic AMP 
and cyclic GMP phosphodiesterases are reported to be 
elevated compared to control cells (Hait and Weiss, 1976, 
1977, 1979; Epstein et al., 1977; Weiss and Winchurch, 
1978). Cyclic AMP phosphodiesterase activity has also 
been reported to be decreased (Konings et al., 1974;
Scher et al., 1976) or normal (Peracchi et al., 1980). 
These discrepancies remain unexplained, though as 
discussed in Section 3.2, the use of inappropriate control
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cells makes interpretation of results obtained from 
leukemic cells difficult.
The activities of the enzymes in established 
solid tumours do not form any consistent pattern of 
alteration. It seems likely that the analysis of gross 
changes in 'total' phosphodiesterase activity is not 
the most suitable approach for studying these enzymes 
in tumour cells. This is highlighted by some observa­
tions that indicate that subtle changes in the responses 
of specific forms may be important in the control of 
cyclic nucleotide degradation in neoplasia. Takemoto 
et al. (1978) observed a consistent difference between
lymphocytes from normal donors and leukemic lymphocytes 
from patients and 'B' and 'T' leukemic cell lines. The 
cyclic AMP phosphodiesterase activity of normal 
lymphocytes was inhibited by greater than 80% by micro­
molar concentrations of cyclic GMP. These concentrations 
of cyclic GMP had little or no effect on the hydrolysis 
of cyclic AMP by the enzyme from transformed cell lines 
or from the leukemic cells of patients. Hence the 
tumour cells exhibited an alteration in the enzyme 
responsible for cyclic AMP degradation, the functional 
significance of which remains unclear.
Boyd et al. (1978b) reported that the cyclic
GMP phosphodiesterase activities in the soluble and 
particulate fractions of rat liver homogenates exhibited 
non-linear Lineweaver-Burk plots with apparent km values 
of approximately 30 and 60 yM (soluble) and 10 and 110 yM 
(particulate). In chemically-induced cholangiocarcinomas,
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however, the kinetic plots were linear with apparent 
km values of approximately 140 yM (soluble) and 80 yM 
(particulate). Again, the functional significance of 
these alterations remains to be established. Uenishi 
et al. (1980) have demonstrated that in the Morris
hepatoma cell line 3924A there is an increase in the 
amount of the Ca2tcalmodulin responsive form of 
phosphodiesterase compared to control liver. Singer 
et al. (1976) noted that the levels of calmodulin in
human mammary carcinomas are supranormal and that this 
was accompanied by an increased activity of cyclic 
nucleotide phosphodiesterases.
3.7 Cyclic Nucleotide Metabolism in the
Preneoplastic Period
The studies of altered cyclic nucleotide 
metabolism in tumour cells represent a very heterogeneous 
set of observations from which it has proved difficult to 
draw any general conclusions, particularly in regard to 
the abnormal regulation of cellular proliferation 
(Sections 3.2 - 3.6). In comparison there is a remarkable 
degree of consistency in the observations that have been 
made on aspects of cyclic AMP metabolism in what is 
referred to as the 'preneoplastic' phase of hepatic 
carcinogenesis. These observations have stemmed from 
different laboratories using a range of chemical 
carcinogens (ethionine, 2-acetylaminofluorene,
3'-methyl-4-dimethylaminoazobenzene, 4'dimethylamino- 
azobenzene). The basal adenylate cyclase activity in 
liver tissue from rats fed carcinogens is supranormal
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(Christoffersen et al. , 1972; Boyd et al. , 1974; 
Christoffersen et al., 1974; Boyd and Martin, 1976; 
DeRubertis and Craven, 1976; Boyd et al., 1978a).
The responsiveness of the enzyme to stimulation by 
ß-adrenergic agonists is also markedly enhanced 
(Christoffersen et al., 1972; Boyd et al., 1974; 
Christoffersen et al., 1974; Christoffersen and $ye, 
1974; Christoffersen and Berg, 1975; Christoffersen, 
1975; Boyd and Martin, 1976; Boyd et al., 1978a; 
Br^nstad et al., 1978). Boyd and Martin (1976) 
suggest that this is due to an increase in the total 
number of receptors and not an alteration in receptor 
affinity. Figure 3.2 and associated legend exemplifies 
these changes in the hormone-sensitive adenylate 
cyclase system. Christoffersen and 0ye (1974) have 
noted that adrenalectomy and diabetes can result in 
an increase in the adrenalin-sensitivity of hepatic 
adenylate cyclase. Measurement of the blood levels of 
corticosteroids, insulin and glucose did not indicate 
that 2-acetylaminofluorene, at least, was acting via 
altered adrenal or pancreatic function. The glucagon 
responsiveness of the enzyme has been reported to be 
subnormal (Boyd et al., 1974; Boyd and Martin, 1976), 
normal (Christoffersen et al., 1972; Christoffersen 
et al. , 1974; Christoffersen and 0ye, 1974;
Christoffersen and Berg, 1975; Boyd et al., 1978a) 
or supranormal (Br^nstad et al., 1978) during the 
preneoplastic period. Tissue levels of cyclic AMP are 
elevated in the preneoplastic period (Christoffersen
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FIGURE 3.2
ALTERATIONS IN LIVER ADENYLATE CYCLASE DURING 
CARCINOGENESIS
(After Boyd and Martin, 1976).
Sprague-Dawley rats were fed a diet ad libitum containing 
0.06% 3'-methyl-4-dimethylaminoazobenzene (3'-MeDAB). 
Control animals were fed the same diet without the 
carcinogen. At weekly intervals, up to 12 weeks, rats 
were killed in groups containing one control and two 
test animals. Binding of 3'-MeDAB metabolites to crude 
liver membrane preparations reached a peak at 3 weeks. 
Tumours were histologically detectable between 10-20 
weeks after commencement of the diet. Adenylate 
cyclase activity from carcinogen-treated animals is 
expressed as a percentage of that found in livers from 
control animals under identical conditions of assay.
A value of 100% indicates no change, and deviations 
upward or downward indicate increases or decreases in 
adenylate cyclase activity, respectively.
Basal activity 
Glucagon 10-6 M 
Isoproterenol 10-4 M
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et al. , 1974; DeRubertis and Craven, 1976 ; Boyd et al., 
1978a) and cyclic AMP-phosphodiesterase activity may be 
normal (Christoffersen et al., 1974; DeRubertis and 
Craven, 1976) or supranormal (Boyd et al., 1978a).
Basal protein kinase activity and the cyclic 
AMP-PK activity ratio are also elevated (DeRubertis and 
Craven, 1976) , suggesting that there is an increase in 
the effective, as well as total, cyclic AMP. As the 
cyclic AMP system mediates the effects of primary 
stimuli on hepatic glycogenolysis and gluconeogenesis 
these alterations should have consequences for the 
normal regulation of carbohydrate metabolism. DeRubertis 
and Craven (1976) showed that the proportion of the 
total glycogen synthetase in the physiologically active 
form was reduced in ethionine fed animals two and eight 
weeks after commencement of the diet, and that this 
reduced activity was maintained through to hepatoma 
development. These observations are interesting when 
the histological study of 3'-MeDAB hepatic carcinogenesis 
by Boyd et al. (1978c) is considered. The continuous 
feeding of the chemical resulted in a 100% incidence of 
cholangiocarcinoma by ten weeks. At three weeks, which 
coincides with the increased ß-adrenergic responsiveness 
of the adenylate cyclase enzyme, small, acidophilic 
hepatocytes were observed in the periportal regions of 
liver lobules. These cells were not necrotic, were 
actively proliferating and were deficient in glycogen. 
This type of cell persisted throughout the treatment 
period and was found in established tumours but was
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replaced predominantly by smaller cells that were also 
glycogen deficient. Boyd et al. (1978a/c) have proposed
that the altered metabolism of cyclic AMP may have a 
functional role in the carcinogenic process. It is 
postulated that the increased responsiveness of 
adenylate cyclase to stimulation by ß-adrenergic 
agonists is associated with the appearance of small 
glycogen deficient cells and represents a mechanism 
of 'initiation'. From Week 4 onwards the Gpp(NH)p 
responsiveness of the enzyme is enhanced and this 
coincides with the appearance of even smaller, 
glycogen deficient cells. Boyd postulates that this 
may be a mechanism that allows rapid promotion of 
cholangiocarcinoma development by circulating cate­
cholamines. The hypothesis is speculative and awaits 
further support, but it is interesting to note the 
observation of Br^nstad et al. (1978) that PGE1
responsiveness of adenylate cyclase, as well as 
adrenalin, altered during 2-acetylaminofluorene 
carcinogenesis, and that the two responses developed 
very differently. The adrenalin response increased 
during the first weeks of carcinogen treatment and 
then declined between Weeks 7 and 12, but never 
returned to normal control values. In contrast, the 
increased PGEi response appeared much later and was 
not maximal until hepatoma development. It is 
unfortunate that Boyd et al. (1978a) did not assess
prostaglandin responsiveness. The increased Gpp(NH)p 
response that they observed may indicate an increase
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in the amount of 'N-protein' in these membranes 
possibly facilitating enhanced responsiveness of the 
system to agonist stimulation. This could allow both 
prostaglandins and circulating catecholamines to 
promote tumour development. Trevisani et al. (1980)
have reported Yoshida hepatoma AH130 cells to produce 
more PGE2 than normal hepatocytes when incubated in 
vitro. Using cultured cells it has been shown that 
transformation by carcinogens or viruses is followed 
by an increased production of prostaglandins (Hong 
et al. , 1977). It would seem worthwhile, therefore, 
to assess the prostaglandin production by the 
chemically-induced hepatoma cells.
Alterations in hormonal responsiveness of 
adenylate cyclase during carcinogenesis may provide 
tentative support for the ’retrogenic expression’ 
hypothesis of Cikes (1978, see Section 3.3).
Christoffersen et al. (1973) observed that seven days
prior to birth rat liver contains an adenylate cyclase 
enzyme that expresses basal and fluoride stimulated 
activity. The enzyme was not responsive to glucagon or 
adrenalin. Two days before birth the basal activity 
was sensitive to fluoride, adrenalin and glucagon 
stimulation. The response to the two hormones increased 
and reached maximal values at seven days after birth, 
following which the adrenalin responsiveness gradually 
declines while the glucagon response persists.
Olsen and Russell (1979) have demonstrated 
that a single carcinogenic injection of diethylnitrosamine
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causes a rapid increase in the activity ratio of hepatic 
cyclic AMP-PK followed by the induction of ornithine 
decarboxylase (ODC), the rate limiting enzyme in the 
biosynthetic pathway of polyamines. The induction of 
this enzyme is proposed to be a marked early event in 
the initiation of cell growth, and increased enzyme 
activity and accumulation of polyamines occur during 
the growth of experimental animal tumours and human 
tumours (Jänne et al., 1978). The increased cyclic 
AMP-PK activity ratio and ODC activity resulting from 
the single injection of carinogen persisted for seven 
days compared to control animals. The isoenzyme ratio 
of Type I to Type II was unaltered. A single non- 
carcinogenic dose did not increase the activity ratio 
or result in ODC induction. It would be of interest 
to assess the induction and activity of ODC in relation 
to the changes'in cyclic nucleotide metabolism during 
hepatic carcinogenesis. It may be that the hyper­
responsiveness of adenylate cyclase to 3-adrenergic 
agonists results, via the activation of cyclic AMP-PK, 
in a primary induction of ODC and that this is 
maintained following the decline in adrenergic respon­
siveness by the emergence of further altered 
characteristics of the enzyme, e.g. enhanced PGE1 
responsiveness (Br^nstad et al., 1978).
The abnormal regulation of cyclic AMP metabolism 
during the preneoplastic phase does not appear to be 
specific to hepatic carcinogenesis. Transplacental 
administration of ethylnitrosurea (ENU) by intravenous
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injection of pregnant rats results in the induction of 
brain tumours (Racagni et al., 1979). The induction 
process is characterized by different stages, with the 
'tumoural phase' commencing at approximately the fourth 
month of life and resulting in a variety of neoplasms.
The basal adenylate cyclase activity was subnormal in 
all established tumours. Prior to four months of age 
'tumoural development' is characterized by 'early 
neoplastic proliferation and microtumours composed of 
proliferating glial cells with few mitoses and low 
cell density'. The basal adenylate cyclase activity 
of ENU-treated rats during this early phase was 
significantly elevated compared to control animals. The 
responsiveness of the enzyme to agonist stimulation was 
not studied. Whether the increased activity results 
from the 'microtumours' observed in this period or is 
characteristic of the cell population 'en masse' was 
not established. Kemp et al. (1975) have reported
similar enhanced characteristics in cyclic AMP metabolism 
in the preleukemic period of thymic lymphoma development 
in AKR mice. Both basal adenylate cyclase activity and 
intracellular cyclic AMP levels were elevated compared to 
control tissue.
There is little information on cyclic GMP 
metabolism in the preneoplastic period (DeRubertis and 
Craven, 1976; Boyd et al., 1978b). No general conclusions 
can be made.
The relative consistency of these reports in 
the premalignant period of tumour development has
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prompted this study of the levels of cyclic nucleotides, 
the activity and responsiveness of adenylate cyclase, 
and the activities of cyclic nucleotide phosphodiesterases 
in the thymuses of AKR mice.
CHAPTER FOUR
METHODS
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4.1 Assay of Adenylate Cyclase Activity
4.1.1 Introduction
Early studies of the adenylate cyclase enzyme 
complex were limited to the use of biological assays 
for cyclic AMP (Rail and Sutherland, 1958, 1962;
Posner et al., 1964; Breckenridge, 1964). These assays 
were susceptible to interference, in that the adenylate 
cyclase preparations may have contained inhibitors and/or 
activators of any one of the enzymes utilized in the 
coupled reaction series, ultimately yielding sources of 
error (Bradham and Woolley, 1964). The techniques were 
tedious and involved extensive purification procedures. 
However, when properly controlled such assays provided a 
reasonable estimate of cyclic AMP production and therefore 
of adenylate cyclase activity (Perkins, 1973). Today this 
technology has been surpassed by the advent of rapid, 
more sensitive assays for cyclic nucleotide determinations 
(see Section 4.2).
It was the availability of radioactively labelled 
ATP (32P, 3H, 14C) and the introduction of new purifica­
tion procedures for cyclic AMP that allowed the develop­
ment of direct radiometric assays for adenylate cyclase 
in broken cell preparations. Initially, however, the 
purification techniques employed were long and complex, 
utilizing various forms of paper and thin layer
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chromatography (Hiratu and Hayaishi, 1965; Rabinowitz 
et al. , 1965; Jungas, 1966; Streeto and Reddy, 1967;
Bär and Hechter, 1969).
A more rapid method of assessing adenylate 
cyclase activity was developed by Krishna and coworkers 
(1968) , in which isolation of cyclic AMP formed during 
an incubation was achieved by chromatography on Dowex 
50-H+ columns. This was followed by precipitation of 
all nucleotides and inorganic phosphates by ZnS04-Ba(OH)2 
treatment, leaving the cyclic AMP in the supernatant 
fluid. The method of Nakai and Brooker (1975) also 
utilizes this barium-zinc precipitation but the 
separation of AT32P from [32P]-cyclic AMP is achieved by 
acid destruction of ATP (1 N HCl, 10 minutes, 90°C).
The single step chromatographic procedure using 
neutral aluminium oxide as described by Ramachandran 
(1971) and White and Zenser (1971) is rapid, simple and 
convenient. This method is based upon the preferential 
adsorption of polyvalent anions on hydrous aluminium 
oxide; cyclic AMP is a monovalent anion whereas ATP, ADP, 
AMP and Pi are all multivalent anions at neutral pH.
The method of choice to assess enzyme activity 
and hormone responsiveness in the experiments on mouse 
thymus adenylate cyclase in this thesis is that of 
Salomon et al. (1974), recently expanded upon by Salomon 
(1979), with slight modifications as described by Hunt 
et al. (1976) . The isolation procedure combines 
chromatography on Dowex 50, as suggested by Krishna 
et al. (1968) as a first step, with chromatography on
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neutral aluminium oxide as described by Ramachandran 
(1971) and White and Zenser (1971) as the second step.
The difficulties that are encountered in the 
assay of adenylate cyclase in vitro result partly from 
the fact that it is present in homogenates and membrane 
preparations in small amounts, such that only a small 
fraction (0.01 - 0.25%) of the labelled substrate 
supplied will undergo catalytic conversion to cyclic 
AMP. The sensitivity and reliability of the assay is 
therefore dependent upon, and proportional to, the 
efficiency with which cyclic AMP can be separated from 
the unconverted substrate and other contaminating 
radioactive products. These contaminants can accumulate 
rapidly due to the activity of other enzymes in the 
preparations, e.g. ATPase, cyclic nucleotide phospho­
diesterases (see Perkins, 1973, for further discussion). 
Hence the sensitivity of the assay approaches a maximum 
as the radioactivity (cpm32P) in the assay blanks 
approaches zero. In the original description of the 
adenylate cyclase assay formulated by Salomon et al.
(1974) a comparative study of the sequential column 
chromatography on Dowex and neutral alumina and the 
single step chromatographic methods of Krishna et al. 
(1968) and White and Zenser (1971) is documented. The 
results show that, using cpm32P in the blank as a 
criterion of sensitivity, the dual column chromatographic 
procedure is clearly preferable where an assay of high 
sensitivity is required. The assay also permits a 
recycling of columns with a corresponding reduction in
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time, effort and expense. Wineck and Sweat (1975) have 
described a procedure that has comparable assay 
sensitivity, the protocol of which is essentially 
similar. However, the necessity to evaporate 8 ml of 
buffer from the scintillation vials results in a 
slightly longer process.
The assay procedures applied to mouse thymus 
adenylate cyclase will now be described in detail. It 
should be appreciated that recognition of the potential 
problems and pitfalls in the assay of this enzyme is a 
prerequisite in the aim of elucidating the mechanisms 
of regulation as studied in vitro. In consideration 
of this, wherever possible, the problems that have been 
encountered by workers in the past, and the methods 
utilized in attempts to overcome these problems, will 
be highlighted in the following text.
4.1.2 Preparation of homogenates
Animals were killed by cervical dislocation. 
The thymuses were removed, taking care not to excise 
the internal mammary lymph nodes with the tissue. Any 
further extraneous material was discarded and the 
individual thymuses were then weighed. Preliminary 
studies varying the homogenization conditions and 
protein concentration were carried out. Optimal assay 
conditions were established as described below:
(1) After being weighed the tissue was chopped in
2 ml of 'buffer electrolyte' (see Appendix III) 
and preincubated for a period of 15 minutes at 
4°C. The tissue was then homogenized with
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5 strokes of a tight-fitting Dounce 
hcmogenizer (Kontes Glass).
(2) Following homogenization, the appropriate 
dilution was made on the basis of 133 yl 
buffer electrolyte per mg wet weight of 
tissue. The homogenate was then filtered 
through a double layer of moistened gauze to 
remove any large aggregates and the enzyme 
activity was assayed immediately.
These conditions maintained basal adenylate 
cyclase activity and hormone responsiveness whilst 
allowing a sufficient volume in the preparation to 
implement the desired treatments. The conditions as 
established in our laboratory for mouse thymus differ 
from those outlined by Polgar et al. (1973) who found
that, for human leukocytes and lymphocytes, homogeni­
zation in a glass homogenizer in the presence of 0.25 M 
sucrose preceded by swelling in the slightly hypotonic 
medium retained adenylate cyclase activity, whilst 
other procedures such as sonication or homogenization 
in the absence of sucrose resulted in a variable loss 
of activity.
4.1.3 Incubation conditions
All manipulations were carried out in 
triplicate. Each incubation tube contained in a total 
volume of 100 yl: 25 yl of buffer electrolyte or 
hormone or nucleotide or sodium fluoride as appropriate 
(dilutions of hormones, etc. were all in buffer 
electrolyte), 25 yl of AT32P reaction mixture and
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50 yl of the homogenate preparation (containing 
approximately 40-60 yg of protein). As documented in 
Appendix III the buffer system incorporated into the 
assay was Tris-HCl. Magnesium ions are supplied at a 
concentration of 4.5 mM, this ion representing an 
essential cofactor for the enzymatic reaction (Perkins, 
1973). There are several constituents of the AT32P 
reaction mixture that warrant discussion. The substrate 
is supplied at a concentration of 1 mM (a-32P)ATP with 
a specific activity of approximately 10 cpm/pmol. In 
the introductory discussion of this method it was 
implied that, as adenylate cyclase has proved difficult 
to obtain in a purified form, whole homogenates or washed 
membrane fractions are used as enzyme preparations. These 
preparations contain contaminating enzymes, such as 
ATPases. In theory a linear reaction rate could be 
maintained if the level of ATP employed in the assay was 
sufficient to saturate the adenylate cyclase enzyme even 
in the face of destruction of ATP by competing enzymes. 
The Km for ATP in the presence of excess Mg2+ is 
usually in the range of 0.08-0.5 mM (Perkins, 1973). It 
should be noted that very high ATPase activities,
0.6 ymole/min/mg protein (Drummond and Duncan, 1970), 
have been observed in some membrane preparations. An 
alternative method for maintaining substrate concentra­
tion at a reasonably constant level is to include 
ATP-regenerating systems in the reaction mixture. The 
most commonly used are phosphocreatine plus creatine 
phosphokinase or phosphoenolpyruvate (P.E.P.) plus
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pyruvate kinase. The latter system is that utilized in 
our enzyme assay with concentrations of 2.5 mM P.E.P. 
and 1.5 i.u. of pyruvate kinase.
Cyclic nucleotide phosphodiesterases, the 
enzymes that catalyse the conversion of cyclic 
nucleotides to their respective nucleotide monophos­
phates (Section 2.5), are also contaminants of 
homogenates and their activity is often orders of 
magnitude greater than that of adenylate cyclase 
(Perkins, 1973). This problem has been surmounted by 
the incorporation of high concentrations of unlabelled 
cyclic AMP, with or without methylxanthines, in order 
to saturate and inhibit cyclic AMP phosphodiesterases, 
thus protecting the labelled product from degradation.
In our assay system, unlabelled cyclic AMP at a 
concentration of 1 mM was used; this represents a 
107-fold excess over the labelled cyclic AMP formed.
The incubation was initiated by the addition 
of 50 yl of the homogenate. Following a period of 
12 minutes at 37°C in a shaking water bath the incuba­
tion was terminated by the addition of excess unlabelled 
substrate (100 yl of 40 mM ATP) and boiling for a period 
of 2 minutes. Sodium fluoride (NaF, 10 mM) was included 
as a positive control in all experiments. This agent 
stimulates adenylate cyclase from virtually all sources 
studied, the only exception being certain bacteria 
(Perkins, 1973). A second basal determination was made 
in each assay to ensure that the activity of the 
homogenate preparation was stable throughout the
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addition and incubation procedures. The assay blank 
represented tubes to which 100 yl of 40 mM ATP had 
been added prior to the addition of 50 yl of the 
homogenate. The tubes were boiled for 2 minutes 
immediately following homogenate addition.
4.1.4 Purification of product
4.1.4.1 Column preparation
Packing of Dowex 50 columns 
Dowex resin (see Appendix II) was stirred 
overnight in 1 N HCl at 4°C. The acid was decanted 
and the resin resuspended in 0.33 N HCl. The volume of 
the suspension that resulted in a packed resin volume 
of 1 ml was estimated. Glass wool-stoppered columns 
(see Appendix II) were filled with the resin slurry 
and the acid allowed to drain. The columns were then 
washed with two 10 ml volumes of glass distilled 
water. Columns were stored at room temperature. On the 
day of use columns were washed with 10 ml of glass 
distilled water.
Packing of alumina columns
Using a calibrated tube 0.5-0.6 g of dry 
neutral alumina (see Appendix II) was added to glass 
wool-stoppered columns. The columns were washed with 
two 10 ml volumes of 0.1 M Imidazole-HCl buffer, 
pH 7.5 (see Appendix III). Columns were stored at 
room temperature and on the day of use were washed 
with 10 ml of 0.1 M Imidazole buffer.
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Column recycling
Immediately after use, the columns were washed. 
To the Dowex columns 4 ml of 0.33 N HC1 was added and 
allowed to drain. Ten ml of glass distilled water was 
then added. The alumina columns were washed with 10 ml 
of 0.1 M Imidazole buffer. This recycling procedure was 
utilized until such time as assay blank values (cpm32P) 
became unacceptably high or when recovery of 3H cyclic 
AMP dropped to below 50%. New columns were then 
prepared. The status of the columns, i.e. washed, not 
washed, samples applied, etc. was always recorded on 
cards to avoid errors.
4.1.4.2 Column elution profiles
Dowex columns
For each set of columns which was prepared, the 
elution profiles of AT32P and [3H]-cyclic AMP were 
determined. A mixture that corresponded to the assay 
blank (without homogenate) was prepared as outlined 
below:
250 y1 4 mM ATP/cyclic AMP
750 yl Buffer Electrolyte
1 ml 40 mM ATP
8 ml Glass Distilled Water
This 10 ml volume was divided into two 5 ml aliquots.
To one approximately 1 x 104cpm AT32P was added and to 
the other approximately 1 x 104cpm [3H]-cyclic AMP. A 
1 ml aliquot was then removed from each to score as a 
'total count'. Six Dowex columns were selected at random 
from the prepared batch and divided into two triplicate
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sets. One ml of the mixture containing AT32P was added 
to each of one set of triplicates and 1 ml of the 
mixture containing [3H]-cyclic AMP to the other 
triplicate set. The eluates were collected into 
plastic scintillation vials containing 10 ml of 
scintillant (see Appendix III), 0.5 ml of glass 
distilled water was added to each column and the 
eluates collected into a separate scintillation vial.
This procedure was repeated five times. The elution volume 
was then increased to 1 ml and this procedure repeated 
four times. The scintillation vials were counted for 
2-5 minutes in a Packard Tri-carb scintillation counter 
(Model 3255) . Using this information', an elution 
profile from the Dowex columns for the two isotopically 
labelled nucleotides can be established as shown in 
Figure 4.1.
Alumina columns
To establish the elution profile of [3H]-cyclic 
AMP from the alumina columns the information obtained 
from the above procedures for the Dowex columns has to 
be used, i.e. the volume of glass distilled water that 
is used to elute the cyclic AMP from the Dowex on to the 
alumina columns, because purification of product from 
unconverted substrate is achieved by sequential column 
chromatography. Approximately 1 x 105cpm [3H]-cyclic 
AMP in a volume of 5 ml of glass distilled water was 
applied to each of three randomly selected alumina 
columns and allowed to drain. One ml of 0.1 M Imidazole 
buffer was applied to each column and the eluates
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FIGURE 4.1
ELUTION PROFILES OF DOWEX AND ALUMINA COLUMNS 
The shaded area represents the sample volume.
Using the elution profiles a purification protocol 
to separate the product (cyclic AMP) from the 
large excess of unconverted substrate (ATP) was 
derived. The sample was applied in a 1 ml volume;
2 ml of glass distilled water was added and allowed 
to drain. The eluate was discarded. Cyclic AMP was 
eluted from the Dowex column by the addition of 5 ml 
of glass distilled water. This volume was collected 
on to the alumina column and allowed to drain. The 
eluate was discarded. Cyclic AMP was eluted from the 
alumina column by the addition of 4 ml of 0.1 M 
Imidazole-HCl buffer pH 7.5 and collected into a 
scintillation vial.
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collected into plastic scintillation vials containing 
10 ml of scintillant. This was repeated seven times.
The scintillation vials were then counted for 2-5 
minutes as before. Using this information the elution 
profile of [3H]-cyclic AMP from the alumina columns 
was established as shown in Figure 4.1.
4.1.4.3 Purification protocol
Prior to application of the samples to the 
columns approximately 2000 cpm/sample of [2,8-3H]-cyclic 
AMP was added to estimate the percentage recovery of 
[32P]-cyclic AMP from the purification procedure.
700 y1 of glass distilled water was added to each tube 
and the samples were then centrifuged at approximately 
2000 g for 10 minutes. This avoids application of 
coagulated protein in the samples to the columns, which 
would eventually affect column flow rate.
The sample supernates are applied to the Dowex 
columns and the eluates discarded. On the basis of the 
elution profiles previously established (Figure 4.1),
2 ml of glass distilled water was applied and the 
eluates again discarded. Five ml of glass distilled water 
was applied and the eluates collected onto the alumina 
columns and allowed to drain. Four ml of 0.1 M 
Imidazole buffer was added and collected into plastic 
scintillation vials containing 10 ml of scintillant.
4.1.5 Counting of samples
AT3 2P and [2,8-3H]-cyclic AMP total counts were 
quenched appropriately. The Packard-Tricarb scintillation
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counter was adjusted to allow simultaneous counting 
of 3H and 32P so that minimal crossover occurred 
between appropriate channels. Counts originating from 
3H can be eliminated completely from the 32P channel 
and >97% of the counts originating from 32P can be 
eliminated from the 3H channel. Vials were counted 
for 5-10 minutes.
4.1.6 Calculation of results
A computer program for carrying out the 
calculation of adenylate cyclase activity (expressed 
as pmol cyclic AMP produced/12 min/mg protein) was 
devised (Hunt, 1979). The mean, standard deviation and 
standard error of each triplicate was obtained. Enzyme 
activation was expressed as percentage increase over 
and above basal activity.
4.2 Assay of Cyclic Nucleotides
4.2.1 Introduction
'Methodology continues to limit the rate of 
progress in this area.'
(Sutherland, 1971)
'Cyclic nucleotide related literature has 
grown at an exponential rate, in part, because 
of the development of newer and improved 
methodology.'
(Hardman, 1974)
As implied in Section 4.1.1, and by the above 
quotations, the study of cyclic nucleotide metabolism 
and the biological actions of these compounds has met 
with formidable technical problems. The seemingly 
ubiquitous occurrence of cyclic AMP and cyclic GMP made 
it increasingly desirable to be able to measure these
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cyclic nucleotides in tissues and body fluids with 
ease and dependability. Problems arise automatically 
in that these compounds are present in extremely low 
concentrations (Steiner et al. , 1972a) and therefore 
methods developed for the assay of cyclic nucleotides 
must contend with high concentrations of interfering 
non-cyclic nucleotides and other substances.
During the 1960s biological assays were most 
commonly used to measure cyclic AMP. These utilized the 
activation of phosphorylase kinase by the cyclic 
nucleotide (Rail and Sutherland, 1958) or involved the 
conversion of cyclic AMP to ATP and subsequent 
utilisation of this in enzymatic reactions (Goldberg 
et al., 1969a). This latter technique was also used 
for the measurement of cyclic GMP (Goldberg et al., 
1969b). These enzymatic procedures all require, as an 
initial step, the separation of the cyclic nucleotide 
from other tissue nucleotides. The number of steps 
involved in these purification procedures prevents 
the rapid analysis of many preparations.
It was the advent of sensitive assays based 
upon competitive ligand binding to endogenous proteins 
with affinity for cyclic nucleotides (Gilman, 1970;
Brown et al., 1972; Murad and Gilman, 1971) or to 
specific antibodies (Steiner et al., 1972b) that allowed 
the change of emphasis in cyclic nucleotide research 
from assay development to a deeper appraisal of the 
biological functions of these compounds.
The cyclic AMP and cyclic GMP concentrations in
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mouse thymus (see Chapter Seven) were estimated by 
utilization of radioimmunoassays for the respective 
cyclic nucleotides. These assays are sensitive and allow 
the rapid analysis of a large number of samples. The 
specificity makes extensive purification procedures 
unnecessary. Radioimmunoassay was used in preference 
to a protein binding assay because of its greater 
sensitivity.
4.2.2 Principle of radioimmunoassay 
Competitive radioimmunoassay (RIA) is a
general method for the determination of the concentra­
tion of virtually any substance which is, or can be 
rendered, immunogenic (Yalow, 1973, 1980). The 
principle (see Figure 4.2) is simply that of 
competition between labelled and unlabelled substances 
for a limited number of combining sites on a specific 
reactor which, in the case of RIA, is a specific 
antibody. This results in a progressive inhibition 
of the binding of the labelled substance as the 
concentration of the unlabelled substance is increased. 
The concentration in an unknown sample is determined 
by comparing the degree of inhibition of the binding 
of the labelled substance observed in that sample 
with that produced by known standards.
4.2.3 Tissue fixation
The concentrations of cyclic nucleotides 
within most tissues are subject to rapid fluctuations 
which are dependent upon the status of the synthetic
PRINCIPLE OF RADIOIMMUNOASSAY.
A g - A b A g —A b
Specific Antibody
Ag
Ag^—Ab
Free Labelled Antigen
Unlabelled Antigen (in known standard solutions
or unknown samples)
Labelled Antigen-Antibody Complex
Ag—Ab Unlabelled Antigen-Antibody Complex
FIGURE 4.2
PRINCIPLE OF RADIOIMMUNOASSAY
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and degradatory enzymes involved in the metabolism 
of cyclic nucleotides, i.e. adenylate and guanylate 
cyclase and the cyclic nucleotide phosphodiesterases. 
Hence the speed and efficacy of tissue fixation is of 
paramount importance in any in vivo study. In 
animals, tissue can be quickly excised into a 
fixative (e.g. trichloroacetic acid, perchloric acid) 
or freeze clamped in situ (Mayer et al., 1974). This 
freeze clamping technique as applied to whole animals 
requires anaesthesia which may itself modify cyclic 
nucleotide concentrations in various tissues (Kimura 
et al. , 1974). It should be appreciated that freeze 
clamping does not irreversibly inactivate the enzymes 
and therefore the tissue still has to be subjected to 
some treatment which denatures proteins. Any thawing 
of the tissue prior to this could result in the 
enzymes again becoming active.
Schmidt, Schmidt and Robison (1971), taking 
advantage of the heat-stable nature of cyclic AMP 
(Sutherland and Rail, 1958), utilized microwave 
irradiation as a means of rapidly and irreversibly 
inactivating adenylate cyclase and phosphodiesterase 
in various areas of rat brain. This technique allows 
for rapid tissue fixation whilst preserving anatomical 
integrity such that it may be possible to examine 
hormonal effects upon discrete groups of cells. 
Microwave irradiation has also been applied to chicken 
(Nahorski et al., 1976) and rat kidney preparations
(Hunt et al., unpublished observations).
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This method of rapid tissue fixation was 
adopted in the preparation of samples for cyclic 
nucleotide determinations. Preliminary studies were 
carried out to validate the inactivation of enzymes 
involved in cyclic nucleotide metabolism in the 
thymus, and the results of these studies are shown 
in Figures 4.3, 4.4 and 4.5. Basal and NaF (10 mM) 
stimulated adenylate cyclase activity was assayed 
as outlined in Section 4.1. Cyclic nucleotide phospho­
diesterase activity was assayed at 1 and 100 yM 
substrate concentrations as outlined in Section 4.3.
The procedures were validated for mouse thymus and 
kidney preparations as it was known that irradiation 
was effective in enzyme inactivation in chicken and 
rat kidney. Adenylate cyclase, both basal and fluoride 
stimulated activity, was totally inactivated by seven 
seconds of microwave irradiation. High affinity (low 
Km) and low affinity (high Km) cyclic AMP and cyclic 
GMP phosphodiesterase activities were totally inactivated 
by twenty seconds of microwave irradiation. Note, however, 
that ten seconds irradiation results in approximately 
90% of the control activities being destroyed. From 
these preliminary studies it was decided that a twenty 
second period of microwave irradiation would be employed 
in all further experiments.
4.2.4 Preparation of samples
Mice were initially stunned and placed into a 
glass beaker which was then transferred to a constant 
position inside the microwave oven (National NE 1110,
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INACTIVATION OF MOUSE THYMUS AND KIDNEY 
ADENYLATE CYCLASE ACTIVITY BY MICROWAVE IRRADIATION.
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FIGURE 4.3
INACTIVATION OF MOUSE THYMUS AND KIDNEY ADENYLATE 
CYCLASE ACTIVITY BY MICROWAVE IRRADIATION 
Basal and sodium fluoride-stimulated adenylate 
cyclase activity was assayed in thymus ( /\ ) and 
kidney (^|) homogenates as described in Section 4.1. 
Control enzyme activities (means ± S.E.M.), expressed 
as cyclic AMP pmol produced/12 min/mg protein, were 
as shown below.
Treatment Thymus (n=2) Kidney (n=3)
Basal 584 ± 84 113 ± 10
Sodium fluoride (10-2 M) 2562 ± 375 1710 ± 155
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INACTIVATION OF MOUSE THYMUS AND KIDNEY 
HIGH AFFINITY CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
BY MICROWAVE IRRADIATION.
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FIGURE 4.4
INACTIVATION OF MOUSE THYMUS AND KIDNEY HIGH AFFINITY 
(LOW KM) CYCLIC AMP AND HIGH AFFINITY (LOW KM) CYCLIC 
GMP PHOSPHODIESTERASE ACTIVITY BY MICROWAVE IRRADIATION
Enzyme activity was assayed in mouse thymus ( /\ ) and
kidney fj^) homogenates, at a substrate concentration 
of 1 yM, as described in Section 4.3. Control enzyme 
activities (means ± S.E.M.), expressed as cyclic 
nucleotide pmol hydrolysed/min/mg protein, were as 
shown below.
Enzyme Thymus (n=4) Kidney (n=3)
Cyclic AMP-PDE 28.7 ± 1.4 61.8 ± 13.6
Cyclic GMP-PDE 14.1 ± 1.9 75 ± 15.5
Standard errors were always <20% of the corresponding mean value.
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INACTIVATION OF MOUSE THYMUS AND KIDNEY 
LOW AFFINITY CYCLIC NUCLEOTIDE PHOSPHODIESTERASES
BY MICROWAVE IRRADIATION.
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FIGURE 4.5
INACTIVATION OF MOUSE THYMUS AND KIDNEY LOW AFFINITY 
(HIGH KM) CYCLIC AMP AND CYCLIC GMP PHOSPHODIESTERASE 
ACTIVITY BY MICROWAVE IRRADIATION
Enzyme activity was assayed in mouse thymus (/\ ) and 
kidney homogenates, at a substrate concentration
of 100 yM, as described in Section 4.3. Control enzymes 
(means ± S.E.M.), expressed as cyclic nucleotide pmol 
hydrolysed/min/mg protein, were as shown below.
Enzyme Thymus (n=4) Kidney (n=3)
Cyclic AMP-PDE 871 ± 130 1730 ± 230
Cyclic GMP-PDE 787 ± 130 2798 ± 400
Standard errors were always <20% of the corresponding mean value.
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Output 1.1 kw, Frequency 2450 MHz). After 20 seconds 
of microwaving the mice were removed and the thymuses 
were dissected as described in Section 4.1.2. The 
thymuses were weighed and placed into 1 ml of 4.96%
(v/v) perchloric acid at 4°C.
The tissue was homogenised (12 strokes, custom 
made motor driven homogeniser) and the homogenates 
centrifuged at 5000 g for 10 mins. The supernates were 
transferred to plastic test tubes and the pellets 
retained for protein determinations (see Section 4.4). 
Each supernate was individually and precisely 
neutralised to pH 7.0-7.2 using 3 M potassium hydroxide 
Any supernates that became too basic during the 
neutralisation procedure were acidified by using 
glacial acetic acid. This was the acid of choice 
because the radioimmunoassays were conducted in a 
sodium acetate buffer. The tubes were centrifuged at 
5000 g for 10 minutes. The supernates were removed 
into plastic test tubes and the volumes were 
accurately assessed.
Throughout the above procedures extreme care 
was taken in the transfer of tissue and perchloric 
acid to the homogeniser, transfer of the homogenates 
back into test tubes and separation of supernates from 
pellets at the two centrifugation steps. This care was 
necessary as it is usual to incorporate [3H]-cyclic 
nucleotide to monitor the percentage recovery of the 
cyclic nucleotide from the homogenisation and neutralis 
ation or extraction procedures. However, in these
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experiments, cyclic AMP and cyclic GMP determinations 
were made upon the same sample so that it was not 
feasible to incorporate radioactively labelled cyclic 
nucleotides to estimate recoveries. The homogenisation 
and neutralisation procedures and the radioimmunoassay 
itself have been extensively validated (see Sections 
4.2.11 and 4.2.12).
Bulk volumes of 4.96% perchloric acid were 
neutralised, using 3 M potassium hydroxide, with each 
batch of samples prepared and the supernates of a 5000 g,
10 minute centrifugation were then used to dilute 
standards in the radioimmunoassays. In some experiments 
the supernates removed from the homogenisation step 
were stored at -20°C until neutralisation was accomplished. 
All samples were stored at -20°C until assayed, as was the 
neutralised perchloric acid.
4.2.5 Preparation of cyclic nucleotide antibodies
Antibodies to cyclic AMP and cyclic GMP were 
obtained by N.H. Hunt following the procedure outlined 
by Steiner et al. (1972b). As stated in Section 4.2.2,
competitive radioimmunoassays can be established for 
any substance that is, or can be rendered, immunogenic. 
Cyclic nucleotides are ubiquitous, low molecular weight 
compounds and as such cannot provoke a humoral immune 
response. Therefore, it is necessary to confer 
immunogenic potential on the cyclic nucleotides and 
this is achieved by conjugation to large molecular 
weight proteins such as human serum albumin, poly-l-lysine 
polymers or keyhole limpet haemocyanin. In an effort to
165
increase the specificity of any antibodies obtained, 
a conjugate was prepared in which neither the purine 
or pyrimidine rings nor the diester 3',5' bonds of 
the cyclic nucleotide were altered. This can be 
achieved by synthesising the 2'-0 succinylated 
derivative of the cyclic nucleotide by modifications 
of the method of Falbriard et al. (1967) as outlined
by Steiner et al. (1972b). Conjugation of the
succinyl 2,-0-cyclic NMP to the hapten can then be 
achieved with the free carboxyl group of this 
derivative. The succinyl 2'-0 derivatives of cyclic 
AMP and cyclic GMP are now available commercially at 
a cost that alleviates the necessity to synthesise these 
compounds in the laboratory.
The antibodies obtained by Hunt utilised as 
the antigenic stimulus succinyl 2'-0-cyclic NMPs 
coupled to keyhole limpet haemocyanin. The coupling agent 
was 1-ethyl-3(3-dimethylaminopropyl) carbodiimide-HCl.
The conjugated derivatives were emulsified with 
Freund's complete adjuvant before injection into 
popliteal lymph nodes of albino rabbits. Multiple 
booster injections were given 4-6 weeks after the 
primary, either to the foot pads or to the back of the 
animals. Ten to fourteen days after the secondary 
injections the animals were bled from the ear vein. 
Another booster injection was given at the same time.
This process was continued until suitable antisera were 
obtained. Brooker et al. (1979) have stated that the
specificity and sensitivity of the antisera improve
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upon repeated injections of antigen.
The antisera were tested for their ability to 
bind [125I]-tyrosine methylester-ScAMP [1251]-TME-ScAMP 
or [125I]-TME-ScGMP (see Section 4.2.6) in the absence 
of unlabelled cyclic nucleotide. Those antisera 
displaying adequate binding of the iodinated ligand 
were subjected to cross-reactivity studies with possible 
interfering substances, especially other nucleotides.
This is especially important for cyclic GMP antisera as 
in most tissues the level of cyclic AMP exceeds that of 
cyclic GMP by 10-100 fold (Brooker et al., 1979). As a 
consequence, cyclic GMP measurements on unpurified 
samples will obviously have to contend with relatively 
high levels of cyclic AMP. Table 4.1 shows the affinity 
of cyclic AMP and cyclic GMP antisera for a range of 
nucleotides. High specificity of both antisera for their 
respective cyclic nucleotides is demonstrated. Appropriate 
antisera were kept frozen at -20°C in 500 y1 aliquots. 
Working stocks of cyclic AMP antisera were diluted 1/300 
with radioimmunoassay buffer (see Appendix III) . These 
were diluted 1/300 - 1/400 for use in RIAs. Working 
stocks of cyclic GMP antisera were diluted 1/20 with RIA 
buffer. These were diluted 1/60-1/90 for use in RIAs. It 
is worthwhile noting that the correct dilutions of 
antisera and tracer in the RIA vary with the age of the 
latter, i.e., to give suitable binding (40-60%) of 
tracer in the absence of unlabelled cyclic nucleotide.
The working solutions of both antisera were aliquoted in 
small volumes to ensure that no serum was subjected to
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TABLE 4.1
CROSS REACTIVITY OF CYCLIC NUCLEOTIDE ANTISERA 
WITH VARIOUS NUCLEOTIDES
Nucleotide Cyclic AMP RIA Cyclic GMP RIA
Cyclic AMP 1 > 1 0 6
Cyclic GMP > 1 0 5 1
5'-AMP 1 0 6 > 1 0 6
ADP 5 x 105 > 1 0 6
ATP 1 0 5 > 1 0 6
5'-GMP - 2.5 x 104
GDP >4 x 107 1 0 4
GTP Oi—1XA 2.5 x 104
Figures represent the relative amount of each nucleotide 
required for half maximal displacement of [1251]-TME-ScNMP 
in each assay. Units are arbitrary.
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more than a few freeze-thaw cycles (Brooker et al., 1979)
4.2.6 Preparation of [125I]-TME-ScAMP and [125I]-
TME-ScGMP
The synthesis of radioligands was accomplished 
by the method of Hunter and Greenwood (1962) as 
developed by Steiner et al. (1972b). Radioactive
derivatives of cyclic nucleotides were synthesised by 
iodination of the tyrosine moiety of the appropriate 
TME-ScNMP. The TME-ScNMPs can be synthesised as 
described by Steiner et al. (1969). However, as with the 
succinyl 2'-0 derivatives, these compounds are 
commercially available. Stock solutions of the TME 
derivatives were stored at -20°C at a concentration of 
5.1 x 10-4 M in 50% ethanol.
20 yl of 0.5 M potassium phosphate buffer, 
pH 7.4, was added to a small glass or plastic test tube 
on ice. To this was added 20 y1 of the appropriate 
stock TME-ScNMP. This was reacted with 10 yl (1 mCi) of 
carrier free 125i (see Appendix II) by adding 20 yl of 
chloramine T (15 mg/10 ml 0.05 M potassium phosphate 
buffer pH 7.4) as the oxidising agent. The incubation 
was at room temperature for 15-20 seconds, at which time 
100 yl of sodium metabisulphite (25 mg/10 ml 0.05 M 
potassium phosphate buffer, pH 7.4) was added to 
eliminate reactive 125I2. Following the addition of 
500 yl of phosphosaline buffer (0.15 M NaCl/0.01 M KH2P0 
K2HP04, pH 7.4, 4°C), sodium or potassium iodide (100 yl 
H20 containing 10 mg) was added to act as a carrier and 
the reaction mixture was then maintained on ice until
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the purification procedure. All steps described above 
were carried out in a well ventilated fume hood. The 
synthesis of iodinated ligands was carried out 
routinely every 2-3 months (half-life of 125I -60 days).
4.2.7 Purification of [125I]-TME-ScNMPs
The purification of the iodinated cyclic 
nucleotide derivatives is accomplished in a single 
step. This can be by column chromatography on Sephadex 
G-10 or by thin layer chromatography on cellulose as 
described by Steiner et al. (1972b) or by descending 
paper chromatography as described by Brooker et al.
(1979). Chromatography on a G-10 Sephadex column 
(20-25 cm x 0.9 cm) was used in the purification 
described here. Sephadex G-10 (5 g) was swelled in 
phosphosaline buffer at room temperature for 4 hours. 
Following the removal of the 'fine' Sephadex particles 
the column was poured and washed with approximately 
10 bed volumes of phosphosaline buffer. The column 
was washed with 1 ml of bovine serum albumin (3 g/
100 ml of phosphosaline buffer). The reaction mixture 
was applied to the column and fractions (2-3 ml) eluted, 
at room temperature, with phosphosaline buffer. 10-20 y1 
of each aliquot was counted on a Packard auto gamma 
scintillation spectrophotometer (Model 578) and an 
elution profile,similar to that shown in Figure 4.6, 
obtained. Three distinct peaks of radioactivity were 
found; peak 1 (void volume) has not been identified, 
peak 2 is free 125i and peak 3 is [125I]-ScNMP.
The degree of tracer binding to antibody was
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checked, under normal assay conditions, in the absence 
of any unlabelled cyclic nucleotide. Non-specific 
binding (NSB) and displacement of labelled TME-ScNMP 
by 2 pmol of cNMP was also checked for appropriate 
fractions. A representative set of results for these 
criteria is shown in the legend to Figure 4.6. The 
fractions giving best results, i.e., high binding in 
the absence of unlabelled cyclic nucleotide, low NSB 
(<5% of total counts bound) and good displacement by 
2 pmol of cNMP, were pooled. Aliquots of the pooled 
fractions were dispensed into 10 ml plastic tubes, each 
containing 7-9 x 105 cpm (enough for approximately 80 
assay tubes). The tracer was stored at -20°C.
4.2.8 Radioimmunoassay procedure
Samples were assayed by a procedure similar to 
that described by Brooker et al. (1979). Standard
solutions of cNMP were stored frozen at -20°C in 
aliquots of 1000 pmol of cyclic nucleotide/100 y1 of 
radioimmunoassay buffer. On thawing the standard was 
diluted appropriately to give a range of concentrations 
from 0 to 2000 fmol/100 yl for the cyclic AMP RIA and 
from 0 to 500 fmol/100 yl for the acetylated (see 
Section 4.2.10) cyclic GMP RIA. All procedures were 
carried out in 12 x 75 mm plastic test tubes maintained 
on ice. Cyclic AMP determinations were carried out in 
triplicate on 1/5, 1/10 and 1/20 dilutions of the 
neutralised supernates, using RIA buffer to dilute the 
samples. The standard curve for the cyclic AMP assay was 
diluted with a 1/5 dilution of the bulk neutralised 4.96%
. —  FRACTIONS USED 
~  IN BINDING STUDY
0 5 10 15 20 25
FRACTION NUMBER.
FIGURE 4.6
TYPICAL ELUTION PROFILE FOR IODINATION OF TME-ScNMP 
FROM A SEPHADEX G-10 COLUMN
Aliquots of the fractions used in the binding study 
were diluted in radioimmunoassay buffer to give 
approximately 10,000 cpm/tube. Non specific binding, 
binding in the absence of unlabelled cyclic nucleotide 
and displacement of the radioligand were assessed. A 
set of representative results, expressed as the 
bound/free ratio, are shown below.
Fraction number N.S.B.
1 1.51
11 0.07
12 0.06
13 0.06
14 0.05
0 added CN +2 pmol CN
1.53 1.53 
0.51 0.07 
0.55 0.08 
0.58 0.06 
0.57 0.07
15 0.06 0.53 0.07
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perchloric acid as discussed in Section 4.2.4. Cyclic 
GMP determinations were carried out in quadruplicate 
on supernates diluted 1/2 with RIA buffer. The standard 
curve for the cyclic GMP assay was correspondingly 
diluted with a 1/2 dilution of the bulk neutralised 
perchloric acid. Both standard curves were prepared 
in triplicate.
Assay tubes contained 100 yl of [125I]-TME-ScNMP 
(approximately 10,000 cpm/tube) and 100 yl of standard 
or sample appropriately diluted. Non specific binding 
(NSB) was assessed in tubes containing 100 yl of 
[12 51]-TME-ScNMP, 100 yl of RIA buffer and 100 yl of 1/5 
dilution of neutralised perchloric acid in the cyclic 
AMP RIA or 100 yl of 1/2 dilution of acetylated 
neutralised perchloric acid in the cyclic GMP RIA. No 
antibody was added to these tubes. The NSB represents 
binding of the radioligand to components of the assay 
system, other than the added antisera, which cannot be 
separated from antibody bound ligand in the charcoal 
separation procedure outlined below.
The incubation was started by the addition of 
100 yl of antibody, appropriately diluted in RIA buffer.
The tubes were mixed and the binding reaction (final 
volume 300 yl) allowed to proceed for 14-28 hours at 
4°C, a sufficient time to allow complete equilibriation.
4.2.9 Separation of bound and free radioligand
Many techniques are available for the separation 
of antibody-bound and free labelled antigen in radioimmuno­
assay (Yalow, 1973). The method employed in the cyclic
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nucleotide radioimmunoassays was the addition of a 
suspension of bovine serum albumin-coated charcoal.
The suspension consisted of 2 mg/ml Norit A charcoal 
(see Appendix II) and 2.5 mg/ml BSA made up with 
100 mM potassium phosphate buffer pH 7. After 
stirring at 4°C, 1 ml of the suspension was added to 
each tube and the tubes were vortexed. All procedures 
were carried out on ice. Exactly 15 minutes after the 
final addition of the charcoal suspension the tubes 
were centrifuged at 2000 g for 10 minutes at 4°C in 
a MSE Mistral 6L centrifuge. Tubes were replaced on to 
ice and the supernates transferred with care and 
accuracy into plastic test tubes. This procedure was 
accomplished as rapidly as possible to prevent dis­
sociation of radioligand from the charcoal. Both bound 
(supernates) and free (charcoal pellets) forms were 
counted for 2-5 minutes as described previously. The 
counting time employed should be sufficient to reduce 
the counting error below the inherent radioimmunoassay 
error (Brooker et al., 1979).
In some later experiments the above procedure 
was modified in that only the bound form of the 
radioligand was counted. This was achieved by removing 
1 ml of the supernates into plastic tubes and counting 
for 5 minutes. This procedure was implemented after the 
adoption of a computer program to calculate results 
(see Section 4.2.13).
4.2.10 Acetylation of radioimmunoassays
Steiner et al. (1972b) found that antibodies
173
demonstrated a higher affinity to cyclic nucleotides 
substituted in the 2'-0 position. This is because the 
immunogenic stimuli utilised in the generation of 
antisera represented keyhole limpet haemocyanin 
coupled to the 2'-0 succinylated derivatives of cyclic 
nucleotides.
Cailla et al. (1973) devised a method to
succinylate cyclic nucleotides in tissue extracts at 
the 2'-0 position, thus achieving a potentially more 
sensitive radioimmunoassay. This procedure, however, 
leaves the tissue sample in 0.5 M succinate which must 
be either diluted or removed to prevent interference 
in the RIA. Harper et al. (1975) overcame these
problems by the 2'-0 acetylation of cyclic nucleotides 
by acetic anhydride. In this reaction acetate is the 
by-product. As the assay is performed in acetate 
buffer, and because acetate does not interfere with the 
binding of [1251]-TME-ScNMP to antibody, this technique 
increases the sensitivity of the RIA by 40-100 fold 
(Brooker et al., 1979).
This acetylation technique was adopted for the 
measurement of cyclic GMP, as the levels of this nucleo­
tide were low in comparison to cyclic AMP. Samples were 
diluted 1/2 with RIA buffer. Standards were diluted in 
a 1/2 dilution of the bulk neutralised perchloric acid. 
To a 500 yl volume 10 yl of triethylamine was added and 
vortexed immediately. 5 yl of acetic anhydride was 
rapidly added and the sample or standard again vortexed 
immediately.
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4.2.11 Validation of assay
Whenever the radioimmunoassay techniques for 
measuring cyclic nucleotides are to be applied to a 
new tissue there are several necessary experiments that 
need to be applied to validate the measurements that are 
made. This is because tissue extracts may contain substances 
which interfere with the antibody-radioligand interaction.
It was planned initially to utilise the method of Tihon 
et al. (1977) to prepare samples for RIA. In their
procedure, neutralisation of the TCA extract is achieved 
by the addition of successive amounts of finely powdered 
calcium carbonate (CaC03). This reaction is rapid and, 
according to the authors, can be monitored simply: as 
long as free TCA is present the CaC03 dissolves rapidly; 
this is accompanied by a brisk evolution of C02. When the 
sample is neutralised, C02 evolution ceases, and the 
excess reagent remains undissolved. Exact titration was 
apparently unnecessary as excess CaC03 did not signifi­
cantly affect the pH of the neutralised mixture. Several 
preliminary studies were undertaken with the view of 
adopting this procedure to prepare the thymus extracts 
for RIA. A standard curve diluted in 6% TCA which had 
been neutralised with CaC03 as outlined by Tihon et al. 
(1977) was compared to a standard curve diluted in RIA 
buffer. Interference and reduced sensitivity was noted 
when a comparison of the two standard curves was made. 
Several alternative procedures were implemented in an 
effort to remove this interference from the assay. These
included:
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(1) Precise neutralisation of 6% TCA using CaC03 
to pH 7.0-7.2.
(2) Neutralisation of 6% TCA with 1 M sodium 
hydroxide.
(3) Neutralisation of 6% TCA with 1 M sodium 
hydroxide to approximately pH 6.0 followed 
by the addition of excess CaC03.
(4) Incorporation of a pH indicator and 
neutralisation with CaC03.
(5) Acetylation of assays in an effort to increase 
the sensitivity of the RIA.
(6) Increasing the buffering capacity of the 
system from 50 mM to 100 mM sodium acetate.
(7) Increasing the BSA concentration in the assay 
buffer from 1 mg/ml to 5 mg/ml.
(8) Samples of very high or variable ionic strength 
often do not read true in the RIA (Brooker et al 
1979). A calcium chloride solution was used to 
simulate an excess of Ca2+, as may be present in 
the CaC03-neutralised TCA solutions. The calcium 
ion concentration used (0.184 M) did not 
interfere with the RIA. This observation would 
seem to suggest that variability in the ionic 
strength of neutralised solutions was not the 
cause of the interference observed and that, 
presumably, traces of unneutralised soluble 
trichloroacetate were interfering with the 
binding of radioligand by the antibody in a 
manner analogous to that observed in the Gilman
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protein-binding assay for cyclic AMP (Wright,
1975).
None of the above treatments succeeded in 
eliminating the interference obtained in the assay, 
even at 1/2 or 1/5 dilutions of the neutralised 6%
TCA solutions. It should be noted that Tihon et al.
(1977) accept that non specific interference with the 
RIA is apparent and that, in order to compensate for 
this, cyclic AMP values were calculated from 
standard curves which were prepared for every experiment 
and based on known amounts of cyclic AMP treated in a 
manner identical to that of the unknown samples.
To establish an alternative procedure to the 
TCA/CaC03 neutralisation that would allow the assay of 
both cyclic AMP and cyclic GMP on the same sample, 
perchloric acid (4.96%) was used to prepare thymus 
extracts, and the acid was then neutralised with 3 M 
potassium carbonate. This method proved unsatisfactory, 
because neutralised solutions (pH 7.0-7.2) when left 
overnight at 4°C tended to become increasingly basic, 
possibly because of the loss of dissolved C02. The 
procedure outlined in Section 4.2.4 was adopted for 
the preparation of thymus extracts for RIA. Cyclic 
nucleotides were extracted with perchloric acid and the 
pH of the solution carefully adjusted with 3M potassium 
hydroxide, the perchlorate being eliminated as the 
sparingly soluble potassium salt. As shown in Figures 
4.7 and 4.8, bulk volumes of perchloric acid neutralised 
in this way exhibited no interference in the RIA and did
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FIGURE 4.7
CYCLIC AMP RADIOIMMUNOASSAY STANDARD CURVES 
Radioimmunoassay buffer (RIA) |
Neutralised perchloric acid diluted 1/5 with 
RIA buffer /\
Validation of assay by dilution of sample and addition of cyclic AMP
LEFT 1THYMUS RIGHT 1THYMUS
Dilution Calculated Expected Calculated Expected
fmol/100 yl fmol/100 yl fmol/100 yl fmol/100 yl
1/5 440 - 460 -
1/10 230 220 220 230
1/20 115 110 115 115
1/40 60 55 64 57.5
1/80 32 27.5 26 28.75
1/20 plus
20 fmol cyclic AMP 240 240 250 250
: 0.7-
<  0.6
ff. 0.4
Z  0.2
50 100 200
LOG PLOT OF CYCLIC GMP CONCENTRATION
(FMOL /  IOOmI)
FIGURE 4.8
CYCLIC GMP RADIOIMMUNASSAY STANDARD CURVES 
All cyclic GMP radioimmunoassays were carried out 
using acetylated standards and samples. 
Radioimmunoassay buffer (RIA)
Neutralised perchloric acid
Neutralised perchloric acid diluted 1/2 with 
RIA buffer
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not effect the sensitivity.
The samples and standards were always assayed 
in the same relative concentrations of neutralised 
perchloric acid and RIA buffer. Brooker et al. (1979)
have suggested two methods for validating RIA 
procedures. These can be summarised as:
(1) demonstrating parallelism between the assay 
standard curve and serial dilutions of 
samples; and
(2) demonstrating full recovery of known amounts 
of unlabelled cyclic nucleotides added to 
samples.
Both these criteria have been fully satisfied 
in the RIA of cyclic nucleotides as applied to mouse 
thymus extracts (see legend of Figure 4.7).
The susceptibility of samples to cyclic 
nucleotide phosphodiesterase degradation has been cited 
as proof that the immunoreactive substances in tissue 
extracts are cyclic nucleotides. Brooker et al. (1979)
have found, however, that the purest commercially 
available enzyme preparations may themselves be 
contaminated with cyclic nucleotides, their binding 
proteins and other degradative activities. Therefore, 
application of cyclic nucleotide phosphodiesterases to 
verify RIA procedures can be difficult to interpret.
For this reason, phosphodiesterase degradation of 
samples was not employed in validation of the assays.
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4.2.12 Validation of cyclic nucleotide recovery 
As stated in Section 4.2.4, the use of 
tritiated cyclic nucleotides to monitor the 
percentage recovery of unlabelled cyclic nucleotides 
from the extraction and neutralisation procedures 
could not be applied to the measurements of cyclic 
AMP and cyclic GMP made upon mouse thymus. It was 
necessary to show that the various manipulations 
yielded very high percentage recoveries of the cyclic 
nucleotides. Preliminary studies showed that with 
necessary care, 100% recovery of added [3H]-cyclic 
nucleotides could be obtained from the homogenization 
and centrifugation procedures. The neutralisation and 
associated centrifugation step similarly yielded >95% 
of added [3H]-cyclic nucleotide. A comparison of the 
PCA/KOH extraction and neutralisation with the 
commonly used TCA/ether extraction procedures in terms 
of the percentage recovery of added [3H]-cyclic 
nucleotide was carried out. The results of this are 
shown in Table 4.2. The results show the validity of 
the procedure which has been adopted.
4.2.13 Analysis of data
In experiments where both bound (supernates) 
and free (charcoal pellet) radioactivity was counted 
the bound to free (B/F) ratio was estimated according 
to the formula:
B/F = BS - BNSB 
FS + BNSB
where BS = bound counts in sample or standard,
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TABLE 4.2
RECOVERY OF [3H]-CYCLIC NUCLEOTIDES 
FROM PCA/KOH AND TCA/ETHER EXTRACTION PROCEDURES
Cyclic
Nucleotide
Extraction
Procedure Tissue
[3H]-cNMP 
cpm added
[3H]-cNMP 
cpm recovered % recovery
PCA/KOH Thymus 3700 3666 99
Kidney 3700 3636 98
CYCLIC AMP
TCA/ether Thymus 3700 2744 74
Kidney 3700 1874 50
PCA/KOH Thymus 3700 3662 99
Kidney 3700 3602 97
CYCLIC GMP
TCA/ether Thymus 3700 866 23
Kidney 3700 930 25
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FS = free counts in sample or standard, BNSB = bound 
counts in non-specific binding tube.
A program for accomplishing this calculation 
was devised by Hunt (1978). This program was used with 
a Texas Instruments TI 59 programmable calculator. As 
stated earlier (Section 4.2.9), in later experiments 
only the bound form of the cyclic nucleotide was 
counted. This procedure was adopted because of the 
utilization of the CFit algorithm computer program as 
formulated by Brooker et al. (1979). This has three 
advantages:
(1) The program improves the interpretation of the 
assay at low standard concentrations, especially 
when acetylation techniques are employed.
(2) The program allows for direct calculation and 
print out of results without the necessity for 
a graphical representation.
(3) The program provides an assessment of the 
precision of the standard curve fitted to the 
points. The curve can be recalculated to 
exclude 'outliers'.
4.3 Cyclic Nucleotide Phosphodiesterase Activity
4.3.1 Introduction
Cyclic nucleotide phosphodiesterases represent 
a class of enzymes that catalyse the hydrolysis of the 
3',5'-diester bond of 3',5'-cyclic nucleotides, 
yielding the 5'-mononucleotides (see Section 2.5).
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Hence,
3'/5'-cyclic adenosine monophosphate— ► 5'-adenosine monophosphateA
PhosphodiesterasesY3'/5'-cyclic guanosine monophosphate — ► 5'-guanosine monophosphate 
As with the assays of cyclic nucleotides 
themselves, and the enzymes involved in their synthesis 
(see Sections 4.1 and 4.2), research into the complexity 
of the phosphodiesterases was severely limited until the 
development of assays that were sufficiently sensitive to 
allow detection of the very small amounts of products 
formed. The limitations were alleviated by the 
introduction of radioactively labelled substrates which 
allow detection of the product in the picomole range 
(Thompson et al., 1974). Labelled cyclic nucleotides are 
now extensively utilized in the assay of cyclic AMP 
phosphodiesterases (Appleman and Kemp, 1966; Beavo et al., 
1970; Thompson and Appleman, 1971) and cyclic GMP 
phosphodiesterases (Brooker et al. , 1968; Beavo et al.,
1970; Thompson and Appleman, 1971) .
The variety of methods available for assaying 
cyclic nucleotide phosphodiesterases and the problems 
associated with these techniques have been extensively 
reviewed (Appleman et al., 1973; Thompson et al., 1974b; 
Wells and Hardman, 1977; Thompson et al., 1979). Thompson 
et al. (1979), in the most recent review, document the major
advantages and disadvantages of current assays and also 
review the resolution of the multiple molecular species of 
phosphodiesterase by the methods of ion exchange
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chromatography, preparative acrylamide gel electro­
phoresis coupled with isoelectric focussing and 
sucrose-gradient ultracentrifugation.
The method of assaying 'total' cyclic nucleotide 
phosphodiesterase activity (Appleman et al., 1973) in 
homogenates of mouse thymus in the experiments 
documented in this thesis has been that of Boudreau and 
Drummond (1975) , which is a modification of the procedure 
of Thompson and Appleman (1971) .
4.3.2 Principle of assay
The 'batch' assay of Thompson and Appleman (1971), 
or modifications of the procedure, provides a relatively 
simple, sensitive and reproducible method of activity 
analysis in crude or partially purified enzyme preparations. 
Tritiated substrates are converted by phosphodiesterase 
preparations to the respective 5'-mononucleotides. The 
separation of the 5'-mononucleotides from the unconverted 
substrate is facilitated by enzymatic conversion to the 
nucleotides by the 5'-nucleotidase activity present in 
snake venom (see Figure 4.9). The nucleotides can then 
be separated from the charged cyclic nucleotide substrates 
by precipitation with an anion-exchange resin, leaving 
the radioactivity associated with the nucleotides in 
the supernate. This can then be measured by liquid 
scintillation counting.
The coupled series of enzyme reactions can be 
performed in a scintillation vial such that the phospho­
diesterase and snake venom are incubated together and 
termination of the reaction is achieved by addition of
5’ - AMP
OH
HO OH
ADENOSINE
OH
HO OH
5’ - GMP GUANOSINE
FIGURE 4.9
PRINCIPLE OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ASSAY
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the anion-exchange resin. The resin absorbs unreacted 
substrate and quenches its scintillation. This is 
therefore a one-step reaction. Alternatively, the 
conversion of [3H]-substrate by phosphodiesterase 
can be accomplished in the absence of snake venom. 
Termination of the phosphodiesterase reaction is then 
followed by a second incubation in which the snake 
venom nucleotidase actively degrades the products 
of the initial reaction. This two-step procedure 
minimises possible effects of snake venom preparations 
upon the activity of the phosphodiesterases and was 
adopted in these experiments.
The limits of detection of these techniques 
are determined by the specific activities of the 
tritiated labelled substrates available and according 
to Thompson et al. (1979) are ~10 nM for cyclic AMP
phosphodiesterase and ~30 nM for cyclic GMP phospho­
diesterase. Comments by Thompson et al. (1979)
regarding the problem of direct stoichiometry of the 
reactions and also non-specific nucleotide binding to 
commercially available anion-exchange resins highlight 
the care necessary in interpretation of results. The 
stoichiometry problem is particularly pertinent to 
tissue homogenates and can be minimised by short 
incubation times. Theoretically, if reaction side-products 
are uncharged they do not bind to the anion-exchange 
resins. Non-specific binding of product to the resins 
would lead to an under-estimation of total enzyme 
activity. Modifications to the method of Thompson and
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Appleman (1971) using a methanol-resin slurry (Thompson 
et a_l. , 1976) , an ethanol-resin slurry (Londesborough, 
1976) or acidification of the resin (Boudreau and 
Drummond, 1975) have been reported to alleviate this 
problem.
4.3.3 Preparation of homogenates
Animals were killed by cervical dislocation.
The thymuses were removed as stated in Section 4.1.2.
The individual thymuses were weighed and then placed 
in 2 ml of 'phosphodiesterase assay buffer' (see 
Appendix III) at 4°C. The EGTA (250 yM) incorporated 
in the assay buffer serves to eliminate Ca2+-dependent 
alterations in cyclic nucleotide hydrolysis (Boudreau 
and Drummond, 1975). Preliminary experiments were 
carried out to establish the appropriate dilution of 
the tissue on a wet weight basis. It was found that the 
addition of 200 yl of phosphodiesterase assay buffer 
per mg wet weight of tissue resulted in a suitable 
substrate conversion when assayed at 1 yM and 100 yM 
substrate, incubated for 20-30 minutes and 90-120 
minutes respectively. The tissue was chopped and 
transferred to the homogeniser. The appropriate volume 
of assay buffer was then added and the tissue homogen­
ised with 12 strokes of a tight-fitting Dounce 
homogenizer (Kontes Glass). The homogenate was then 
filtered through a double layer of moistened gauze to 
remove any large aggregates and the enzyme activity was
assayed immediately.
185
4.3.4 Purification of [3H]-cyclic AMP and
[3H]-cyclic GMP
The tritiated labelled substrates for the 
phosphodiesterase assay were obtained from the 
Radiochemical Centre, Amersham, UK (see Appendix II). 
There are inherent problems with tritium exchange and 
substrate instability, factors which are especially 
relevant to the cyclic GMP phosphodiesterase assay 
(Thompson et al., 1974b). For this reason the tritiated 
substrates were 'purified' prior to their use in assay 
procedures. During the course of these experiments two 
protocols were followed to achieve this purification of 
labelled substrate.
The first of these was based upon ion-exchange 
resin column chromatography (Schultz et al., 1974) using 
the Dowex 50 columns described in Section 4.1.4.1. To 
20 y1 of the tritiated stock cyclic nucleotide, 480 yl 
of glass distilled water was added. This volume was then 
applied to a prewetted Dowex column and the eluate 
collected into a glass scintillation vial. Aliquots 
(500 yl x 8) of glass distilled water were then added 
to the column and the eluates collected into separate 
glass vials. A 10 yl sample of each aliquot was then 
counted following the addition of 5 ml of scintillation 
fluid. Using the counts per minute obtained, an elution 
profile was established. Appropriate aliquots were 
pooled and a 10 yl sample counted. Using the value 
(cpm) obtained, an appropriate volume of the 
labelled nucleotide was aliquoted into 4 ml plastic test 
tubes, such that the total radioactivity in the
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[3H]-cyclic AMP aliquots was 1.2 x 106 cpm (i.e. 
sufficient for 60 tubes, 50 yl per tube equivalent 
to 20,000 cpm) , and in the [3H]-cyclic GMP aliquots 
was 1 x 106 cpm (i.e. sufficient for 50 tubes, 50 yl 
per tube equivalent to 20,000 cpm). These aliquots 
were frozen and stored at -20°C. It should be noted 
that the elution profiles of cyclic AMP and cyclic GMP 
from the Dowex 50 anion-exchange columns are different 
(for details see Schultz et al. , 1974).
The second purification procedure resulted 
from a personal communication with M.M. Appleman (1980). 
As the majority of the tritium-exchange occurs between 
the labelled nucleotides and water it is possible to 
purify the nucleotides by removing the water in the 
stock solutions. This can be achieved by drying an 
aliquot of the stock under a stream of nitrogen or air. 
A volume (20-50 yl) of the stock nucleotide was added 
to a small volume (200-300 yl) of absolute ethanol in 
a plastic test tube. The tube was then clamped in ice 
and a stream of nitrogen or air passed into the test 
tube. Phosphodiesterase assay buffer (500 yl) was 
added to the tube which was then vortexed thoroughly.
A 10 yl aliquot of the solution was counted following 
the addition of 5 ml of scintillation fluid. Using the 
value obtained (cpm) an appropriate volume of the 
solution was aliquoted to give a total amount of 
radioactivity similar to that described in the first 
purification procedure. Aliquots were frozen and stored 
at -20°C prior to use. This latter technique was much
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simpler than the anion-exchange column chromatography 
procedure and in terms of assay blank values obtained 
was clearly preferable, especially for cyclic GMP 
phosphodiesterase assays. Purification of the stock 
nucleotides was carried out prior to a series of 
experiments to minimise increases in blank values due 
to tritium exchange occurring in the stored frozen 
aliquots.
4.3.5 Preparation of the anion-exchange resin
The preparation of the anion-exchange resin 
for-use in the second stage of the reaction, i.e.
5'-AMP ► Adenosine, was similar to that described by
Boudreau and Drummond (1975). Dowex anion-exchange 
resin (Bio-rad, 1X8, 200-400 mesh, chloride form, 1000 g) 
was stirred continuously for 20-30 minutes in 2 litres 
of 0.5 N NaOH. The suspension was filtered under low 
pressure and the resin resuspended in 2 litres of glass 
distilled water. This was stirred for 20-30 minutes, 
filtered and again resuspended in 2 litres of glass 
distilled water and the stirring procedure repeated. 
Following filtration the resin was resuspended in 
2 litres of 0.5 N HCl and stirred for 20-30 minutes.
The resin was washed with 4 litres of glass distilled 
water before being resuspended in three resin volumes 
of 0.1 N HCl and allowed to stand overnight at 4°C.
The next day the resin was washed exhaustively (5x3 
litres glass distilled water) and finally resuspended 
in 3 resin volumes of glass distilled water and kept 
at 4°C prior to use. The pH of the resin suspension was
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For each new batch of resin prepared in the 
manner described a control experiment was carried out 
using 1 yM and 100 yM substrate concentrations and 
incorporating an assay blank. The same phosphodiesterase 
preparation was utilized but a comparison of 'old* 
versus 'new' Dowex resin was performed. The resin was 
only utilized in subsequent experiments if the 
substrate conversion and the blank values were comparable 
for the two resin preparations. If discrepancies were 
observed the new resin was washed further and the 
control experiment repeated.
4.3.6 Preparation of assays
All phosphodiesterase assays were carried out 
in 12 x 75 mm disposable plastic test tubes. The assays 
were aliquoted, as outlined below, in batches of twelve 
(i.e. sufficient for six animals as the phosphodiesterase 
activities of the thymuses from one animal were assayed 
independently). The assay tubes were stored at -20°C 
prior to use. The unlabelled substrates (cyclic AMP and 
cyclic GMP) were stored at -20°C in a range of 
concentrations from 2 yM to 2000 yM. Although phospho­
diesterase activity was assayed at 1 yM and 100 yM 
substrate concentrations in homogenate preparations, 
the kinetic analysis of soluble and particulate 
fractions required the utilization of the range of 
cyclic nucleotide concentrations (see Section 4.3.9).
The tubes aliquoted for each assay consisted
of:
-5 .
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(1) Total added radioactivity ('total count')
50 y1 of tritiated cyclic nucleotide, 150 yl 
of phosphodiesterase assay buffer, 100 yl of 
a 'stopping solution' (see Section 4.3.7),
50 yl of glass distilled water, 1 ml of 3 mM 
acetic acid (cyclic AMP-PDE) or 1 ml of 115 yM 
formic acid (cyclic GMP-PDE). Note that the 
total counts are appropriately quenched in all 
respects when compared to the assay blank and 
tubes containing substrate.
(2) Assay blank
50 yl of tritiated cyclic nucleotide and 150 yl 
of phosphodiesterase buffer.
(3) 1 yM substrate
50 yl of tritiated cyclic nucleotide and 50 yl 
of a 4 yM solution of unlabelled substrate.
(4) 100 yM substrate
50 yl of tritiated cyclic nucleotide and 50 yl 
of a 400 yM solution of unlabelled substrate.
All determinations were carried out in 
triplicate. The stored aliquots of 'purified' labelled 
cyclic nucleotide were taken up in 3 ml ([3H]-cyclic 
AMP) or 2.5 ml ([3H]-cyclic GMP) of phosphodiesterase 
assay buffer.
4.3.7 Incubation 1: phosphodiesterase
The assay tubes were placed in a shaking water 
bath maintained at 37°C. The incubation was initiated by 
the addition of 100 yl of the homogenate, which was kept 
on ice. As discussed in Section 4.3.9, the time of
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incubation and dilution of sample was such that substrate 
conversion was below 25% of the total substrate available 
to the enzymes. The phosphodiesterase reaction was 
terminated by the addition of 100 yl of a 'stopping' 
solution which consisted of 50 mM EDTA and 30 mM 
theophylline in glass distilled water. The EDTA serves to 
chelate the magnesium ions whose function is to fulfil 
the divalent ion requirement for the enzyme catalysis. 
Theophylline, a methylxanthine, is an inhibitor of 
phosphodiesterase activity which has been extensively 
used to minimize cyclic nucleotide degradation (Appleman 
et al. , 1973). The assay blank tubes, i.e. those tubes 
receiving assay buffer to replace unlabelled substrate 
and enzyme preparation, also received 100 yl of the 
stopping solution. The tubes were then frozen and kept 
at -20°C until the second incubation could be carried 
out. Magnesium ions are not required for the 
5'-nucleotidase reaction.
4.3.8 Incubation 2: 5'-nucleotidase
The assay tubes were placed in a shaking water 
bath maintained at 37°C. The nucleotidase reaction was 
initiated by the addition of 50 yl of the enzyme 
preparation to blank, 1 yM and 100 yM assay tubes.
During the course of these experiments two different 
sources of 5'-nucleotidase activity were used. Initially 
a partially purified enzyme preparation (5‘-nucleotidase, 
grade IV, Sigma N5880) was used, such that 2.5 units of 
activity was added in 50 yl volume. One unit of enzyme 
activity hydrolyses 1 yM of inorganic phosphorus from
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adenosine 5'-monophosphate per minute at pH 9 at 37cC.
The nucleotidase was aliquoted in disposable plastic 
test tubes sufficient, in total, for 50 assay tubes and 
stored at -20°C. Upon use the aliquots were taken up in 
2.5 ml of glass distilled water. The above procedure 
was modified to utilize the 5'-nucleotidase activity 
present in snake venom (Crotalus atrox, Western Diamond- 
back rattlesnake, Sigma V7000). The venom was used at a 
concentration of 1 mg/ml and aliquoted as described 
above for the 5'-nucleotidase preparation. The phospho­
diesterase enzyme activity of the same preparation was 
found to be identical when assayed at 1 yM and 100 yM 
substrate concentrations using the partially purified 
5'-nucleotidase or the snake venom in the segond 
incubation. The blank values were similarly unaltered by 
this modification (Appleman, personal communication, 
1980).
After a 20-minute incubation the reaction was 
terminated by the addition of 1 ml of a resin slurry 
(3 parts 3 mM acetic acid to 1 part resin for cyclic AMP 
phosphodiesterase assay and 3 parts 115 mM formic acid to 
1 part resin for cyclic GMP phosphodiesterase assay). 
These modifications to the Thompson and Appleman (1971) 
procedure as outlined by Boudreau and Drummond (1975) 
are documented as improving the recovery of the 
respective nucleotides without increasing the amount of 
radioactivity obtained in the assay blank. The tubes are 
then incubated at room temperature for 10 minutes at 
which time they are vortexed and then centrifuged at 
2000 g for 5 minutes. A 500 yl aliquot of the supernates
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was withdrawn immediately and placed into plastic 
scintillation vials containing 7 ml of scintillation 
fluid. A 500 yl aliquot was withdrawn from the 'total 
count' tubes and treated similarly. All vials were 
vortexed and counted in a Packard Tri-carb scintil­
lation counter for 5 minutes.
4.3.9 Kinetic analysis
Assays of phosphodiesterase activity to obtain 
estimates of the Km and Vmax were carried out in a 
manner similar to that which has been described above. 
Assays were performed in triplicate using a range of 
substrate concentrations between 0.5 yM and 500 yM.
The homogenate preparations were separated into soluble 
and particulate fractions by a 30 minute centrifugation 
at 100,000 x g (maintained at 4°C) in a Beckman L3-50 
ultracentrifuge. The soluble fraction was removed and 
kept at 4°C until assayed, whilst the particulate 
fraction was resuspended in phosphodiesterase assay 
buffer and rehomogenized by 6 strokes of a tight-fitting 
Dounce homogeniser. The preparation was filtered through 
a double layer of moistened gauze to remove any large 
aggregates and the soluble and particulate fractions 
were then assayed for activity immediately. The time of 
incubation and dilution of sample were adjusted to keep 
substrate conversion below 25%.
The average cyclic nucleotide substrate 
concentration during the incubation was calculated and 
used in plots of [S]/v versus [S]. This procedure 
represents a slight modification of the Lineweaver-Burk
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equation (Lineweaver and Burk, 1934) as described by 
Lee and Wilson (1971). For a comparison of the 
hypothetical plots see Figure 4.10. The presence of 
two forms of the enzyme in each fraction was suggested 
by the form of the kinetic plots, i.e. non-linear 
(see Figures 4.11 and 4.12). Similar data has been 
obtained for phosphodiesterase preparations from many 
sources and is considered to indicate the presence of 
high and low affinity forms of the enzyme. It should 
be appreciated that kinetic evidence is only suggestive 
of multiple enzyme forms and that confirmation of this 
requires physical separation followed by characteriza­
tion of the isolated enzymes (Appleman et al., 1973) . 
Least-squares regression was used to calculate Km values 
after assignment of the break-off points from the plots 
of [S]/v vs [S] .
Estimates of the Km and Vmax of cyclic AMP 
phosphodiesterases for soluble and particulate fractions 
were obtained for mouse thymus and mouse kidney 
preparations and are documented in Chapter Six.
4.3.10 Calculation of results
Results are expressed as pmol of cyclic nucleotide 
hydrolysed per minute per milligram protein. Programs to 
calculate percentage conversion of substrate, reaction 
velocity (v) in pmol/min/yg protein and [S] from 
percentage conversion were formulated by Hunt (personal 
communication, 1978) and run on a Texas Instruments TI59 
programmable calculator.
X =  - r r *
max
max
S
Lineweaver and Burk (1934)
max
max
Lee and Wilson (1971)
FIGURE 4.10
COMPARISON OF THE HYPOTHETICAL KINETIC PLOTS OF 
LINEWEAVER AND BURK (1934) AND LEE AND WILSON (1971)
V = reaction velocity
S = substrate concentration
S = average substrate concentration for incubation
time t.
So = substrate concentration at time zero 
St = substrate concentration at time t
Vmax = maximum reaction velocity
Km = substrate concentration at half maximal velocity,
i.e. the Michaelis constant
[s]
J________________ I__
300 4000 100 200
[s]
500
FIGURE 4.11
PLOT OF [S]/v VERSUS [S] FOR 'SOLUELE' CYCLIC AMP 
PHOSPHODIESTERASE ACTIVITIES OF MOUSE THYMUS 
The enzyme preparation is described in Section 4.3.9. 
Phosphodiesterase activity was assayed over a 
concentration range of 0.5 to 500 yM cyclic AMP.
The insert represents the low concentration range 
plotted on an appropriate scale. For this preparation 
the kinetic parameters, calculated as in Section 4.3.9, 
were as shown below.
Km (yM) Vmax (pmol cA hydrolysed/min/mg protein)
3.48 72.8
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FIGURE 4.12
PLOT OF [S]/v VERSUS [S] FOR 'PARTICULATE' CYCLIC AMP 
PHOSPHODIESTERASE ACTIVITIES OF MOUSE THYMUS 
The enzyme preparation is described in Section 4.3.9. 
Phosphodiesterase activity was assayed over a 
concentration range of 0.5 to 500 yM cyclic AMP. The 
insert represents the low concentration range plotted 
on an appropriate scale. For this preparation the 
kinetic parameters, calculated as in Section 4.3.9, 
were as shown below.
Km (yM) Vmax (pmol cA hydrolysed/min/mg protein)
2.3 60.3
203 1036
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4.4 Assay of Protein
The results contained in this thesis are 
expressed as:
(1) for adenylate cyclase activity - pmol of cyclic 
AMP produced per 12 minute incubation per 
milligram protein;
(2) for phosphodiesterase activity - pmol of cyclic 
nucleotide hydrolysed per minute per milligram 
protein; and
(3) for cyclic nucleotide concentrations - pmol of 
cyclic nucleotide per milligram protein.
Determination of the amounts of protein present 
in the respective assays was by the method of Lowry et al., 
(1951) using bovine serum albumin (fraction V, Armour 
Pharmaceuticals, Eastbourne, UK) as a standard. The 
standards (0-400 yg/ml) and samples were assayed in 
triplicate. Homogenates of tissue that had been stored 
frozen at -20°C for a period of time proved difficult to 
rehomogenize for protein estimation. To avoid this 
problem, when homogenization procedures were carried out 
a 100 yl aliquot of the homogenate was taken, in 
duplicate, into 100 yl of 6% (w/v) TCA. This procedure 
precipitated the protein present in the homogenate.
These samples were stored at 4°C until assayed. The 
precipitated protein was pelleted by centrifugation 
at 2000 x g for 10 minutes at 4°C and the TCA was 
removed by aspiration. The pellet was resuspended in 
a volume (usually 1 or 2 ml) of solution C (Lowry 
et al. , 1951). This procedure precipitated all of the
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protein in the 100 y1 aliquot of the homogenate, as 
shown in Table 4.3.
The protein pellets derived from the centrifu­
gation procedures described in Section 4.2 (i.e. from 
PCA treated tissue) were redissolved in a small volume 
(200-500 yl) of 1 N NaOH. This procedure was followed 
by a 1 in 10 dilution of the 1 N NaOH with glass 
distilled water. Aliquots for protein determination 
were then taken into 100 yl of TCA.
The concentration of bovine serum albumin 
present in the buffer electrolyte used in the assay 
of adenylate cyclase (Section 4.1) was taken into 
consideration in calculating the amount of protein 
present in the homogenates.
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TABLE 4.3 
VALIDATION OF THE
TRICHLOROACETIC ACID (TCA) PRECIPITATION PROCEDURE 
USED IN THE ASSAY OF PROTEIN
A volume of the standard solutions used in the assay was 
taken into an equal volume of 6% (w/v) TCA and stored at 
4°C overnight. The precipitated protein was pelleted and 
treated as described in Section 4.4. A comparative assay 
of normal standard solutions versus the known amounts of 
precipitated protein was carried out.
Concentration
(yg/ml) Normal
Absorbance Reading
TCA-precipitated
25 16 14
50 33 30
100 67 60
200 124 114
400 217 218
Units are arbitrary.
CHAPT ER F I V E
H O R M O N E - S E N S I T I V E  ADENYLATE CYCLASE 
IN NORMAL,  P R E N E O P L A S T I C  AND N E O P L A S T I C  THYMUSES
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Thymus Adenylate Cyclase
Activation of adenylate cyclase by hormones and 
other agents
Preliminary studies using thymus homogenates from 
C576J mice were carried out to establish some basic 
properties of the system. The response of the enzyme to a 
range of hormones is shown in Figure 5.1. The basal 
activity was enhanced by noradrenaline, adrenaline, 
isoproterenol (a ß-adrenergic agonist), dopamine, 
prostaglandin E x, 5' -hydroxytryptamine and sodium fluoride. 
Glucagon, parathyroid hormone (PTH), histamine and salmon 
calcitonin (not shown in Figure 5.1) had no stimulatory or 
inhibitory effects. These observations are in agreement 
with previously published studies on the responsiveness of 
thymus adenylate cyclase. Makman (1971) observed that the 
enzyme activity of rat and mouse thymus could be enhanced 
by adrenaline, noradrenaline and fluoride, but not by 
histamine, adrenocorticotropic hormone (ACTH), PTH or 
glucagon. Similarly Huang et al. (1973), using mouse 
thymocytes, obtained stimulation of adenylate cyclase 
activity by noradrenaline, adrenaline, prostaglandin E 1 
and fluoride but no effect with glucagon, ACTH, growth 
hormone, prolactin, thyroid-stimulating hormone, 
prostaglandin F 2a, histamine and insulin.
Adrenaline (10— 4 M) was observed to produce a 
greater activation of the enzyme than noradrenaline at the
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FIGURE 5.1
RESPONSE OF MOUSE THYMUS ADENYLATE CYCLASE TO VARIOUS 
HORMONES
Values represent means ± S.E.M. of a triplicate 
determination from a single representative experiment
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Glucagon 10“6 M 
C = Glucagon 10”4 M 
D = Parathyroid hormone 2 i.u.
E = Histamine 10“4 
F = 5-Hydroxytryptarnine 10“4 M 
G = Prostaglandin Ex 10“4 M 
H = Dopamine 10”4 M 
I = Noradrenaline 10”4 M 
J = Adrenaline 10“4 M 
K = Isoproterenol 10”7 M 
L = Isoproterenol 10”6 M 
M = Isoproterenol 10”5 M 
N = Isoproterenol 10“4 M 
= Sodium fluoride 10-2 M0
199
same concentration (300% and 130% increase over basal 
activity respectively). This differential sensitivity 
to the two catecholamines is consistent with previous 
reports (Makman, 1971; Huang et al.,1973). Dose-response 
curves for activation of the enzyme by isoproterenol and 
adrenaline in the presence and absence of alprenolol 
(10“4 M), a ß-adrenergic antagonist, are shown in 
Figures 5.2 and 5.3. Half maximal stimulation was 
obtained with approximately 10-6 M and 6 x 10-5 M 
agonist respectively. The blockade by alprenolol suggests 
that the catecholamines act through ß-adrenergic receptors. 
Makman (1971) noted that catecholamine activation could be 
blocked by propanolol (a ß-adrenergic antagonist) but not 
phentolamine (an a-adrenergic antagonist). This 
observation was confirmed by Singh et al. (1979) who also
demonstrated that L-[propyl-2,3-3H]-dihydroalprenolol, a 
radioligand for ß-adrenergic receptors, was specifically 
bound by foetal and young adult mouse thymocytes.
Where possible all agents added to incubation 
tubes for the assay of adenylate cyclase were dissolved 
and/or diluted in buffer electrolyte (Section 4.1). 
Prostaglandin E , however, was dissolved and stored in 
ethanol (20 yg/10 yl). These aliquots were appropriately 
diluted with buffer electrolyte to give final concentra­
tions in the incubation of 10“6 - 10“4 M. It was found 
that 10 yl of ethanol diluted appropriately to give 
equivalent concentrations to those present in the 10-6 - 
10~4 prostaglandin E1 incubations caused activation of 
the enzyme at the low, but not at the higher,dilutions.
9  loo
io7 io6 io5 io4
[Isoproterenol]  (moi/i)
FIGURE 5.2
DOSE-RESPONSE RELATIONSHIP OF ACTIVATION OF MOUSE THYMUS 
ADENYLATE CYCLASE BY THE 3“ADRENERGIC AGONIST, 
ISOPROTERENOL
Values represent means ± S.E.M. where n = 4 in each case.
Isoproterenol alone
Isoproterenol plus alprenolol (10-4 M)
O
400
FIGURE 5.3
DOSE-RESPONSE RELATIONSHIP OF ACTIVATION OF MOUSE THYMUS 
ADENYLATE CYCLASE BY ADRENALIN
Values represent means ± S.E.M. where n = 2 in each case.
Adrenalin alone
iiiiiiiiiniiiniiiBiiiii^  ^Adrenalin plus alprenolol (10“4 M)
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An 'ethanol control' was subsequently incorporated into 
all assays and values presented for 10~4 M prostaglandin E1 
represent corrected enzyme activities. The stimulatory 
effect of ethanol has also been observed by Hynie et al. 
(1980) who noted that cyclic AMP levels were increased 
by ethanol, and the stimulation of cyclic AMP production by 
isoproterenol, prostaglandin E ± and adenosine potentiated, 
in human peripheral blood lymphocytes. Rabin and Molinoff 
(1980) have also shown that ethanol elicits a dose 
dependent increase in both basal- and dopamine-stimulated 
adenylate cyclase activity in mouse striatal tissue.
These effects of the solvent are suggested to result from 
an alteration in the 'fluidity' of the cell membrane 
(Hynie et al., 1980) and they clearly demonstrate the 
necessity for appropriate controls.
As discussed in Section 2.2.4 it has been shown 
that GTP is required for hormonal activation of adenylate 
cyclase in all cell types that have been studied in detail. 
GTP itself stimulates cyclic AMP production in broken cell 
preparations and the dose-response relationship is shown in 
Figure 5.4. Gpp(NH)p, a stable analogue of GTP, stimulates 
enzyme activity and the dose-response curve is also shown 
in Figure 5.4. Half maximal stimulation was obtained at 
approximately 8 x 10“5 M for both agents. Gpp(NH)p 
produced a much greater activation than GTP at 10"4 M 
(480% and 100% increase over basal activity respectively). 
This difference presumably reflects the destruction of the 
GTP-liganded, active form of the enzyme complex by 
hydrolysis of GTP to GDP by the GTPase activity putatively
I—
O
—
I
FIGURE 5.4
DOSE-RESPONSE RELATIONSHIP OF ACTIVATION OF MOUSE THYMUS 
ADENYLATE CYCLASE BY GTP AND ITS STABLE ANALOGUE Gpp(NH)p 
Values represent means ± S.E.M. where n = 4 in each case 
for Gpp(NH)p and n = 2 in each case for GTP.
O  GTP
O ' " " .. .........h Q  Gpp (NH) p
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associated with the 'N-protein'. As Gpp(NK)p is resistant 
to hydrolysis by GTPase it is capable of producing a 
persistently activated state of the enzyme (for example 
Schramm and Rodbell, 1975; Michelangeli et al., 1977).
Using the information discussed above it was 
decided to assess the responsiveness of the adenylate 
cyclase system to stimulation by isoproterenol 
(10~7 - 10“5 M) , prostaglandin Ex (10~6 - 10“1* M) ,
Gpp(NH)p (10-7, 10-5 M) and NaF (10— 2 M) in the thymuses 
of AKR and C576J mice at various ages (see Section 5.2).
5.1.2 Combined effects of hormones and Gpp(NH)p and
preincubation studies
It has been demonstrated in other systems that 
combinations of hormones and guanyl nucleotides, particularly 
Gpp(NK)p, can activate adenylate cyclase to a level that is 
higher than the sum of the activities produced by the agents 
when added separately (Londos et al., 1974; Rodbell et al., 
1975; Schramm, 1975; Schramm and Rodbell, 1975; Hunt et al., 
1976; Michelangeli et al., 1977). The elevated responses 
have been referred to as being 'supra additive'. The recent 
model of Rodbell (1980), that was discussed in Section 2.2.6, 
may provide one of the most plausible explanations of this 
phenomenon. Should oligomeric structures between RN units 
exist within cell membranes then such an arrangement would 
allow for homotropic interactions (i.e. interactions 
between similar units within a complex). Occupation of only 
a small number of receptors by hormone, in the presence of 
saturating GTP, could therefore generate near maximal 
production of the RN-GTP monomer that activates the
202
catalytic unit. Rodbell proposes,therefore,that ’although 
full occupation of receptor subunits may drive complete 
coupling of RN with C, coupling may occur even when these 
units are not occupied with hormone'. It should be 
appreciated that 'free' RN units must exist within 
membranes to allow for activation of the enzyme by guanyl 
nucleotides in the absence of added hormone. Figure 5.5 
demonstrates that the 3-adrenergic-sensitive adenylate 
cyclase system of mouse thymus does not exhibit 'supra 
additive' effects of combinations of hormone and Gpp(NH)p.
It may be speculated that the RN units in the thymus 
membranes do not exist as oligomeric structures, thus 
effectively removing possible homotropic interactions 
that could result in near maximal cyclase activation with 
only minimal occupation of receptors. Rodbell (1980) has 
suggested that certain differences in the properties of 
adenylate cyclase from turkey erythrocytes, liver and 
adipose tissue may reflect the observed lack of an 
oligomeric structure of RN in isolated erythrocyte membranes. 
In this respect, mechanistic interpretation of 'supra 
additivity' is made more difficult by the studies of 
Bilezikian and Aurbach (1974) and Aurbach et al. (1975)
which clearly demonstrate 'supra additive' responses to 
isoproterenol and Gpp(NH)p in turkey erythrocyte 
preparations. The observation that the thymus system does 
not even show additivity is difficult to interpret, 
especially as at low concentrations of hormone and 
nucleotide the system is not stimulated to maximal 
capacity.
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FIGURE 5.5
ACTIVATION OF MOUSE THYMUS ADENYLATE CYCLASE BY 
ISOPROTERENOL AND Gpp(NH)p, AND COMBINATIONS OF 
THE TWO AGONISTS
Values represent means ± S.E.M. of a triplicate 
determination from a single representative experiment. 
The hatched areas over columns H-0 indicate the 
expected enzyme activities if the responses to the 
two agonists were 'additive'.
Code Treatment
A = Buffer electrolyte
B = Isoproterenol 10“7
C = Isoproterenol 10“6
D = Isoproterenol 10“5
E = Isoproterenol 10“4
F = Gpp(NH)p 10“6 M
G = Gpp(NH)p 10“5 M
H = Isoproterenol 10“7
I = Isoproterenol 10“6
J = Isoproterenol 10"5
K = Isoproterenol 10"4
L = Isoproterenol 10“7
M = Isoproterenol 10“6
N = Isoproterenol 10“5
0 = Isoproterenol 10“4
(basal enzyme activity) 
M 
M 
M 
M
M plus Gpp(NH)p 10“6 M 
M plus Gpp(NH)p 10-6 M 
M plus Gpp(NH)p 10“6 M 
M plus Gpp(NH)p 10“6 M 
M plus Gpp(NH)p 10"5 M 
M plus Gpp (NH)p 10“ 5 M 
M plus Gpp(NH)p 10“ 5 M 
M plus Gpp(NH)p 10“ 5 M
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Figure 5.6 demonstrates that, in contrast to 
combinations of isoproterenol and Gpp(NH)p, the combined 
effects of PGE1 and the nucleotide analogue do give 
additive, and at some concentrations small 'supra 
additive',effects. Why this distinction between the 
effects of the two hormones exists is not clear from the 
experiments reported here. Clearly to further investigate 
these preliminary observations a detailed study of the 
kinetics of the reactions would need to be undertaken.
Preincubation of some adenylate cyclase 
preparations with hormones has been shown to produce an 
activated state that is not readily reversible by 
washing (for example Rodbell et al., 1974; Schramm and 
Rodbell, 1975; Michelangeli et al., 1977). In addition 
to the enhanced basal activity of preincubated 
preparations the response, in terms of cyclic AMP 
generated in the"subsequent assay, to guanyl nucleotides 
can also be markedly enhanced (Michelangeli et al., 1977). 
Thymuses, dissected as described in Section 4.1.2, were 
washed in RPMI 1640 medium supplemented with 5% (v/v)
foetal calf serum (FCS) prior to being finely chopped and 
subdivided into roughly equal amounts. A preincubation 
period was initiated by the addition of the tissue to 
either 4 ml of RPMI 1640/5% FCS (buffer alone) or 4 ml 
of 10-7 M or 10”5 M isoproterenol in RPMI 1640/5% FCS.
The tubes were continuously rotated at 37°C for 20 minutes 
at which time 6 ml of cold buffer electrolyte was added. 
The tubes were immediately centrifuged (2000 rpm, 4°C,
3 minutes in a Damon PR-6000 centrifuge). The supernates
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FIGURE 5.6
ACTIVATION OF MOUSE THYMUS ADENYLATE CYCLASE BY 
PROSTAGLANDIN E 1 AND Gpp(NH)p, AND COMBINATIONS 
OF THE TWO AGONISTS
Values represent means ± S.E.M. of a triplicate 
determination from a single representative experiment 
Where the two agonists were used in combination the 
contribution of each to the observed enzyme activity 
is indicated by the use of appropriate hatching.
Code Treatment
A = Buffer alone (basal enzyme activity)
B = Prostaglandin Ex 10"5 M
C = Prostaglandin E1 10“4 M
D = Gpp(NH)p 10“6 M
E = Gpp(NH)p 10"5 M
F = Prostaglandin Ex 10"5 M plus Gpp(NH)p 10“6 M
G = Prostaglandin E-l 10~5 M plus Gpp(NH)p 10”5 M
H = Prostaglandin Ex 10“4 M plus Gpp(NH)p 10“6 M
= Prostaglandin E 1 10“4 M plus Gpp(NH)p 10”5 MI
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of this first spin were discarded and a further 10 ml 
of buffer electrolyte added to each tube. The tissue 
was resuspended and subjected to a further centrifuga­
tion as described above. The supernates of this second 
spin were again discarded and the tissue resuspended in 
an appropriate volume of buffer electrolyte and 
homogenized as in Section 4.1.2. The homogenates were 
immediately assayed for basal adenylate cyclase activity 
and response to stimulation by Gpp(NH)p 10“7 - 10-5 M. 
The results of these studies are shown in Figure 5.7.
It can be seen that preincubation with hormone had 
little effect on the basal enzyme activity in the 
subsequent assay. Basal activities (mean ± S.E.M. n=3) 
were 524 ± 48, 508 ± 63 and 579 ± 38 pmol of cyclic AMP 
generated per 12 minutes per mg protein for tissue 
preincubated in buffer alone, 10“7 M and 10~5 M 
isoproterenol respectively. The response to stimulation 
by Gpp(NH)p was also unaltered by the different 
preincubation conditions (see legend of Figure 5.7).
That these observations reflected the true properties 
of the thymus adenylate cyclase system, and were not 
due to an inability to observe hormone-induced activated 
states in the assay system used, was confirmed by 
experiments using chick kidney membranes and parathyroid 
hormone. The enzyme preparation was as described by Hunt 
et al. (1976) . The membranes were preincubated for 
6 minutes, as described above, in a total volume of 2 ml 
of 'buffer alone' or PTH (10 i.u./ml). The preincubation 
period was terminated as described previously and the
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FIGURE 5.7
EFFECT OF PREINCUBATING MOUSE THYMUS TISSUE WITH 
ISOPROTERENOL ON THE RESPONSE OF MOUSE THYMUS 
ADENYLATE CYCLASE TO STIMULATION BY Gpp(NH)p 
IN THE SUBSEQUENT ASSAY
Values represent means ± S.E.M. where n = 3 in each case. 
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Gpp(NH)p 10"7 M 
C = Gpp(NH)p 10-6 M 
D = Gpp (NH) p 10" 5 M
The increases in cyclic AMP production over basal levels 
produced by the addition of Gpp(NH)p were calculated and 
the results, means ± S.E.M., are shown below.
Preincubation Condition Assay Addition
Gpp (NH) p 
10“7 M
Gpp (NH) p 
10"6 M
Gpp(NH)p 
10“5 M
'Buffer alone'i 156 ± 74 481 ± 43 1206 ± 158
Isoproterenol 10"7 M 77 ± 41 436 ± 36 1232 ± 83
Isoproterenol 10“5 M 109 ± 83 578 ± 128 1465 ± 273
205
homogenates assayed immediately for basal activity and 
response to Gpp(NH)p (10~7 - 10-5 M) and NaF (10-2 M).
The results of this experiment are shown in Figure 5.8. 
The observations of Michelangeli et al. (1977) are
confirmed in that basal enzyme activity of membranes 
preincubated with PTH was elevated when compared to 
those membranes preincubated in 'buffer alone'
(984 ± 255 and 261 ± 19 respectively). The changes in 
cyclic AMP production resulting from the addition of 
Gpp(NH)p were also elevated in membranes preincubated 
with hormone (see legend of Figure 5.8). In summary, 
isoproterenol does not induce an activated state of 
thymus adenylate cyclase that is resistant to washing 
procedures. The subsequent responses to Gpp(NH)p 
stimulation in tissue preincubated with the agonist are 
normal.
5.1.3 Effects of a-adrenergic agonists on thymus
adenylate cyclase activity
As discussed in Sections 2.2.1 and 2.2.6 the 
inhibition of adenylate cyclase by a variety of hormones 
and neurotransmitters has received considerable attention 
recently. GTP and, in most studies, sodium ions have been 
shown to be necessary to demonstrate hormone-induced 
inhibition. Using the a2-adrenergic agonist clonidine 
(Wikberg, 1979),in the presence and absence of added GTP 
and sodium ions, inhibition of basal or GTP-stimulated 
enzyme activity could not be demonstrated in thymus 
preparations (see Figure 5.9). The assay of the same 
enzyme preparation was carried out in either buffer
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FIGURE 5.8
EFFECT OF PREINCUBATING CHICK KIDNEY MEMBRANES 
WITH PARATHYROID HORMONE ON THE BASAL ADENYLATE CYCLASE 
ACTIVITY AND RESPONSE TO STIMULATION BY Gpp(NH)p AND 
NaF IN THE SUBSEQUENT ASSAY
Values represent means ± S.E.M. of a triplicate 
determination from a single representative experiment. 
Basal adenylate cyclase activities were 261 ± 19 and 
984 ± 255 for tissue preincubated in 'buffer alone' and 
parathyroid hormone (10 i.u./ml) respectively.
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Gpp(NH)p 10~7 M 
C = Gpp(NH)p 10“6 M 
D = Gpp(NH)p 10~5 M 
E = NaF 10“2 M
The increases in cyclic AMP production over basal 
levels produced by the addition of Gpp(NH)p and NaF 
were calculated and the results, mean ± S.E.M., are 
shown below.
Preincubation
Condition Assay Addition
Gpp(NH)p 
10"7 M
Gpp(NH)p 
10"6 M
Gpp(NH)p 
10-5 M
NaF
10"2 M
'Buffer alone' 211 ± 30 947 ± 73 1788 ± 163 2129 ± 185
Parathyroid 
hormone 
(10 i.u./ml)
875 ± 91 1936 ± 117 2961 ± 180 1605 ± 46
600
—  500 “  
E
CM
c  
<d 
o 
a
400
o
E
3
a
LU
u
3
QoO'
Q_
Q_
2<
300
U
>-u 200
100
Assay Buffer 25 mM NaCl 100 mM NaCl
FIGURE 5.9
EFFECT OF THE cx-ADRENERGIC AGONIST CLONIDINE ON 
BASAL AND GTP-STIMULATED MOUSE THYMUS ADENYLATE 
CYCLASE ACTIVITY
Values represent means ± S.E.M. of a triplicate 
determination from a single representative 
experiment.
Code Treatment
A = Buffer electrolyte (basal enzyme activity) 
B = GTP 10“4 M 
C = Clonidine 10-5 M
D = GTP (10-4 M) plus Clonidine (10 5 M)
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electrolyte, buffer electrolyte containing 25 mM NaCl 
or buffer electrolyte containing 100 mM NaCl. In the 
system employed the addition of NaCl to the assay 
buffer produced an inhibition of basal enzyme activity 
(466 ± 19, 285 ± 11 and 203 ± 13 respectively). The 
reason for this solute-induced inhibition is not known 
but it may be speculated that the addition of large 
amounts of sodium and/or chloride ions interferes with 
the interactions of the catalytic unit with its 
Mg2+-ATP substrate. No inhibitory effects of clonidine 
upon enzyme stimulation produced by isoproterenol 
(10“5 M) , Gpp(NH)p (10— 5 M) or NaF (10-2 M) were observed. 
Methoxamine (10“6 - 10-4 M ) , an a1-adrenergic agonist 
(Wikberg, 1979), similarly had no effect upon basal, GTP 
(10— 5 M) , isoproterenol (10— 5 M) or NaF (10~2 M) 
stimulated enzyme activity (data not shown). The evidence 
therefore suggests that thymus preparations do not 
contain a-adrenergic receptors that are functionally 
coupled to Ni units to produce inhibition of adenylate 
cyclase activity. Whether the tissue contains any 
a-adrenergic receptors could be determined only by 
specific radioligand binding studies.
5.1.4 Desensitization of isoproterenol-sensitive
adenylate cyclase
Agonist-induced desensitization of adenylate 
cyclase systems was discussed in Section 2.2.5. Thymus 
tissue was preincubated in 'buffer alone', 10 7 M 
isoproterenol or 10”5 M isoproterenol as described in 
Section 5.1.2. Basal enzyme activity and the response to
207
isoproterenol (10-7 - 10“4 M) stimulation in the 
subsequent assay was assessed. The results of these 
experiments are shown in Figure 5.10 and associated 
legend. It is clearly demonstrated that preincubation 
of thymus tissue with the agonist induces a desensitized 
state of the isoproterenol-sensitive adenylate cyclase. 
Whether this refractoriness to subsequent stimulation is 
a consequence of 'down-regulation' of receptor number or 
occurs by some other mechanism would require the use of 
specific radioligand binding techniques. The desensitiza­
tion of isoproterenol-sensitive adenylate cyclase is 
discussed further in Section 5.4 where the phenomenon is 
considered in thymuses of young, old and tumour-bearing 
AKR mice.
5.2 Hormone-sensitive Adenylate Cyclase in
Preneoplastic Thymuses
The primary objective of this investigation was 
to examine possible aberrations in cyclic nucleotide 
metabolism occurring in the preneoplastic period of 
thymic lymphoma development. A progressive pattern of 
alteration in basal adenylate cyclase activity and in 
the responsiveness of the enzyme to stimulation by 
catecholamines has been observed in the preneoplastic 
phase of hepatic carcinogenesis. Figure 3.2 is 
illustrative of such changes. The time course of 3'-MeDAB 
hepatoma induction in rats is markedly different from 
that of lymphoma development in the thymuses of AKR mice 
(i.e. approximately 12-14 weeks and 6 months respectively). 
However, the chronic ingestion of ethionine results in
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FIGURE 5.10
DESENSITIZATION OF ISOPROTERENOL-SENSITIVE MOUSE 
THYMUS ADENYLATE CYCLASE
Values represent means ± S.E.M. where n = 3 in each case. 
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Isoproterenol 10“7 M
C = Isoproterenol 10”6 M
D = Isoproterenol 10“5 M
E = Isoproterenol 10“4 M
The increases in cyclic AMP production over basal 
levels produced by the addition of isoproterenol 
were calculated and the results, means ± S.E.M., 
are shown below.
Preincubation
Condition Assay addition (Isoproterenol)
10"7 M 10"6 M 10"5 M 10“-4 M
'Buffer alone' 243 ± 58 667 ± 119 887 ± 207 835 ± 215
Isoproterenol 10“ 7 M 26 ± 20 135 ± 22 256 ± 69 221 ± 27
Isoproterenol 10“ 5 M 12 ± 12 92 ± 45 173 ± 71 209 ± 98
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hepatoma induction at approximately 30-35 weeks after 
the commencement of the diet (DeRubertis and Craven,
1976) and as such has a somewhat similar time course 
to the lymphoma development. Alterations in cyclic 
nucleotide metabolism were observed at early time 
points in the ethionine induction and these changes 
persisted through to hepatoma development. Kemp et al.
(1975) have suggested that basal adenylate cyclase 
activity increases significantly in the preleukemic 
period and that this enhanced activity persists in 
the established thymic lymphomas of AKR mice. They also 
noted an age-related decrease in the epinephrine-induced 
stimulation of adenylate cyclase, with established 
tumours exhibiting a further diminished response that was 
significantly different from that of preleukemic mice of 
the same age. Kemp et al. (1975) divided AKR mice into
three groups:
(a) a nonleukemic group less than 5 months 
of age;
(b) a preleukemic group of approximately 7 
months of age; and
(c) a leukemic group with established thymic 
lymphomas and, frequently,metastases to 
the spleen and lymph nodes.
As progressive alterations in basal adenylate 
cyclase activity and responses of the enzyme to agonists 
have been observed in other systems the AKR and C576J 
mice used in this study were killed at carefully controlled 
ages such that the data obtained could be assigned to
209
tightly defined age groups. Figure 5.11 shows the age- 
related basal adenylate cyclase activity (pmol cyclic 
AMP produced/12 minutes/mg protein; mean ± S.E.M.) of 
thymuses of AKR and C576J mice. Care should be taken 
in observation of the results, in that not all age 
groups for the two strains are directly comparable.
Results obtained from established thymic lymphomas have 
not been incorporated into the data expressed in this 
Figure. It should be noted that C576J mice, up to an 
age of 360 days, never exhibited a thymic lymphoma, 
suggesting that this strain represented a suitable 
control for these studies. Expression of the results 
in this form suggests that no consistent pattern of 
progressive alteration in basal enzyme activity occurs 
in the preneoplastic period of lymphoma development.
The basal adenylate cyclase activities for all animals 
studied were 218 ± 9 for the AKR strain (n=49) and 
208 ± 7 for the C576J strain (n=54). For AKR mice the 
lowest basal enzyme activity, 170 ± 33, was observed 
in mice aged between 130-140 days and the highest,
281 ± 35, in mice aged between 230-240 days. The 
corresponding values for C576J mice were 133 ± 19 at 
270-280 days and 253 ± 13 at 290-300 days. The results 
suggest that the basal enzyme activity is reasonably 
constant with age and comparable in the two strains of 
mice. That the total capacity of the adenylate cyclase 
system also remains fairly consistent as the mice age 
is suggested by the results shown in Figures 5.12 and 
5.13. The response of the enzyme to stimulation by 10"7 M
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FIGURE 5.11
AGE-RELATED BASAL ADENYLATE CYCLASE ACTIVITY IN THE 
THYMUSES OF AKR AND C576J MICE
Values represent means ± S.E.M. The hatched lines 
that run parallel to the horizontal axis represent 
the mean of the means of all age groups considered.
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Values represent means. Standard errors were always
less than 20% of the mean value.
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and 10“5 M Gpp(NH)p is shown in Figure 5.12. For clarity 
of representation, particularly in later Figures where 
the responses of the adenylate cyclase system to 
different concentrations of isoproterenol and 
prostaglandin E1 are considered, the data is expressed 
as the percentage increase over basal activity produced 
by the agonist. No progressive alteration in Gpp(NH)p 
responsiveness is seen at either concentration. The 
mean percentage increase in activity for all age groups 
caused by 10~7 M Gpp(NH)p was 15% for AKR and 14% for 
C576J mice. At 10“5 M the corresponding values were 380% 
and 342%. Activities expressed as pmol of cyclic AMP 
produced/12 minutes/mg protein for all age groups for 
10“7 and 10“5 M Gpp(NH)p in AKR and C576J mice 
respectively were 251 ± 13 and 1049 ± 50, and 237 ± 13 
and 912 ± 43. Figure 5.13 shows the response of the 
enzyme to stimulation by 10”2 M sodium fluoride. The 
mean percentage increases for all age groups considered 
were 523% and 541% for AKR and C576J mice. Enzyme 
activities (expressed as above) were 1343 ± 82 for AKR 
and 1288 ± 53 for C576J mice.
The responsiveness of adenylate cyclase to 
stimulation by 10“7 - 10”5 M isoproterenol in thymuses 
of AKR and C576J mice is shown in Figure 5.14. The mean 
percentage increases over basal activity produced by 
10”7, 10-6 and 10 5 M agonist in AKR and C576J mice for 
all age groups were 25, 98 and 219, and 29, 105 and 236 
respectively. Enzyme activities for all age groups 
(expressed as above) of AKR and C576J mice were 273 ± 13,
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FIGURE 5.14
AGE-RELATED ISOPROTERENOL ACTIVATION OF ADENYLATE 
CYCLASE IN THE THYMUSES OF AKR AND C576J MICE 
Values represent means. Standard errors were always 
less than 20% of the mean value.
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410 ± 23 and 696 ± 38, and 270 ± 18, 423 ± 28 and 698 ± 42 
respectively. The results show that the isoproterenol 
stimulation of adenylate cyclase remains reasonably 
constant and comparable as the mice of both strains age, 
although as will be discussed in Section 5.3 the mice in 
the earliest age group (50-80 days) are seen to have 
elevated responses to isoproterenol in terms of cyclic AMP 
produced in the assay.
Figure 5.15 shows the age-related prostaglandin E1 
(10-6 - 10 4 M) stimulation of thymus adenylate cyclase in 
the two strains of mice. The prostaglandin E responsive­
ness, expressed as percentage increase over basal enzyme 
activity, was much more variable than any other of the 
agonists discussed above, this being especially so for the 
control C576J series. The cause of this variability is 
unknown. The mean percentage increases for all AKR and 
C576J age groups caused by 10“6 , 10-5 and 10 4 M agonist 
were 13, 40 and 66 and 10, 37 and 78 respectively. Enzyme 
activities (expressed as above) were 247 ± 12, 306 ± 15 
and 362 ± 19 for AKR mice and 230 ± 12, 283 ± 17 and 
367 ± 22 for C576J mice for increasing concentrations of 
the agonist.
Therefore, the expression of data in small, 
carefully defined age groups suggests that no consistent 
pattern of progressive alteration in basal enzyme activity 
or responses to agonists occurs in the preneoplastic 
period of thymic lymphoma development. This seems to be 
the case whether one considers the AKR strain alone, or 
compares the AKR to the control C576J series.
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5.3 Hormone-sensitive Adenylate Cyclase in
Preneoplastic and Neoplastic Thymuses
To accommodate a more comprehensive statistical 
analysis of the data the results were subdivided into 
large age groups, these being <100, 100-200 and >200 
days. The data obtained from established thymic lymphomas 
was also introduced to compare the basal activity and 
responsiveness to agonist stimulation in neoplastic 
thymuses with that observed in normal and preleukemic 
tissue. The earliest age at which a tumour was observed 
in this study was 195 days. Figure 5.16 shows the basal 
adenylate cyclase activities and responses to stimulation 
by isoproterenol for AKR and C576J mice classified into 
the large age groups and established tumours. The 
respective n values for each group are given in the 
Figure legend. Neoplastic thymuses exhibited a significantly 
elevated basal adenylate cyclase activity (p <0.01) when 
compared to all other AKR and C576J age groups (see 
Tables 5.1 and 5.2). This observation is in agreement 
with Kemp et al. (1975). However, the basal enzyme
activity of the >200 day AKR group was not significantly 
different (p >0.1) from the <100 and 100-200 day age 
groups of the same strain, or the C576J age groups (see 
Table 5.1). This observation, that the basal enzyme 
activity is not elevated in the thymuses of preleukemic 
mice, is not consistent with the previous study of Kemp 
and coworkers. Should this discrepancy be due to some 
intrastrain variation between animals maintained in 
different environments then it can be suggested that the 
altered adenylate cyclase activity observed by Kemp et al.
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TABLE 5.2
STATISTICAL ANALYSIS OF TUMOUR BASAL ADENYLATE CYCLASE ACTIVITY 
AND OF AGONIST INDUCED INCREASES IN CYCLIC AMP PRODUCTION
The data obtained for lymphomas (see Table 5.1) was compared to 
that obtained for large age groups of AKR mice. Statistical 
analysis was by the Mann-Whitney rank test. Values of P <0.05 
were considered significant.
Age Group (days) <100 100-200 >200
Basal P <0.01 P <0.01 P <0.01
Isop. 10“7 M P >0.1 P >0.1 P >0.1
Isop. 10“6 M P >0.1 P >0.1 P >0.1
Isop. 10-5 M P >0.1 P >0.1 P >0.1
PGEi 10-6 M P >0.1 P >0.1 P >0.1
PGEi 10"5 M P <0.05 P <0.01 P <0.01
PGEi 10“4 M P >0.1 P <0.01 P <0.01
Gpp(NH)p 10”7 M P <0.02 P <0.01 P <0.01
Gpp(NH)p 10“° M P <0.05 P <0.01 P <0.01
NaF 10“2 M P <0.05 P <0.01 P <0.01
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(1975) in the preneoplastic thymus may not be related 
to the ultimate development of the lymphoma. The 
assumption that the percentage incidence of lymphoma 
development was comparable for the mice used in the 
two studies would have to be made.
To take into account the enhanced basal 
activity in the established tumours the increase in 
cyclic AMP production resulting from the addition of 
various concentrations of isoproterenol was calculated 
for each group. These values, expressed as mean ± S.E.M., 
are presented in Table 5.1. The increases in cyclic AMP 
production caused by isoproterenol in established tumours 
were not significantly different to those observed for 
the AKR large age groups (p >0.1; see Tables 5.1 and 5.2). 
It can be seen from Table 5.1 that, particularly at higher 
concentrations of the agonist, mice from the <100 day age 
group exhibited an enhanced responsiveness to isoprotere­
nol when compared to older age groups. Therefore the small 
age-related decrease in catecholamine responsiveness 
observed by Kemp et al. (1975) is supported by these
results. However, the further decrease in catecholamine 
responsiveness in established tumours (discussed earlier) 
is not observed if the data of the present study is 
expressed as the increase in cyclic AMP production, as 
shown in Table 5.1. Kemp et al. (1975) based their
conclusion that catecholamine responsiveness was decreased 
in tumours by presenting data as the percentage increase 
in enzyme activity caused by the agonist. When expressed 
in this form the <100 day AKR mice showed 20, 94 and 250%, 
the 100-200 day mice 30, 93 and 230%, the >200 day mice
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21, 80 and 200% and the established tumours 15, 56 and 
116% increases for 10“7, 10~6 and 10-5 M isoproterenol 
respectively. Therefore the present data when expressed 
in a similar fashion is in agreement with the suggestion 
of Kemp and coworkers. However, this apparent decrease 
in percentage catecholamine responsiveness is clearly a 
function of the increased basal enzyme activity if the 
absolute increases in cyclic AMP production are 
considered (Table 5.1).
Figure 5.17 shows the basal adenylate cyclase 
activities and responses to stimulation by prostaglandin El 
for AKR and C576J mice classified into large age groups 
and tumours. The general format of the figure is as 
described for Figure 5.16. Basal enzyme activities have 
been included to allow visual assessment of the activation 
produced by the agonist. It can be seen from Tables 5.1 
and 5.2 that the established thymic lymphomas exhibited 
significantly elevated responses to prostaglandin E 1 when 
compared to AKR mice in the age groups 100-200 and >200 
days. The enhanced responsiveness was particularly evident 
at higher agonist concentrations. It should be noted that 
the tumour responsiveness to prostaglandin Ex was not 
significantly different from AKR mice in the <100 day age 
group, except at a concentration of 10~5 M agonist. The 
prostaglandin E1 responsiveness of C576J mice in the <100 
day age group was significantly elevated (p <0.05) when 
compared to AKR mice of the same age. The C576J strain 
exhibited an age-related decrease in prostaglandin E 1 
responsiveness which was not apparent in the AKR strain.
C
Y
C
LI
C
 A
M
P
 P
R
O
D
U
C
E
D
 (
pm
o
l/m
g 
pr
ot
ei
n/
12
m
in
1000
2576} AKR
BASAL PROSTAGLANDIN E
(M)
FIGURE 5.17
BASAL AND PROSTAGLANDIN E 1-STIMULATED ADENYLATE CYCLASE 
ACTIVITIES IN THE THYMUSES OF AKR AND C576J MICE 
CLASSIFIED INTO LARGE AGE GROUPS AND ESTABLISHED 
LYMPHOMAS
Values represent means ± S.E.M.
C576Jr J <100 days
m m m m m m i  100-200 days
1 >200 days
AKR
I I <100 days
100-200 days 
>200 days 
Thymic lymphomas
(n = 5) 
(n = 18) 
(n = 31)
(n = 5) 
(n = 24) 
(n = 21) 
(n = 7)
217
The significance of this observation in relation to the 
development of the lymphoma is not clear. It is 
interesting to note that Brdnstad et al. (1978)
observed enhanced responsiveness to prostaglandin E 1 
stimulation in chemically-induced hepatomas and that 
Trevisani et al. (1980) have observed Yoshida hepatoma
AH130 cells to produce significantly greater amounts of 
prostaglandins than normal hepatocytes. It would be of 
interest to assess the production of prostaglandins by 
normal, preleukemic and leukemic thymuses to see if the 
neoplastic tissue is capable of producing larger 
quantities of the compounds to which it exhibits enhanced 
responses.
Figure 5.18 shows the basal adenylate cyclase 
activities and responses to Gpp(NH)p and NaF for AKR and 
C576J mice classified into large age groups and tumours. 
The format of the Figure is that described previously 
for Figure 5.16. The activation of adenylate cyclase 
produced by 10~7 and 10~5 M Gpp(NH)p was significantly 
elevated in the established lymphomas when compared to 
mice of all other age groups (see Tables 5.1 and 5.2). 
Similarly, the stimulation produced by NaF was 
significantly elevated in established tumours when 
compared to all other age groups of C576J and AKR mice 
(see Tables 5.1 and 5.2). Both Gpp(NH)p and NaF require 
interaction with the 'N-protein' to activate adenylate 
cyclase. Therefore it is interesting to speculate that 
the membranes of established tumours have an increased 
amount of 'N-protein'. This speculation is amenable to
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experimental investigation and will be discussed in 
more detail in Chapter Eight. Whether the enhanced basal 
enzyme activity observed in established tumours results 
from an alteration in the amount of 'N-protein' alone 
or also requires an increased number of available 
catalytic units is not known. It could be argued that 
the increase in specific activity of adenylate cyclase 
observed in tumours was a consequence of a lower amount 
of protein in the assays. However, the fact that the 
expression of cyclic nucleotide levels in thymuses as 
pmol of cyclic nucleotide per mg protein or per mg weight 
(see Chapter Seven) did not result in a qualitative 
difference in the data suggests that the expression of 
enzyme activities as per mg protein is a valid 
representation. Interestingly, Boyd et al. (1978)
similarly observed the basal adenylate cyclase activity 
to be increased, and the responsiveness to stimulation 
by Gpp (NH)p and NaF to be enhanced, in 3'-MeDAB-induced 
cholangiocarcinomas.
An interesting qualitative observation can be 
made if Figures 5.16 - 5.18 are considered. The basal 
enzyme activity of C576J mice is highest in the youngest 
age group and exhibits a small age-related decrease.
The responses of the enzyme to stimulation by agonists 
follow a similar age-related profile to that seen for 
basal activity. The AKR mice, however, exhibit a decreased 
basal enzyme activity in the intermediate age group, a 
trend that is reversed in animals >200 days of age. As 
shown earlier, tumour basal enzyme activity was
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significantly elevated when compared to all other age 
groups. The responsiveness to agonist stimulation follows 
a similar age-related profile to that exhibited by the 
basal enzyme activity. The profile can qualitatively be 
described 'V-shaped'. The significance, if any, of this 
observation is obscure. It may be speculated that a cell 
type that has the enzyme characteristics observed in 
cells from established tumours emerges in one of the 
thymuses of animals >200 days of age. The presence of a 
focal proliferation of these cells may be the cause of 
the apparent 'reversal' of the decrease in basal enzyme 
activity seen in animals aged between 100 and 200 days. 
Selective proliferation of such a cell type could then 
result in the enzyme characteristics observed in the 
established tumours. As discussed in Section 1.3, the 
age-related thymic involution, a process that is evident 
from the thymus weights shown in Table 5.1, necessitated 
that the two thymuses of a single animal be combined for 
the assay of adenylate cyclase. The hypothetical 
discussion above suggests that it would be of interest 
to assess the enzyme activity and responsiveness to 
agonist stimulation in the individual organs of a single 
animal. It would be particularly beneficial to be able 
to compare the basal enzyme activity and responses to 
agonists in a thymic lymphoma with the 'partner thymus' 
from the same animal that has not been infiltrated with 
the neoplastic cells.
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5.4 Desensitization of Isoproterenol-sensitive
Adenylate Cyclase in Preneoplastic and
Neoplastic Thymuses
It was shown in Figure 5.10 (discussed in 
Section 5.1.4) that a desensitized state could be induced 
in the isoproterenol-sensitive adenylate cyclase system 
of thymuses from C576J mice by preincubation of the tissue 
with the agonist. Figure 5.19 shows that thymuses from 
AKR mice of <100 days of age when treated in a manner 
similar to that described in Section 5.1.2 also exhibited 
a reduced sensitivity to subsequent stimulation when 
preincubated with isoproterenol. Basal adenylate cyclase 
activities of tissue preincubated in 'buffer alone',
10 7 M or 10-5 M isoproterenol were 482 ± 23, 433 ± 22 
and 489 ± 39 pmol of cyclic AMP produced/12 minutes/mg 
protein respectively. The increases in cyclic AMP 
production over basal levels caused by the addition of 
10-7 - 10-4 M isoproterenol, 10“7 - 10~5 M Gpp(NH)p and 
10 2 M NaF to the incubation are shown in Table 5.3. It 
was decided to further investigate this agonist-induced 
desensitization of isoproterenol-sensitive adenylate 
cyclase in AKR mice of >200 days of age and in established 
thymic lymphomas. The rationale for carrying out such 
experiments was that should the preneoplastic or neoplastic 
tissue not exhibit agonist-induced desensitization then the 
cells could respond in a continuous fashion which 
theoretically might bestow some selective advantage upon 
them. Figure 5.20 shows the results of experiments with 
AKR mice that were >200 days of age. The basal adenylate 
cyclase activities, expressed as above, of tissue
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FIGURE 5.20
DESENSITIZATION OF ISOPROTERENOL-SENSITIVE ADENYLATE 
CYCLASE IN THYMUSES FROM AKR MICE >200 DAYS OF AGE 
Values represent means ± S.E.M. where n = 4 for tissue 
preincubated in ’buffer alone' and n = 5 for tissue 
preincubated in 10-7 or 10-5 M isoproterenol.
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Isoproterenol 10~7 M
C = Isoproterenol 10“6 M
D = Isoproterenol 10”5 M
E = Isoproterenol 10“4 M
F = Gpp(NH)p 10“7 M
G = Gpp(NH)p 10“6 M
H = Gpp(NH)p 10"5 M
I = NaF 10~2 M
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TABLE 5.3
INCREASE IN CYCLIC AMP PRODUCTION OVER BASAL LEVELS PRODUCED 
BY ISOPROTERENOL, Gpp(NH)p AND NaF IN AKR THYMUS TISSUE 
PREINCUBATED UNDER DIFFERENT CONDITIONS 
(Values represent means ± S.E.M.
Data expressed as pmol cyclic AMP produced/12 minutes/mg protein)
Preincubation
Condition
Incubation 
Additions (mol/1) <100 days >200 days Lymphomas
Isoproterenol icr7 229 ± 29 70 ± 33 56 ± 20
Isoproterenol IO'6 553 ± 67 219 ± 74 114 ± 45
Isoproterenol icr5 787 ± 83 431 ± 132 172 ± 58
Isoproterenol icr4 739 ± 117 390 ± 134 186 ± 76
Buffer alone Gpp (NH)p io-7 97 ± 47 82 ± 29 82 ± 10
Gpp(NH)p 10"6 444 ± 96 612 ± 106 608 ± 85
Gpp (NH)p icr5 1258 ± 81 1345 ± 179 1447 ± 431
NaF IO-2 1589 ± 
(n=4)
241 1793 ± 
(n=4)
250 1493 ± 
(n=4)
458
Isoproterenol icr7 45 ± 24 60 ± 19 23 ± 13
Isoproterenol icr6 142 ± 26 94 ± 24 46 ± 25
Isoproterenol io-5 285 ± 71 189 ± 61 77 ± 46
Isoproterenol io"4 248 ± 51 155 ± 66 74 ± 44
Isoproterenol 
10"7 M Gpp (NH)p icr7 95 ± 34 104 ± 25 88 ± 22
Gpp(NH)p icr6 457 ± 67 473 ± 108 703 ± 131
Gpp(NH)p io-5 1317 ± 135 1098 ± 319 1524 ± 260
NaF icr2 1349 ± 
(n=4)
133 1219 ± 
(n=5)
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1
1281 ± 
(n=4)
245
Isoproterenol icr7 30 ± 22 34 ± 12 19 ± 5
Isoproterenol io"6 96 ± 53 99 ± 18 62 ± 21
Isoproterenol 10~5 160 ± 20 172 ± 37 23 ± 14
Isoproterenol io-4 182 ± 28 189 ± 47 70 ± 27
Isoproterenol 
10"5 M Gpp(NH)p 10"7 91 ± 26 130 ± 19 115 ± 35
Gpp (NH)p io"6 500 ± 29 608 ± 67 603 ± 104
Gpp (NH)p icr5 1297 ± 63 1310 ± 147 1214 ± 231
NaF 10"2 1373 ± 
(n=4]
62
1
1551 ± 
(n=5
167
)
956 ± 
(n=4]
212
)
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preincubated in 'buffer alone', 10-7 M or 10-5 M 
isoproterenol were 358 ± 34, 195 ± 33 and 215 ± 32 
respectively. The reason for this increased variability 
in basal activity when compared to that observed in 
young AKR and C576J mice is unclear. It can be seen 
from Figure 5.20 that preneoplastic thymuses did 
exhibit agonist-induced desensitization. To accommodate 
the variation in basal enzyme activity observed, the 
increases in cyclic AMP production over basal levels 
produced by the addition of the various agents to the 
incubation were calculated and are shown in Table 5.3.
If the tissue preincubated in 'buffer alone' is 
considered and the results obtained for the mice in the 
older age group compared to those in the <100 day age 
group then the age-related decrease in catecholamine 
responsiveness discussed in Section 5.3 is confirmed by 
these results.
Figure 5.21 shows the results of a similar 
series of experiments using tissue from established 
thymic lymphomas. The basal adenylate cyclase activities, 
expressed as above, for tissue preincubated in 'buffer 
alone', 10""7 M or 10-5 M isoproterenol were 345 ± 38,
312 ± 43 and 190 ± 34 respectively. Therefore, as seen 
with mice from the older age group, the tumour tissue 
subjected to different preincubation conditions exhibited 
greater variation in basal enzyme activity when compared 
to the young AKR and C576J mice. To compensate for this 
variation in basal activity the increases in cyclic AMP 
production over basal levels were calculated and are
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FIGURE 5.21
DESENSITIZATION OF ISOPROTERENOL-SENSITIVE ADENYLATE 
CYCLASE IN ESTABLISHED THYMIC LYMPHOMAS
Values represent means ± S.E.M. where n = 4 in each case.
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Isoproterenol 10~7 M
C = Isoproterenol 10-6 M
D = Isoproterenol 10~5 M
E = Isoproterenol 10~4 M
F = Gpp(NH)p 10“7 M
G = Gpp(NH)p 10“6 M
H = Gpp(NH)p 10“5 M 
I = NaF 10“2 M
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shown in Table 5.3. It can be seen from Figure 5.21 that 
the established lymphomas exhibited agonist induced 
desensitization. A surprising observation from Figures 
5.19 - 5.21 and Table 5.3 is that the tumour tissue 
preincubated in 'buffer alone' did show a further decrease 
in catecholamine responsiveness when compared to the >200 
day age group preincubated in a similar fashion. It is 
difficult to compare the results of these studies with 
the results that have been discussed in Sections 5.2 and 
5.3 as the tissue is subjected to very different 
conditions prior to its assay for basal adenylate cyclase 
activity and agonist responsiveness. However, it was 
noted in Section 5.3 that, in contrast to the observations 
of Kemp et al. (1975), the results of the present study 
did not indicate that the established tumours exhibited a 
further decrease in catecholamine responsiveness when 
compared to preleukemic mice of the same age. It is 
interesting to speculate that the 3-adrenergic receptors 
coupled to adenylate cyclase in tumour cell membranes 
are more susceptible to uncoupling by experimental 
manipulation than those of membranes in normal or 
preleukemic thymus. In view of this speculation it should 
be noted that the assay of adenylate cyclase activity by 
Kemp and co-workers (1975) was performed on a 10,000 x g 
sediment fraction of a thymus cell extract that had 
previously been subjected to homogenization, washing and 
sonication procedures. Furthermore, the assay incubation 
period was 1-2 hours.
Figures 5.19-5.21 and Table 5.3 show that
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preincubation of thymus tissue from <100 day, >200 day 
old mice and established thymic lymphomas with 10“7 M 
or 10“5 M isoproterenol had no effect on the subsequent 
stimulation of adenylate cyclase by Gpp(NH)p and NaF.
This result is in agreement with that observed in thymus 
tissue from C576J mice discussed previously in Section 
5.1.2 and shown in Figure 5.7.
A desensitized state could be induced, therefore, 
in normal, preleukemic and leukemic thymus tissue. To 
attempt to quantitate the extent of the desensitization 
produced by preincubation with the different agonist 
concentrations, the mean peak increases in cyclic AMP 
production over basal levels by addition of isoproterenol 
to the incubation can be compared. For example, the <100 
day age group tissue preincubated in 'buffer alone' 
exhibited a maximal increase in cyclic AMP production of 
787 ± 83 pmol. Tissue preincubated with 10“7 M 
isoproterenol showed a maximal increase of 285 ± 71 pmol. 
Therefore, peak stimulation produced by isoproterenol 
following preincubation of tissue with 10“7 M of the 
agonist was only 36% of that seen in tissue preincubated 
in 'buffer alone'. The corresponding value for the 10“5 M 
preincubation was 23%. For the >200 day age group both 
10“7 and 10“5 M preincubations resulted in only 44% of 
the stimulation observed in tissue preincubated in 'buffer 
alone'. Corresponding values for the lymphomas were 41% 
and 38%. Quantitatively, therefore, the extent of 
desensitization produced in the three different groups of 
mice was similar. The results suggest that the >200 day
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age group and tumours did not show enhancement of the 
desensitized state with increasing concentrations of 
isoproterenol in the preincubation. That the desensitized 
state was specific to isoproterenol stimulation was 
suggested by the fact that prostaglandin E stimulation 
of the enzyme activity was not affected by the different 
preincubation conditions (data not shown). The age-related 
decrease in catecholamine responsiveness and, in these 
experiments, the further decrease in responsiveness in 
established tumours did not aid the interpretation of 
these results. It would be interesting to repeat these 
kinds of experiments using prostaglandin to induce 
desensitization, particularly as AKR mice did not exhibit 
an age-related decrease in prostaglandin E.j responsiveness 
and established lymphomas exhibited enhanced responsive­
ness to stimulation by this agonist.
5.5 Adenylate Cyclase Activity and Responsiveness
to Stimulation in Transplanted Lymphoma Cells
As discussed in Section 1.3 and shown in 
Figure 1.7 a cell suspension of a primary thymic lymphoma 
when injected subcutaneously (106 cells/animal) into 
syngeneic recipients resulted in growth of cells at the 
site of injection and dissemination to involve other 
lymphoid organs. The techniques used in the preparation 
of dispersed tumour cell suspensions and their transplan­
tation were essentially those described by Metcalf (1975a) . 
Basal adenylate cyclase activity and responsiveness to 
stimulation by 10“7 and 10-5 M isoproterenol, 10-7 and 
10-5 M Gpp (NH)p, 10"4 M prostaglandin E x and 10-2 M NaF
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was assayed in subcutaneous tumour tissue. The activity 
and responsiveness of the enzyme in thymuses and inguinal 
lymph nodes of animals bearing the transplanted tumour 
cells was also assayed. The animals used in these 
experiments represented the second passage of the 
lymphoma cells. As the subcutaneous tumour contained 
large amounts of diffuse connective tissue homogenization 
procedures were appreciably more difficult. To compensate 
for this, each preparation, following the 15 minute 
preincubation in buffer electrolyte, was homogenized with 
10 strokes of a tight fitting Dounce homogenizer. The 
results of these studies are shown in Figure 5.22. Basal 
adenylate cyclase activities (expressed as before) were 
554 ± 105, 206 ± 43 and 418 ± 103 for thymuses, subcutan­
eous tissue and lymph nodes respectively. The subcutaneous 
tumour tissue therefore exhibited a lower specific activity 
of adenylate cyclase and responsiveness of the enzyme to 
stimulation by agonists (as shown in Figure 5.22). This 
observation contrasts with that made in Section 5.3 where 
primary thymic lymphomas were shown to have significantly 
higher basal adenylate cyclase activities. It is suggested 
that this decrease in the specific activity results from 
the large numbers of dead and 'inert' cells within the 
subcutaneous tumour mass. This suggestion is supported 
by the fact that the inguinal lymph nodes exhibited 
higher specific adenylate cyclase activity when compared 
to the subcutaneous tumour tissue. The nodes were markedly 
enlarged and presumably the majority of the cells present 
were of transplanted tumour cell origin. The proportion of
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FIGURE 5.22
BASAL ADENYLATE CYCLASE ACTIVITY AND RESPONSIVENESS 
TO AGONIST STIMULATION IN TRANSPLANTED LYMPHOMAS,
THYMUSES AND LYMPH NODES OF AKR MICE
Values represent means ± S.E.M. where n = 3 in each case. 
Code Treatment
A = Buffer electrolyte (basal enzyme activity)
B = Isoproterenol 10“7 M 
C = Isoproterenol 10“5 M 
D = Gpp (NH) p 10“7 M 
E = Gpp(NH)p 10“5 M 
F = Prostaglandin Ei 10“4 M 
G = NaF 10"2 M
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dead cells in the lymph nodes was much lower than in 
the subcutaneous tumour tissue.
The thymuses of animals bearing transplanted 
lymphoma cells were observed histologically to be 
infiltrated by these cells. Metcalf (1975a) has 
suggested that transplantation of lymphoid leukemias 
never causes thymic lymphoma formation and that should 
a recipient develop a grossly enlarged thymus then 
this is a primary thymic lymphoma and not a transplanted 
tumour. All animals used as syngeneic hosts in 
transplantation studies were less than 100 days of age 
and as such would not be expected to exhibit neoplastic 
cells within their thymuses. The observation that 
transplanted lymphoma cells do infiltrate the thymuses 
is supported by the work of Meistrich et al. (1981) who
observed that lymphoma cells derived from a spontaneous 
AKR thymic lymphoma, when injected intraperitoneally, 
invaded the recipients' thymuses.
Numerous attempts to purify viable neoplastic 
cells from the subcutaneous tumour mass by centifugation 
of dispersed cell suspensions in Ficoll-hypaque were 
unsuccessful in obtaining a sufficiently high cell yield 
for the assay of adenylate cyclase activity. This was so 
even when the tissues from three animals were combined to 
give starting wet weights of 480 mg, 640 mg and 470 mg 
for thymuses, subcutaneous tumour tissue and lymph nodes 
respectively. A further problem was encountered in 
obtaining broken cell preparations of single cell 
suspensions. Cells from the thymuses and lymph nodes
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purified on Ficoll-hypaque had to be subjected to 
12 strokes of a tight-fitting Dounce homogenizer,
2 cycles of freeze-thawing and a further 2 strokes of 
the homogenizer to suitably disrupt the cells as 
observed microscopically. The basal adenylate cyclase 
activity was not preserved through these procedures.
These limited studies served to emphasise 
some of the problems that are encountered when 
attempting to biochemically analyse transplanted 
tumour cell populations. Clearly the growth of cells 
in suspension culture in vitro would provide a means 
of obtaining sufficient numbers of cells without the 
necessity for extensive purification procedures 
required to obtain meaningful results. The problem 
of preservation of basal adenylate cyclase activity 
and agonist responsiveness in obtaining broken cell 
preparations would require the application of a number 
of different regimes to determine the method most 
applicable to the specific system.
CHAPTER SIX
CYCLIC NUCLEOTIDE PHOSPHODIESTERASES IN 
NORMAL, PRENEOPLASTIC AND NEOPLASTIC THYMUSES
229
230
6.1 Cyclic Nucleotide Phosphodiesterases in
Normal and Preneoplastic Thymuses
The activities of cyclic nucleotide phospho­
diesterase enzymes were assayed in homogenates of 
thymuses from AKR and C576J mice as described in 
Section 4.3. In the following discussion enzyme 
activities obtained at the low (1 yM) and high (100 yM) 
substrate concentrations will be referred to as high 
affinity (low Km) and low affinity (high Km) forms of 
the enzymes, respectively. It is appreciated that, 
ideally, the multiple forms should be physically 
separated and kinetically characterized. However, the 
large numbers of animals used in this study made such 
procedures unfeasible.
As discussed in Section 4.3.9, a series of 
preliminary experiments were carried out to obtain 
estimates of the Km and Vmax of cyclic AMP phospho­
diesterase activities in the soluble and particulate 
fractions of a 100,000 x g centrifugation of 
homogenates of mouse thymus and kidney. The animals 
used in these experiments, the results of which are 
shown in Table 6.1, were C576J mice less than 100 
days of age. The values obtained are similar to 
those reported in other systems (Appleman et al.,
1973), and are comparable to those obtained by 
Menahan and Kemp (1976) for a variety of fractions
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TABLE 6.1
ESTIMATES OF Km AND Vmax OF 
CYCLIC AMP PHOSPHODIESTERASE ACTIVITIES OF 
MOUSE THYMUS AND KIDNEY
(Km values expressed as yM. Vmax expressed as pmol cyclic AMP 
hydrolysed/min/mg protein. Values are means ± S.E.M. where the 
n value was 5 in each case. Soluble and particulate fractions
were prepared and assayed as discussed in Section 4.3.9.)
Organ Fraction Vmax km
Soluble 82 ± 8 3.6 ± 0.2
Thymus 1051 ± 272 194 ± 54
Particulate 54 ± 8 2.23 ± 0.1
804 ± 191 212 ± 43
Soluble 60 ± 9 6.8 ± 1.5
Kidney 3832 ± 263 106 ± 9
Particulate 144 ± 18 3.2 ± 0.1
1855 ± 366 196 ± 8.4
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derived from sonicates of AKR thymocytes. Their data 
suggested at least two activities in each fraction 
analysed, one with a Km of 1-3 yM and the other with a 
Km of 150-500 yM.
As described in Chapter Five, the animals 
used in this study were killed at carefully controlled 
ages so that the data obtained could be ascribed to 
tightly defined age groups. The enzyme activities were 
assayed in the thymuses of each animal, treating each 
organ as an independent entity. All the results 
obtained from the assays of low and high affinity cyclic 
nucleotide phosphodiesterase activities were subjected 
to a comprehensive statistical analysis. To establish 
whether the data was normally distributed the values of 
kurtosis and skew of the distribution were obtained.
These values are shown in Table 6.2. For a normal 
distribution the skew value is approximately 1±0.3 and 
the kurtosis value is approximately 3±1. It can be seen 
that, in general, the data does approximate to a normal 
distribution but that some of the parameters are 
abnormally distributed, e.g. high affinity cyclic GMP 
phosphodiesterase activities. As shown in Table 6.2 
this is more evident when the differences in enzyme 
activities between left and right thymuses are considered; 
the significance of this parameter is discussed later in 
this Chapter. Statistical analysis using Student's t-test 
depends upon the data being normally distributed and, as 
such, this test was not appropriate to apply to the 
results reported here. The Mann-Whitney rank test does
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TABLE 6.2
VALUES OF KURTOSIS AND SKEW FOR 
CYCLIC NUCLEOTIDE PHOSPHODIESTERASE DATA
Parameter Kurtosis Skew N
High affinity1 cA-PDE Left 2.53 1.39 114
High affinity cA-PDE Right 2.63 1.50 114
Low affinity2 cA-PDE Left 3.07 1.48 112
Low affinity cA-PDE Right 2.39 1.35 113
High affinity cG-PDE Left 1.84 1.10 104
High affinity cG-PDE Right 0.6 0.77 104
Low affinity cG-PDE Left 4.61 1.62 103
Low affinity cG-PDE Right 2.10 1.39 103
Left - Right high affinity cA-PDE 6.20 2.17 114
Left - Right low affinity cA-PDE 3.39 1.84 112
Left - Right high affinity cG-PDE 1.98 1.50 104
Left - Right low affinity cG-PDE 5.22 2.03 103
1%High affinity' refers to that activity assayed at 1 yM substrate.
2 'Low affinity' refers to that activity assayed at 100 pM substrate.
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not assume or require a normal distribution and so 
this was used to evaluate the significance of any 
changes in enzyme activities which were observed.
Figure 6.1 shows the age-related activities 
of the high affinity (low Km) cyclic AMP and cyclic 
GMP phosphodiesterases. The values, representing 
means ± S.E.M., for each specific age group have 
been plotted in the middle of the age range of that 
group. No data obtained from lymphomas has been 
incorporated into this representation of the results.
In the youngest animals (50-80 days) cyclic AMP 
phosphodiesterase activity was significantly (p <0.01) 
higher in thymuses from C576J mice. The converse of 
this was observed in animals aged between 105-125 days, 
with the thymuses of AKR mice exhibiting significantly 
(p <0.02) higher activity than C576J animals. It can be 
seen that there was a marked peak in activity of the 
cyclic AMP phosphodiesterase enzyme in thymuses of AKR 
mice aged between 200-220 days. It appears from 
Figure 6.1 that high affinity cyclic AMP phosphodiesterase 
activity increases in the thymuses of AKR mice as the 
animals increase in age. The age-related profiles of 
enzyme activity in the AKR and C576J mice are 
different. This will be discussed in more detail below, 
where the data has been reclassified into larger age 
groups. The mean ± S.E.M. activities of all age groups 
were 25.7±2 and 21.8±1 for AKR and C576J mice 
respectively. Units are pmol of cyclic nucleotide 
hydrolysed/min/mg protein.
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FIGURE 6.1
AGE-RELATED HIGH AFFINITY CYCLIC AMP AND 
HIGH AFFINITY CYCLIC GMP PHOSPHODIESTERASE 
ACTIVITIES IN THYMUSES OF AKR AND C576J MICE 
Values represent means ± S.E.M. Enzyme activity was 
assayed at 1 yM substrate.
C576J Q "  
Age group --- On value
cA-PDE cG-PDE
AKR 
Age group . ... n value
cA-PDE cG-PDE
50- 80 10 10
105-125 10 10
130-140 8 8
150-180 10 -
200-220 10 10
220-260 10 10
260-280 10 10
320-360 4 4
50- 80 10 10
105-125 12 12
130-140 10 10
150-180 10 10
190-200 10 10
200-220 10 10
220-240 8 8
240-260 6 -
280-300 16 14
300-320 26 24
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In the youngest animals the activity of the 
high affinity cyclic GMP phosphodiesterase enzyme was 
significantly (p <0.01) higher in the thymuses of AKR 
mice. The higher activity observed in the AKR strain 
appears to be maintained as the animals age, with the 
C576J mice seeming to exhibit an age-related decrease 
in enzyme activity. The mean ± S.E.M. activities of 
all age groups were 18.7±1 and 11.5±1 for AKR and 
C576J mice respectively.
Figure 6.2 shows the age-related, low 
affinity cyclic nucleotide phosphodiesterase enzyme 
activities of thymuses from AKR and C576J mice. The 
activities of the cyclic AMP phosphodiesterase enzymes 
were not significantly (p >0.1) different in thymuses 
from the youngest age group considered. However, at 
every other age group where a direct comparison 
between the two strains could be made the thymuses 
from AKR mice exhibited significantly higher enzyme 
activity. The AKR strain clearly demonstrated an age- 
related increase in the activity of this enzyme, while 
the control C576J strain exhibited no significant 
changes as the animals increased in age. The mean ±
S.E.M. activities for all age groups considered were 
790155 and 542115 for the AKR and C576J mice 
respectively.
The activities of the low affinity cyclic GMP 
phosphodiesterase enzyme were not significantly (p >0.05) 
different in thymuses from AKR and C576J mice in the 
youngest age group. At every other age group where a
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FIGURE 6.2
AGE-RELATED LOW AFFINITY CYCLIC AMP AND CYCLIC GMP 
PHOSPHODIESTERASE ACTIVITIES IN THYMUSES OF AKR AND 
C576J MICE
Values represent means ± S.E.M. Enzyme activity was 
assayed at 100 yM substrate.
CiWbJ 
Age group n
cA-PDE
"■“ i Jvalue
cG-PDE
AKR ■■•■■■■
Age group n
cA-PDE
value
cG-PE
50- 80 10 10 50- 80 10 10
105-125 10 10 105-125 12 12
130-140 8 8 130-140 10 10
150-180 9 - 150-180 10 10
200-220 10 10 190-200 8 8
220-260 10 10 200-220 10 10
260-280 10 10 220-240 8 8
320-360 4 4 240-260 6 -
280-300 16 14
300-320 26 24
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direct comparison between the two strains could be made 
AKR mice had significantly higher enzyme activity. The 
AKR strain clearly demonstrated an age-related increase 
in the activity of the low affinity cyclic GMP phospho­
diesterase enzyme, while the C576J strain showed no 
significant alterations as the animals increased in 
age. The mean ± S.E.M. activities for all age groups 
considered were 974±69 and 532±19 for AKR and C576J 
mice respectively.
It must be stated, prior to discussing the 
results reclassified into the larger age groups, that 
the expression of the data obtained for the activities 
of cyclic nucleotide phosphodiesterases in small, 
tightly-defined age groups does allow the appreciation 
of age-related, progressive alterations in the 
preneoplastic period of lymphoma development (Figures 6.1 
and 6.2). This observation contrasts with that made for 
the basal adenylate cyclase activity and responsiveness 
of the enzyme to agonist stimulation, where no such 
progressive alterations were apparent.
At this point it is worthwhile reiterating some 
of the information given in Section 2.5.2 on the 
terminology that is most frequently used to describe the 
different forms of phosphodiesterase resolved by chroma­
tographic procedures:
(1) The DI form is a soluble enzyme that has a high 
affinity (low Km) for cyclic GMP and a low 
affinity (high Km) for cyclic AMP. This has been 
referred to as a cyclic GMP phosphodiesterase.
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(2) The DII form is a soluble enzyme that has 
low affinity (high Km) for both cyclic AMP 
and cyclic GMP. This has been referred to 
as a cyclic nucleotide phosphodiesterase.
(3) The Dill form is associated with the 
particulate fraction of the cell and has a 
high affinity (low Km) for cyclic AMP. This 
has been referred to as a cyclic AMP 
phosphodiesterase.
Figures 6.1 and 6.2 suggest that the activities 
of the high affinity cyclic AMP phosphodiesterase and 
the low affinity cyclic AMP and cyclic GMP phosphodies­
terase increase progressively in the thymuses of AKR 
mice as the animals age. Using the above terminology it 
can be suggested, therefore, that the DII and Dill forms 
increase in specific activity in the preneoplastic 
period of thymic lymphoma development in AKR mice, whilst 
the activity of the DI form remains unaltered. It can 
also be suggested that, in contrast to the AKR strain,in 
the control C576J mice the specific activities of the 
DII and Dill forms do not alter, whilst the DI form of 
the enzyme appears to exhibit an age-related decrease in 
specific activity. Again it is appreciated that making 
assertions such as these about enzyme activities derived 
from tissue homogenates is far from ideal. However, it 
is interesting to note that when assaying enzyme activity 
at 100 yM cyclic AMP or cyclic GMP one is presumably 
measuring predominantly the activity of the DII form. It 
can be seen from Figure 6.2 that the age-related changes
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in the activities of the 'low affinity cyclic AMP 
phosphodiesterase' and the 'low affinity cyclic GMP 
phosphodiesterase' are almost identical, whether the 
AKR or the C576J strain is considered. This suggests 
that the activities measured using the different 
substrates could be attributable to the same enzyme 
form.
6.2 Cyclic Nucleotide Phosphodiesterases in
Normal, Preneoplastic and Neoplastic
Thymuses
The activities of the cyclic nucleotide 
phosphodiesterases were reclassified into age groups of 
<100, 100-200 and >200 days. Data obtained from 
established thymic lymphomas was also introduced to 
allow a comparison of the enzyme activities in normal, 
preneoplastic and neoplastic organs. The activities of 
the high affinity forms of the enzymes are shown in 
Figure 6.3. The activity of the high affinity cyclic AMP 
phosphodiesterase enzyme of thymuses from C576J mice 
did not exhibit any significant (p >0.1) changes in the 
three age groups. In contrast to the C576J series, as 
was suggested by Figure 6.1, the AKR mice exhibited an 
age-related increase in the activity of the high affinity 
cyclic AMP phosphodiesterase. The activity in the 100-200 
day age group was significantly elevated (p <0.01) when 
compared to the <100 day old animals. Similarly, the 
activity in the >200 day age group was significantly 
(p <0.01) greater than that in the 100-200 day age group. 
The activity of the enzyme was significantly decreased 
(p <0.01) in established lymphomas when compared to
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FIGURE 6.3
HIGH AFFINITY CYCLIC AMP AND HIGH AFFINITY CYCLIC GMP 
PHOSPHODIESTERASE ACTIVITIES IN THYMUSES OF AKR AND 
C576J MICE CLASSIFIED INTO LARGE AGE GROUPS AND 
ESTABLISHED LYMPHOMAS
Values represent means ± S.E.M. Enzyme activity was 
assayed at 1 yM substrate.
Enzyme form
Code Strain Age group 
(days)
Cyclic AMP--PDE Cyclic GMP' 
n value
A C576J <100 10 10
B C576J 100-200 28 18
C C576J >200 34 34
D AKR <100 10 10
E AKR 100-200 42 42
F AKR >200 66 58
G Thymic lymphomas 25 24
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animals of similar age that did not overtly show 
tumour development (i.e. >200 day old animals). As 
the thymuses were analysed as independent entities 
it was possible to compare the enzyme activities 
from grossly enlarged thymuses with those obtained 
from the macroscopically normal counterparts from 
the same animals. This analysis also showed that the 
high affinity cyclic AMP phosphodiesterase activity 
was significantly decreased ( p <0.05) in thymic 
lymphomas when compared to the uninvolved organs.
These results are in opposition to those reported by 
Menahan and Kemp (1976). They observed that the cyclic 
AMP phosphodiesterase activity, assayed at 1 yM 
substrate, was decreased in thymuses of AKR mice that 
were between 7-9 months of age when compared to 
animals that were approximately 1 month old. The 
youngest animals used in the present study were 
approximately 2-2% months of age. Whether animals that 
are considerably younger than this would exhibit 
enzyme activities higher than those observed in 
animals >200 days of age is not known. Menahan and 
Kemp (1976) also observed that the high affinity 
cyclic AMP phosphodiesterase activity in lymphomas 
was 'much greater than comparably aged non-leukemic 
animals' and 'almost twice that of young animals'.
The reasons for these discrepancies between the two 
studies are not immediately clear. However, the 
large numbers of thymuses assayed as independent 
entities in the present study contrasts with the
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somewhat limited number of animals used by Menahan 
and Kemp (1976). The latter study was also conducted 
by 'pooling' the thymuses from a number of animals, 
a procedure that is open to strong criticism when 
the unilateral nature of the lymphoma development is 
taken into consideration. It should also be noted 
that, as discussed in Section 4.3.3, the phospho­
diesterase assay buffer used in the present 
experiments contained 250 yM EGTA to eliminate 
Ca2+-dependent alterations in cyclic nucleotide 
hydrolysis (Boudreau and Drummond, 1975). As discussed 
in Section 3.6, some neoplastic cells have been shown 
to exhibit an increase in the activity of the Ca2.+ 
calmodulin dependent form of phosphodiesterase. It 
cannot be discounted that the lymphomas show an 
increase in the activity of a CaA+calmodulin dependent 
form of phosphodiesterase that hydrolyses cyclic AMP 
and that was not detected in our assay system. Menahan 
and Kemp (1976) did not incorporate divalent ion 
chelating agents in their assay of phosphodiesterase.
Should this possibility be valid then clearly the 
age-related increase in high affinity cyclic AMP 
phosphodiesterase activity observed in the AKR mice 
(Figures 6.1 and 6.3) cannot be attributed to a 
Ca2.+calmodulin dependent form. The rationale of the 
above discussion is probably not valid, because the 
Ca2.+calmodulin dependent form of phosphodiesterase is 
thought to be DI, i.e. the high affinity cyclic GMP 
phosphodiesterase, although, as discussed in Section 2.5.3,
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Smoake et al. (1981) have recently reported the
presence of a calmodulin dependent, high affinity 
cyclic AMP phosphodiesterase in membranes of hamster 
liver.
The high affinity cyclic GMP phosphodiesterase 
activities for animals subdivided into large age groups 
and tumours are also shown in Figure 6.3. It can 
immediately be stated that the activity of this enzyme 
varies in an age- and strain-related manner that is 
different from that observed for the high affinity 
cyclic AMP phosphodiesterase. This in itself is a 
significant observation as it lends support to the 
concept that the activities of the multiple forms of 
phosphodiesterase enzymes are controlled by independent 
mechanisms. In C576J mice there was no significant 
difference (p >0.1) in the activity of the enzyme in 
the <100 and 100-200 day age groups. The activity of 
the enzyme in the >200 day age group, as suggested by 
Figure 6.1, was significantly lower (p <0.01) when 
compared to the other two groups. In contrast to this 
decrease in enzyme activity observed in 'old' C576J 
mice, the AKR strain did not exhibit any significant 
alteration in the activity of the high affinity cyclic 
GMP phosphodiesterase in any age group. The activity 
of the enzyme was significantly decreased (p <0.01) in 
established thymic lymphomas when compared to mice in 
the >200 day age group. Statistical analysis of 
enlarged thymuses with their macroscopically normal 
counterparts from the same animals also revealed that
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the enzyme activity was significantly decreased (p <0.05) 
in the established tumours. There are no previously 
published reports of the activity of this enzyme in 
thymic lymphomas of AKR mice.
The activities of the low affinity cyclic AMP 
and cyclic GMP phosphodiesterase in thymuses of AKR and 
C576J mice classified into large age groups and lymphomas 
are shown in Figure 6.4. The C576J strain did not show 
any significant alterations (p >0.1) in the activity of 
this enzyme as the animals increased in age. The AKR 
mice, however, as suggested in Figure 6.2, clearly 
demonstrated an age-related increase in the activity of 
this enzyme. Activities observed in animals aged between 
100-200 days were significantly higher (p <0.01) than 
those of the <100 day age group. Similarly, activities 
observed in the >200 day animals were significantly 
elevated (p <0.01) when compared to the 100-200 day age 
group. Enzyme activity was lower in established thymic 
lymphomas than in animals >200 days of age. Statistical 
analysis of the activities obtained from grossly 
enlarged thymuses with those obtained from the normal, 
uninvolved counterparts from the same animals revealed 
no significant alterations in enzyme activity (p >0.1 
for cyclic AMP and p >0.05 for cyclic GMP). The results 
for the low affinity cyclic AMP phosphodiesterase 
activity are again in direct opposition to those 
observed by Menahan and Kemp (1976). They observed 
enzyme activity, assayed at 100 yM substrate, to be 
lower in preleukemic animals than AKR mice approximately
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FIGURE 6.4
LOW AFFINITY CYCLIC AMP AND CYCLIC GMP PHOSPHODIESTERASE 
ACTIVITIES IN THYMUSES OF AKR AND C576J MICE CLASSIFIED 
INTO LARGE AGE GROUPS AND ESTABLISHED LYMPHOMAS 
Values represent means ± S.E.M. Enzyme activity was 
assayed at 100 yM substrate.
Enzyme form
Code Strain Age group 
(days)
Cyclic AMP--PDE Cyclic GMP- 
n value
A C576J <100 10 10
B C576J 100-200 27 18
C C576J >200 34 34
D AKR <100 10 10
E AKR 100-200 40 40
F AKR >200 66 58
G Thymic lymphomas 25 24
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1 month of age and, also, that established tumours 
exhibited significantly higher activity than animals 
of a comparable age that did not overtly show tumour 
development. The comments discussed above in relation 
to the discrepancies between the two studies, 
especially the numbers of animals used and the 
'pooling' of organs, are again applicable. It is also 
worth noting that the study of Menahan and Kemp (1976) 
directly contradicts that of Kemp et al. (1975). In
the latter study the authors suggested that the 
activity of the low affinity cyclic AMP phosphodiesterase 
(i.e. activity assayed at 100 yM substrate) was 
significantly increased in preleukemic animals when 
compared to young AKR mice. This observation is in 
agreement with that of the present study. Kemp and 
coworkers make no attempt to explain the discrepancies 
of their studies. There are no previously published 
reports on the low affinity cyclic GMP phosphodiesterase 
activity in thymic lymphomas of AKR mice.
If the enzyme activities measured at 1 yM cyclic 
AMP, 1 yM cyclic GMP and 100 yM cyclic AMP or cyclic GMP 
can be taken to represent the Dill, DI and DII forms of 
phosphodiesterase enzymes respectively, then it is 
evident that the AKR and C576J strains show marked age- 
related differences in the expression of these enzyme 
activities. In AKR mice, as the animals increase in age, 
the activities of the DII and Dill forms increase, 
whilst the activity of the DI form remains unaltered.
As C576J mice age the DII and Dill forms remain unaltered
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whilst the DI form decreases in activity in thymuses 
from animals >200 days of age. Whether these changes 
are consequences of alterations in the number of 
enzyme molecules present, and therefore dependent 
upon protein synthesis, or whether they represent 
activation or inhibition of pre-existing enzyme 
molecules would be of great interest. Whether the 
apparent differential expression of the enzyme forms 
is simply a strain related phenomenon or represents 
an important factor contributing to the ultimate 
development of thymic lymphomas in AKR mice is 
obviously a very important question. Clearly some of 
these questions could be answered by chromatographi- 
cally separating the different enzyme forms of 
thymuses from AKR, C576J and other strains of mice at 
different ages.
If the activities of the phosphodiesterase 
enzymes are considered with the basal adenylate 
cyclase activities discussed in Chapter Five then it 
is possible to make some predictions about the levels 
of cyclic nucleotides in the thymuses of mice at 
different ages and in established lymphomas. The basal 
adenylate cyclase activity did not show any statisti­
cally significant alterations in the three large age 
groups. Thymic lymphomas exhibited significantly 
elevated basal activity when compared to all age 
groups of both strains. It might therefore be expected 
that the cyclic AMP levels in the thymuses of AKR mice 
would decrease in the preneoplastic period as a result
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of the age-related increase in high affinity cyclic 
AMP phosphodiesterase activity. The activity of 
guanylate cyclase was not assessed in this study.
However, should the activity remain unaltered or 
increase in the preneoplastic period then the 
cyclic GMP:cyclic AMP ratio would increase in the 
thymuses of AKR mice as the high affinity cyclic 
GMP phosphodiesterase activity did not significantly 
change in the three age groups. In established 
thymic lymphomas basal adenylate cyclase activity 
was significantly elevated and the activities of 
the high affinity cyclic AMP and cyclic GMP 
phosphodiesterases significantly decreased when 
compared to AKR mice of a comparable age not 
exhibiting tumours. This would therefore suggest 
that the lymphomas should be characterized by higher 
levels of cyclic AMP, and possibly cyclic GMP 
depending upon the activity of guanylate cyclase. In 
C576J mice the cyclic AMP levels should not significantly 
alter in the three age groups as both basal adenylate 
cyclase activity and high affinity cyclic AMP phospho­
diesterase activity showed no significant alterations 
The C576J mice exhibited a significant decrease in the 
high affinity cyclic GMP phosphodiesterase activity in 
animals >200 days of age. The concentrations of cyclic 
GMP might therefore increase in older animals, but as 
stated above the activity of guanylate cyclase was not 
assessed and so any predictions would be pure speculation. 
The actual concentrations of cyclic AMP and cyclic GMP are
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presented in Chapter Seven.
It was stated in Section 6.1 that all data 
obtained from the assays of phosphodiesterase enzymes 
was subjected to statistical analysis. Table 6.3 shows 
the mean, standard deviation, standard error of the 
mean and the analysis of variance (A.O.V.) for all the 
results, including established lymphomas, broken down 
by thymus, strain and enzyme form. It can be seen that 
the enzyme activities for left and right thymuses 
within a strain are very similar, and that the AKR 
strain exhibits significantly elevated activities of 
the enzymes when compared to the control C576J series.
As the AKR strain does not show significant differences 
between left and right thymuses this would suggest that 
the lymphomas included in the analysis were equally 
distributed between the two organs. This in fact was so, 
with 6 animals showing grossly enlarged left thymuses,
7 animals showing grossly enlarged right thymuses and 
6 animals showing involvement of both organs at the 
time of assay.
The differences in enzyme activities between 
left and right thymuses of single animals could be 
calculated as the organs were assayed independently. 
Table 6.4 shows the mean, standard deviation, standard 
error of the mean and the analysis of variance for the 
differences in enzyme activities between the two 
thymuses. All the data, including lymphomas, was 
incorporated in this analysis. It can be seen that the 
AKR strain exhibited significantly greater differences
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TABLE 6.3
STATISTICAL ANALYSIS OF ALL DATA OBTAINED FROM THE ASSAY OF 
CYCLIC NUCLEOTIDE PHOSPHODIESTERASES BROKEN DOWN BY 
STRAIN, THYMUS AND ENZYME FORM
Variable Mean1 S.D. S.E.M. A.O.V.
(P)
N
High affinity2 cA-PDE Left C576J 21.2 4.3 0.7 <0.01 36" AKR 25.9 10.4 1.2 78
I I  I I II Right C576J 21.7 4.5 0.8 >0.05 36
I I  II II " AKR 25.2 10.7 1.2 78
Low affinity3 cA-PDE Left C576J 535 101 17 <0.001 35
I I  II I I " AKR 847 340 39 77
I I  I I II Right C576J 533 121 20
<0.001
36
" AKR 785 307 35 77
High affinity cG-PDE Left C576J 11.4 3.4 0.6 <0.001 31
I I  I I II " AKR 17.9 8.0 0.9 73
I I  II II Right C576J 11.8 4.1 0.7 <0.001 31
I I  I t II " AKR 17.1 7.1 0.8 73
Low affinity cG-PDE Left C576J 517 137 25 <0.001 31
I I  II II " AKR 1029 433 51 72
I I  I I II Right C576J 541 151 27 <0.001 31
I I  II I I " AKR 1001 434 51 72
1Enzyme activity expressed as pmol cyclic nucleotide hydrolysed/min/ 
mg protein.
2, High affinity' refers to that activity assayed at 1 yM substrate.
3, Low affinity* refers to that activity assayed at 100 yM substrate.
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TABLE 6.4
STATISTICAL ANALYSIS OF THE DIFFERENCES IN ENZYME ACTIVITIES 
BETWEEN LEFT AND RIGHT THYMUSES BROKEN DOWN BY 
STRAIN AND ENZYME FORM
Variable Mean1 S.D. S.E.M. A.O.V. N
(P)
High affinity cA-PDE C576J 2.0 2.4 0.4
<0.001
36
II II I I AKR 5.6 5.5 0.6 78
Low affinity cA-PDE C576J 58 63 11
<0.001
35
I I II II AKR 210 208 24 77
High affinity cG-PDE C576J 1.6 1.8 0.3
<0.001
31
I I I I II AKR 5.0 4.2 0.5 73
Low affinity cG-PDE C576J 59 57 10
<0.001
31
I I II I I AKR 301 301 35 72
1Difference in enzyme activity expressed as pmol cyclic nucleotide 
hydrolysed/min/mg protein.
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in enzyme activities between the left and right thymuses 
when compared to the C576J mice. Therefore, in AKR 
animals both the enzyme activities and the differences 
in activities between thymuses were significantly 
greater than in the C576J mice. This resulted in very 
good strain discrimination when the data was subjected 
to discriminant analysis ('Statistical Package for the 
Social Sciences' computer programme). Using the enzyme 
activity data, the programme correctly assigned 90% of 
C576J mice and 86% of AKR mice. The percentage of all 
animals classified correctly to their respective strain 
was 87%.
If Tables 6.3 and 6.4 are considered it can be 
seen that the mean differences in enzyme activities 
between left and right thymuses for C576J mice are 
approximately 10% of the mean enzyme activities. For AKR 
mice the mean differences in activities between organs 
are approximately 20% of the mean enzyme activities. It 
could be suggested that the differences in enzyme 
activities observed between paired thymuses reflects the 
inherent error of the assay system employed. It would 
therefore have to be argued, to explain the above 
discussion, that the error of the assay was greater when 
applied to AKR mice. That this, almost certainly, is not so 
was evident when the significance of the observation that 
the differences in enzyme activities between thymuses 
were greater in AKR mice was further investigated. This 
was done by calculating the differences in activities 
between left and right thymuses for C576J and AKR mice
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subdivided into <100, 100-200 and >200 day age groups. 
The differences between established thymic lymphomas 
and the uninvolved organs from the same animals were 
also calculated. The results of this analysis are 
shown in Figures 6.5 and 6.6. For all the enzyme forms 
it can be observed that the AKR strain shows a 
progressive increase in the differences in the 
activities between left and right thymuses as the mice 
age. No such progressive increase in the differences 
between the two thymuses was observed in C576J mice.
It would seem most improbable that the error of the 
assay system employed would vary in the strain- and 
age-related fashion that would be required to explain 
these results.
Statistical analysis (see Table 6.5) of the 
differences in enzyme activities between involved and 
uninvolved thymuses from animals bearing lymphomas 
and the differences observed between paired thymuses 
in C576J and AKR mice of <200 days of age shows the 
tumour deviations to be significantly greater. 
Similarly, tumour deviations were significantly 
greater when compared to those observed in C576J mice 
>200 days of age. However, the tumour deviations were 
not significantly different from those observed in 
AKR mice >200 days of age that did not exhibit thymic 
lymphomas. These observations suggest that, prior to 
the development of the lymphoma, differences in the 
activities of the cyclic nucleotide phosphodiesterase 
enzymes exist between the two thymuses and that the
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FIGURE 6.5
DIFFERENCES IN THE ACTIVITIES OF HIGH AFFINITY 
CYCLIC AMP AND HIGH AFFINITY GMP PHOSPHODIESTERASES 
OF PAIRED THYMUSES FROM AKR AND C576J MICE CLASSIFIED 
INTO LARGE AGE GROUPS AND ESTABLISHED LYMPHOMAS 
Values represent means ± S.E.M. Enzyme activity was 
assayed at 1 yM substrate.
Enzyme form
Strain Age group Cyclic AMP-PDE Cyclic GMP-PDE
(days) n value
C576J <100 5 5
C576J 100-200 15 9
C576J >200 18 17
AKR <100 5 5
AKR 100-200 21 22
AKR >200 34 30
Thymic lymphomas 17 16
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FIGURE 6.6
DIFFERENCES IN THE ACTIVITY OF THE LOW AFFINITY 
CYCLIC AMP AND CYCLIC GMP PHOSPHODIESTERASE OF 
PAIRED THYMUSES FROM AKR AND C576J MICE 
CLASSIFIED INTO LARGE AGE GROUPS AND ESTABLISHED 
LYMPHOMAS
Values represent means ± S.E.M. Enzyme activity was 
assayed at 100 yM substrate.
Strain Age group 
(days)
Cyclic AMP
Enzyme form 
-PDE Cyclic GMP-PDE
n value
C576J <100 5 5
C576J 100-200 14 9
C576J >200 18 17
AKR <100 5 5
AKR 100-200 21 22
AKR >200 34 30
Thymic lymphomas 17 16
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TABLE 6.5
STATISTICAL ANALYSIS OF DIFFERENCES IN
CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ACTIVITIES
BETWEEN PAIRED THYMUSES IN ESTABLISHED LYMPHOMAS AND
C576J AND AKR MICE <200 AND >200 DAYS OF AGE
(Analysis of data shown in Figures 6.5 and 6.6 was by the 
Mann-Whitney Rank test. Values of n are those given in the 
legends of Figures 6.5 and 6.6.)
Tumour deviation vs C576J <200 days; vs C576J >200 days
High affinity cA-PDE 
Low affinity cA-PDE 
High affinity cG-PDE 
Low affinity cG-PDE
P <0.01 
P <0.01 
P <0.01 
P <0.01
P <0.01 
P <0.01 
P <0.01 
P <0.01
Tumour deviation vs AKR <200 days; vs AKR >200 days
High affinity cA-PDE P = 0.05 P >0.1
Low affinity cA-PDE P <0.01 P >0.05
High affinity cG-PDE P <0.05 P >0.1
Low affinity cG-PDE P <0.01 P >0.1
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differences persist in the established lymphoma. As the 
lymphomas were observed to have significantly decreased 
activity of the high affinity cyclic nucleotide 
phosphodiesterases it may be speculated that the neoplastic 
transformation occurs in the thymus exhibiting the lower 
enzyme activities.
CHAPTER SEVEN
CYCLIC NUCLEOTIDE CONCENTRATIONS IN NORMAL, 
PRENEOPLASTIC AND NEOPLASTIC THYMUSES
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7.1 Introduction
The levels of cyclic AMP and cyclic GMP in 
thymuses of AKR and C576J mice were measured by radio­
immunoassay as described in Section 4.2. The enzymes 
catalysing the synthesis and degradation of cyclic 
nucleotides were rapidly and irreversibly inactivated 
by exposure of the intact animal to microwave irradiation. 
Preliminary experiments validating the use of such 
procedures were presented in Section 4.2.3. The validation 
of the radioimmunoassay, as applied to extracts of mouse 
thymus tissue, and recovery of cyclic nucleotides from the 
extraction-neutralization protocol was presented in 
Sections 4.2.11 and 4.2.12.
7.2 Cyclic AMP and Cyclic GMP in Normal and
Preneoplastic Thymuses
The two thymuses from a single animal were 
analysed as independent entities when measuring the levels 
of cyclic nucleotides. As discussed previously (Chapters 5 
and 6) the animals were killed at carefully controlled ages 
so that the data obtained could be ascribed to tightly- 
defined age groups. Figure 7.1 shows the age-related cyclic 
AMP concentrations, expressed as pmol/mg protein, in 
thymuses of AKR and C576J mice. No data obtained from 
thymic lymphomas has been incorporated in the results 
expressed in this Figure. The values, representing means 
± S.E.M., for each specific age group have been plotted in
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FIGURE 7.1
AGE-RELATED CYCLIC AMP CONCENTRATIONS IN THYMUSES 
OF AKR AND C576J MICE
Values represent means ± S.E.M. Data expressed as 
pmol cAMP/mg protein.
C576J
Age group n value
(days)
Age group 
(days)
n value
50- 80 8
105-125 9
130-140 10
150-180 10
200-220 10
220-240 10
240-260 10
300-320 10
340-360 8
50- 80 18
105-125 9
130-140 16
150-180 10
200-220 9
220-240 10
240-260 13
270-300 26
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the middle of the age range of that group. It may be 
observed that, at all ages where a direct comparison 
can be made between the two strains, thymuses from 
AKR mice have higher concentrations of cyclic AMP. 
However, only in the age groups 130-140, 150-180 and 
200-220 days were the differences between the two 
strains statistically significant (p <0.01, p <0.01 
and p = 0.02 respectively). An attempt to correlate 
the concentrations of cyclic AMP to the activities 
of the synthetic and degradatory enzymes is made in 
Section 7.3, where the data has been reclassified 
into large age groups and established thymic 
lymphomas. The means ± S.E.M. of all age groups 
considered were 11.9 ± 0.7 and 8.7 ± 0.8 for AKR and 
C576J mice respectively.
Figure 7.2 shows the age-related cyclic GMP 
concentrations, expressed as pmol/mg protein, in 
thymuses from AKR and C576J mice. It can be observed 
that the levels of this nucleotide were considerably 
lower than the corresponding values obtained for cyclic 
AMP. For AKR mice cyclic GMP concentrations were 
approximately 1-3% of the cyclic AMP concentrations. The 
corresponding limits for C576J mice were approximately 
2-7%. In the youngest age group the cyclic GMP levels in 
thymuses from the control series were significantly 
(p = 0.02) higher than those from AKR mice. The converse 
of this was observed in animals from the 105-125 and 
130-140 day age groups where AKR mice had significantly 
higher (p <0.01 and p <0.05 respectively) concentrations
0.5
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FIGURE 7.2
AGE-RELATED CYCLIC GMP CONCENTRATIONS IN THYMUSES
OF AKR AND C576J MICE
Values represent means ± S.E.M.
pmol cyclic GMP/mg protein.
Data expressed as
U D  / d j  y \\^ MKi w ........ l ™Age group n value Age' group n value
(days) (days)
50- 80 10 50- 80 8
105-125 10 105-125 9
130-140 20 130-140 16
150-180 10 150-180 10
200-220 10 200-220 9
220-240 10 220-240 10
240-260 10 240-260 13
300-320 10 270-300 26
340-360 10
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of cyclic GMP when compared to C576J mice. In the 
150-180 and 200-220 day age groups the cyclic GMP 
levels in thymuses from C576J animals were again 
significantly higher (p <0.01) than those of AKR 
mice. In the remaining age groups where a direct 
comparison could be made there were no significant 
differences between the two strains. The means ±
S.E.M. of all age groups considered were 0.27 ± 0.04 
and 0.32 ± 0.03 for AKR and C576J mice respectively.
As discussed in Section 3.2, the most 
appropriate way of expressing cyclic nucleotide 
concentrations, particularly in tumour cell populations, 
is a matter of some controversy. It was decided in this 
study to express the concentrations of cyclic AMP and 
cyclic GMP on a 'per mg protein' and a 'per mg weight' 
basis to see if any qualitative differences existed 
between data expressed in these different ways. It 
should be noted that the expression 'per mg weight' has 
been adopted because the microwaving procedure, 
which inactivates the enzymes involved in the metabolism 
of cyclic nucleotides via the action of heat, negates 
the use of the term 'per mg wet weight'. The assumption 
has to be made that any weight loss resulting from the 
exposure to microwave irradiation was a constant factor 
for all animals. The age-related concentrations of 
cyclic AMP and cyclic GMP, expressed as pmol/mg weight, 
in thymuses from the two strains of mice are shown in 
Figure 7.3. For cyclic AMP it can be observed that, 
qualitatively, the age-related profiles for AKR and C576J
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FIGURE 7.3
AGE-RELATED CYCLIC AMP AND CYCLIC GMP CONCENTRATIONS 
IN THYMUSES OF AKR AND C576J MICE
Values represent means ± S.E.M. Data expressed as 
pmol cyclic nucleotide/mg weight.
r\
Age group 
(days)
Cyclic AMP Cyclic GMP 
n value
AKR|^^ ,,,,l
Age group 
(days)
Cyclic AMP Cyclic 
n value
50- 80 8 10 50- 80 18 8
105-125 9 10 105-125 9 9
130-140 10 20 130-140 16 16
150-180 10 10 150-180 10 10
200-220 10 10 200-220 9 9
220-240 10 10 220-240 10 10
240-260 10 10 240-260 13 13
300-320 10 10 270-300 26 26
340-360 8 10
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mice are very similar to the results expressed as 
pmol/mg protein in Figure 7.1. At all ages where a 
direct comparison between the two strains could be 
made, thymuses from AKR mice had higher concentrations 
of cyclic AMP. The means ± S.E*M. for all age groups 
considered were 1.41 ± 0.1 for AKR, and 0.97 ± 0.1 
for C576J mice.
For cyclic GMP it was observed that, 
qualitatively, the age-related profiles for AKR and 
C576J mice were similar whether the data was expressed 
on a 'per mg weight', or 'per mg protein' basis as in 
Figure 7.2. Cyclic GMP concentrations were again 
approximately 1-3% and 2-7% of the cyclic AMP 
concentrations in thymuses from AKR and C576J mice 
respectively. The means ± S.E.M. for all age groups 
considered were 0.03 ± 0 for AKR, and 0.04 ± 0 for 
C576J mice.
When the data is presented in small tightly- 
defined age groups, on a 'per mg protein' or 'per mg 
weight' basis (Figures 7.1-7.3), it is difficult to 
observe any consistent, progressive alterations in 
the levels of either nucleotide in the preleukemic 
period of thymic lymphoma development. This appears 
to be so whether the AKR strain is considered alone 
or compared to the control C576J series. It was 
discussed in Section 3.2 that several reports in the 
literature have placed less emphasis on the 
independent, absolute concentrations of the cyclic 
nucleotides and more emphasis on their relative
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concentrations. To investigate this, the cyclic GMP: 
cyclic AMP (cG:cA) ratios were calculated from the 
data expressed in Figures 7.1-7.3 and the values 
obtained are shown in Figure 7.4. As expected the 
cG:cA ratios were qualitatively and quantitatively 
similar when calculated using data expressed on a 
'per mg protein' or 'per mg weight' basis. For AKR 
mice the cG:cA ratio was highest in animals from the 
105-125 and 130-140 day age groups. For C576J mice 
the highest cG:cA ratio was also observed in animals 
between 130-140 days of age. It should be noted that 
the cG:cA ratio was always higher in the control 
series, except in animals from the 105-125 day age 
group.
7.3 Cyclic AMP and Cyclic GMP in Normal,
Preneoplastic and Neoplastic Thymuses
As for the enzyme activities discussed in 
Chapters 5 and 6, the cyclic nucleotide concentrations 
in the thymuses of AKR and C576J mice were reclassified 
into larger age groups of <100, 100-200 and >200 days. 
To allow a comparison between normal, preneoplastic and 
neoplastic thymuses the data obtained from established 
thymic lymphomas was also introduced. Figure 7.5 shows 
the cyclic AMP concentrations, expressed as pmol/mg 
protein and pmol/mg weight, for the data reclassified 
in this way. In the control C576J series animals aged 
between 100-200 days had significantly decreased levels 
of cyclic AMP when compared to animals that were <100 
or >200 days of age (p <0.01 and p <0.05 respectively),
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FIGURE 7.4
AGE-RELATED CYCLIC GMP:CYCLIC AMP RATIOS IN THYMUSES 
OF AKR AND C576J MICE
The ratios were calculated using the mean values of 
the data presented in Figures 7.1-7.3.
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FIGURE 7.5
CYCLIC AMP CONCENTRATIONS IN THYMUSES OF
AKR AND C576J MICE CLASSIFIED INTO LARGE AGE GROUPS
AND ESTABLISHED LYMPHOMAS
Values represent means ± S.E.M. Data expressed as pmol 
cyclic AMP/mg protein and pmol cyclic AMP/mg weight.
Code Strain Age group (days) n value
A C576J <100 8
B C576J 100-200 29
C C576J >200 48
D AKR <100 18
E AKR 100-200 35
F AKR >200 58
G Thymic lymphomas 9
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whether expressed 'per mg protein' or 'per mg weight'. 
AKR mice did not exhibit any significant changes in 
cyclic AMP concentration as the animals aged (p >0.1 
for results expressed 'per mg protein' and p >0.05 
for results expressed 'per mg weight'). The cyclic 
AMP concentration in established lymphomas was 
significantly (p <0.01) decreased when compared to 
the large age groups of AKR mice, irrespective of 
how the data was expressed. These observations both 
support and contrast those reported by Kemp et al.
(1975) who observed cyclic AMP levels to be 
significantly higher in 'the thymus' of preleukemic 
animals when compared to young AKR mice and signifi­
cantly lower in established thymic lymphomas when 
compared to young or preleukemic mice.
Figure 7.6 shows the cyclic GMP concentrations, 
expressed as pmol/mg protein and pmol/mg weight, in 
thymuses from AKR and C576J mice classified into large 
age groups and tumours. In the control C576J series no 
significant (p >0.1) changes in the concentration of 
cyclic GMP were observed as the animals aged. In 
thymuses from AKR mice aged between 100-200 and >200 
days the concentration of cyclic GMP was significantly 
(p <0.01) higher than that observed in animals <100 
days of age. Cyclic GMP concentrations in established 
thymic lymphomas were significantly decreased (p <0.01) 
when compared to the 100-200 and >200 day age groups but 
not significantly different (p >0.1) from the <100 day 
animals. There are no previously published reports on
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FIGURE 7.6
CYCLIC GMP CONCENTRATIONS IN THYMUSES OF
AKR AND C576J MICE CLASSIFIED INTO LARGE AGE GROUPS
AND ESTABLISHED LYMPHOMAS
Values represent means ± S.E.M. Data expressed as pmol 
cyclic GMP/mg protein and pmol cyclic GMP/mg weight.
Code Strain Age group (days) n value
A C576J <100 10
B C576J 100-200 40
C C576J >200 50
D AKR <100 8
E AKR 100-200 35
F AKR >200 58
G Thymic lymphomas 9
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the levels of cyclic GMP in thymuses from preleukemic 
and leukemic AKR mice.
The cG:cA ratios were calculated for the 
concentrations of the nucleotides as shown in 
Figures 7.5 and 7.6 and the values obtained are 
shown in Figure 7.7. As decreased levels of cyclic AMP 
and/or increased levels of cyclic GMP purportedly have 
been associated with rapid growth rates (see Section 3.1) 
an increase in the cG:cA ratio would be expected in 
actively proliferating populations of cells. It can be 
observed that, as suggested in Figure 7.4, the cG:cA 
ratio was always higher in the control C576J series than 
in the AKR mice. The cG:cA ratio was higher in AKR mice 
aged between 100-200 and >200 days than in animals in the 
<100 day age group. This increase in the ratio was due to 
an increase in the cyclic GMP concentration as the cyclic 
AMP levels were not significantly different in the three 
large age groups (see Figures 7.5 and 7.6). In the 
established lymphomas the cG:cA ratio was decreased when 
compared to AKR mice >200 days of age. As both cyclic AMP 
and cyclic GMP concentrations were significantly lower in 
tumours this suggests that the fall in cyclic GMP was 
proportionally greater than the fall in cyclic AMP.
It is recognized that normal thymuses and 
thymic lymphomas contain mixtures of cells that vary in 
their size, stage of differentiation and phase of the 
cell cycle. As discussed in Section 1.2, cytological 
studies (Metcalf, 1966a) suggest that, on the basis of 
size, there are at least three classes of lymphocytes:
pmols c N /m g  protein pmols c N /m g  weight
0
FIGURE 7.7
THE CYCLIC GMP:CYCLIC AMP RATIO IN THYMUSES OF 
AKR AND C576J MICE CLASSIFIED INTO LARGE AGE GROUPS 
AND ESTABLISHED LYMPHOMAS
The ratios were calculated from the mean values of the 
data presented in Figures 7.5 and 7.6. Code as in 
Figures 7.5 and 7.6.
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large, medium and small. In thymuses from a 2 month old 
AKR mouse the large cells are reported to divide every 
6.8 hours and the medium cells every 8.2 hours. The 
majority of the small cells appear to be quiescent 
(Metcalf and Wiadrowski, 1966). It has been observed 
repeatedly that cell populations from established thymic 
lymphomas are characterized by higher proportions of 
medium and large cells (for example, Kemp and Duquesnoy, 
1974; Kemp et al., 1975). This displacement of the 
normal cell size distribution in favour of larger cells 
in tumours can clearly be seen in photomicrographs 
1.8.C, 1.8.E and I.8.F. If the large and medium cells 
are actively proliferating then one would expect the 
tumours to show an increased [3H]-thymidine uptake into 
DNA. Lengle et al. (1978) have studied the uptake of
[3H]-thymidine by young, adult nonleukemic and leukemic 
AKR thymocytes cultured in vitro for a 24 hour period.
They observed that cells from young mice incorporated 
more thymidine into cellular DNA than cells from 
non-leukemic adult mice, and that, of the three groups 
studied, neoplastic thymocytes had the highest rate of 
thymidine incorporation. When these results are 
considered together with the concentrations of cyclic AMP 
and cyclic GMP and the cG:cA ratios observed in AKR mice 
and thymic lymphomas it can be stated categorically that 
the results of the present study do not conform to the 
generalizations that have been discussed above and in 
Section 3.1, i.e. that an increased cG:cA ratio is 
associated invariably with increased cellular proliferation.
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It is customary in studies such as those 
reported here to correlate the tissue levels of cyclic 
nucleotides with the activities of the enzymes involved 
in the synthesis and degradation of these compounds.
The validity of such correlations is debatable as 
in vitro assays of enzyme activities are invariably 
carried out under conditions that have been created 
artificially to be 'optimal' for that enzyme system. 
Whether the conditions employed are remotely similar 
to those experienced by the enzyme system in vivo is 
extremely doubtful. These criticisms would seem 
applicable to the metabolism of cyclic nucleotides, 
especially as subcellular compartmentalization has been 
suggested to be an inherent feature of the regulatory 
mechanisms in which the nucleotides participate.
Accepting the limitations of such procedures, it is 
possible to attempt such correlations for cyclic AMP.
The activity of guanylate cyclase was not assessed and 
therefore a similar treatment for cyclic GMP cannot be 
undertaken satisfactorily. To aid in the interpretation, 
only the enzyme activities and cyclic nucleotide levels 
expressed in the large age groups and tumours will be 
considered. In thymuses of C576J mice basal adenylate 
cyclase and high affinity cyclic AMP phosphodiesterase 
activities did not show any significant alterations as 
the animals aged. It is therefore difficult to correlate 
the enzyme activities with the significantly lower 
concentration of cyclic AMP in the thymuses of animals 
aged between 100-200 days. In AKR mice basal adenylate
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cyclase activity did not significantly change in the 
three large age groups. High affinity cyclic AMP 
phosphodiesterase activity significantly increased as 
the animals aged, with this increase being progressive 
in nature. It is, therefore, again difficult to 
correlate the enzyme activities with the concentrations 
of cyclic AMP which did not significantly change in the 
<100, 100-200 and >200 day age groups. It should be 
noted, however, that the mean concentrations of cyclic 
AMP do exhibit a small age-related decrease (see 
Figure 7.5) which could be suggested, perhaps, to 
reflect the increased activity of the degradatory 
enzyme. In the established lymphomas basal adenylate 
cyclase activity was significantly elevated when 
compared to mice of all other age groups. High affinity 
cyclic AMP phosphodiesterase activity was significantly 
lower in tumours when compared to AKR mice of a similar 
age that did not overtly show lymphoma development. It 
would be expected, therefore, that the neoplastic 
thymus would be characterized by elevated concentrations 
of cyclic AMP and yet, as shown in Figure 7.5, the level 
of the nucleotide was significantly decreased when 
compared to AKR mice of all other age groups. Therefore, 
in thymuses from C576J and AKR mice and established 
thymic lymphomas, the activities of the synthetic and 
degradatory enzymes could not be satisfactorily 
correlated with the tissue levels of cyclic AMP. Clearly 
some caution must be exercised when extrapolating results 
obtained from in vitro assays of enzyme activities to the
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concentrations of cyclic nucleotides in intact tissues. 
It should be noted that the activity of the adenylate 
cyclase enzyme was assayed using homogenates of the 
two thymuses from a single animal. It has been 
suggested in Chapter 6 that the phosphodiesterase 
activities of the two thymuses may be regulated 
independently as the AKR mice age. Thus a more valid 
correlation of enzyme activities to cyclic nucleotide 
concentrations could be performed if the adenylate 
cyclase activity had been assayed in each of the two 
thymuses. It should also be noted that the release of 
cyclic nucleotides from the cells has not been 
considered. Beckner et al. (1980) have suggested that 
there is a marked difference in the amount of cyclic AMP 
released from normal and spontaneously transformed 
hepatocytes. In this case the rate of excretion of 
cyclic AMP (i.e. from the cells into the medium) in 
transformed cells was less than 25% of that observed in 
untransformed cells. This decrease in the rate of 
excretion may be a consequence of a reduced rate of 
formation of cyclic AMP; basal adenylate cyclase 
activity was reported to be decreased in transformed 
cells. It could, therefore, be suggested that the 
lymphoma cells, which have significantly higher 
adenylate cyclase activity and significantly lower 
cyclic AMP phosphodiesterase (high affinity) activity, 
excrete more cyclic AMP than normal or preleukemic 
cells. This could explain the decreased concentration 
of cyclic AMP in the neoplastic cells. This suggestion
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could be approached experimentally by isolating normal, 
preleukemic and leukemic thymocytes and culturing the 
cells in vitro. The cyclic AMP content of the cells 
and of the culture medium could then be assayed.
As the cyclic nucleotide concentrations were 
assayed in the two thymuses of a single animal it was 
possible, as discussed in Section 6.3 for the activities 
of cyclic nucleotide phosphodiesterase enzymes, to 
calculate the differences in the concentrations of 
cyclic AMP and cyclic GMP between paired thymuses. This 
was done for AKR and C576J mice subdivided into animals 
that were <200 and >200 days of age. A similar analysis 
could not be done for tumours as 4 out of the 7 animals 
showing lymphoma development clearly exhibited involve­
ment of both organs. The results of this analysis are 
shown in Table 7.1. If the values expressed as pmol 
cyclic AMP/mg protein are considered then the differences 
between the paired thymuses of C576J mice were not 
significantly (p >0.1) altered when the <200 and >200 
day age groups are compared. In contrast to this, in 
the AKR mice, the difference between paired thymuses was 
significantly higher (p <0.05) in the >200 day age group. 
Also, the differences between thymuses in both of the AKR 
age groups were significantly (p <0.01) greater than the 
respective values obtained for the C576J strain. If the 
values expressed as pmol cyclic GMP/mg protein are 
considered then again the differences between paired 
thymuses in C576J mice were not significantly different 
(p >0.1) when the <200 and >200 day age groups are
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TABLE 7.1
DIFFERENCES IN CYCLIC NUCLEOTIDE CONCENTRATIONS 
BETWEEN PAIRED THYMUSES OF AKR AND C576J MICE 
(Values represent mean ± S.E.M.)
Strain Age(days)
Cyclic AMP 
pmol/mg protein
Cyclic GMP (xlO3) 
pmol/mg protein
AKR <200 2.68 ± 0.55 (n=24) 28 ± 9 (n=19)
AKR >200 3.62 ± 0.38 (n=27) 87 ± 5 (n=24)
C576J <200 1.31 ± 0.29 (n=18) 52 ± 5 (n=24)
C576J >200 2.15 ± 0.49 (n=24) 97 ± 25 (n=25)
Strain Age(days)
Cyclic AMP (xlO2) 
pmol/mg weight
Cyclic GMP (xlO3) 
pmol/mg weight
AKR <200 24 ± 5 (n=24) 4 ± 1 (n=19)
AKR >200 31 ± 4 (n=27) 7 ± 1 (n=27)
C576J <200 14 ± 3 (n=23) 5 ± 1 (n=24)
C576J >200 16 ± 5 (n=24) 10 ± 1 (n=25)
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compared. In AKR mice the difference between organs 
was significantly greater (p <0.05) in the >200 day 
age group. The values obtained for the two strains were 
not significantly different when the two age groups were 
compared (p >0.05 for <200 and p >0.1 for >200 days).
As discussed in Section 6.3 it would seem most unlikely 
that the errors of the assay systems employed would 
vary in the strain- and age-related fashion that would 
be required to explain these results. The observations 
suggest that the concentrations of cyclic nucleotides 
in the thymuses of AKR mice may be regulated differently 
in the two organs as the animals increase in age. This 
is consistent with the observations reported in Section 6.3 
where it was shown that the deviation in activities of the 
cyclic nucleotide phosphodiesterase enzymes between paired 
thymuses progressively increased as the AKR animals aged 
with no such progressive divergence between organs being 
observed in the C576J strain.
If the differences were expressed as pmol cyclic 
AMP/mg weight then there were no significant alterations 
in the values when the two age groups of the same strain 
were compared. However, the deviation between organs 
observed in AKR mice >200 days of age was significantly 
greater (p <0.01) than that for C576J mice of the same 
age. For cyclic GMP, expressed as pmol/mg weight, there 
were no significant differences when the two age groups 
of the same strain were compared or when the two age 
groups of the different strains were compared. Why the 
expression of the deviation data as pmol/mg protein and
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pmol/mg weight results in these discrepancies is not 
known.
CHAPTER EIGHT
GENERAL DISCUSSION
269
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The primary objective of this investigation 
was to assess possible alterations in cyclic nucleotide 
metabolism during the preleukemic period of thymic 
lymphoma development in AKR mice. Basal adenylate 
cyclase activities and responsiveness of the enzyme to 
stimulation by various agonists, activities of cyclic 
nucleotide phosphodiesterases and the concentrations of 
cyclic nucleotides in thymuses of AKR and C576J mice 
and in established tumours have been presented and 
discussed in Chapters Five to Seven. A summary of some 
of the results is shown in Table 8.1. There are two 
major aims of this concluding chapter. Firstly, some 
further experiments are suggested that would be useful 
to complement and expand upon the results reported here. 
Secondly, a hypothesis will be developed that implicates 
aberrant cyclic nucleotide metabolism in the evolution of 
a population of cells whose proliferative activity remains 
unimpaired but where the channelling of these 'precursor 
cells' into appropriate differentiation pathways, 
ultimately giving rise to small, quiescent cortical 
thymocytes, seems to be blocked.
It was shown in Chapter Five that basal adenylate 
cyclase activity in thymuses from AKR mice did not 
significantly change in the preleukemic period. As 
stressed previously the two thymuses from a single 
animal were combined for the assay of adenylate cyclase
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activity. Any subsequent studies on the activity of 
this enzyme in the development of the thymic lymphoma 
should endeavour to assay the organs as independent 
entities. This, in contrast to the present experimental 
design, would necessarily require that the amount of 
information obtained from a single organ be limited to 
basal enzyme activity and stimulation by selected 
concentrations of only a few agonists. That this sort 
of approach may be of use is suggested by the observa­
tions made for the activities of the phosphodiesterase 
enzymes and the concentrations of cyclic nucleotides, 
in that the metabolism of these compounds appears to 
be differentially regulated in the two thymuses during 
the preleukemic period (see Chapters Six and Seven).
Basal adenylate cyclase activity in established thymic 
lymphomas was significantly higher when compared to mice 
of all ages from both strains. Similarly, the responsive­
ness of the tumour enzyme to stimulation by Gpp(NH)p and 
NaF was significantly higher than that observed in normal 
and preleukemic thymuses. In Chapter Five it was 
speculated that these observations suggest that the 
membranes of neoplastic cells contain an increased amount 
of the 'N-protein'. The technology required to assess 
this suggestion is available and has been used to demon­
strate that alterations in 'N-protein' activity are 
associated with pseudohypoparathyroidism (PHP) in humans, 
an inherited disorder characterized by target cell 
resistance to multiple hormones that activate adenylate 
cyclase by interaction with specific cell membrane bound
273
receptors (Farfel et al., 1980; Levine et al., 1980;
Farfel et al., 1981a,b). Two assays were used to 
qualitatively assess the 'N-protein' activity in 
erythrocytes from patients with PHP. The first was 
the ability of detergent extracts of cell membranes 
to complement the S49 eye- defect in vitro (see 
Figure 2.5). The second was the measurement of the 
cholera toxin-catalysed transfer of [32P]-ADP-ribose 
from [3 2P]-NAD to the 42,000 dalton peptide subunit of 
the 'N-protein'. Using both assays it was found that 
erythrocyte membranes from PHP patients contained 
reduced 'N-protein' activity, averaging approximately 
50% of that in erythrocytes from normal or 'true' 
hypoparathyroid subjects (Farfel et al. , 1980; Farfel 
et al., 1981a,b). 'N-protein' activity is also reported 
to be deficient in platelets from PHP patients (Farfel 
et al. , 1981a) . There are no reports in the literature 
in which these techniques have been applied to neoplastic 
cells from primary human or animal tumours. It is 
suggested that the assays of 'N-protein' activity should 
be applied to malignant cells derived from thymic 
lymphomas of AKR mice for the following reasons;
(1) Clearly a homogeneous population of cells is 
required for extraction of the 'N-protein' for 
use in the complementation assay. This homo­
geneity could be ensured by culturing the 
lymphoma cells in vitro.
(2) Control tissue is readily available either 
from young or preleukemic AKR mice, or
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possibly from uninvolved organs from the 
same animals exhibiting tumour development.
(3) The present observations have shown the 
tumour enzyme to be more responsive to 
stimulation by both Gpp(NH)p and NaF than 
the enzyme from control tissue.
It would be interesting also to attempt to 
assess the activity of the 'GTPase' enzyme that has 
been suggested by Cassel and Selinger (1976, 1977) to 
constitute a 'turn off' mechanism following adenylate 
cyclase activation (see Section 2.2.4).
The activities of the cyclic nucleotide 
phosphodiesterases were presented in Chapter Six. It 
was suggested that the activities of the different 
enzyme forms altered in both a strain- and age-dependent 
fashion. In AKR mice, activities which probably 
correspond to the DII and Dill forms progressively 
increased in specific activity during the preleukemic 
period. The activity of the DI form did not significantly 
alter as the AKR mice aged. In contrast to the AKR strain, 
in C576J mice the DII and Dill forms of the enzymes did 
not significantly alter, whilst the DI form was 
significantly decreased in animals >200 days of age. It 
has been stressed that correlating activities obtained 
from assays of tissue homogenates to specific enzyme 
forms of phosphodiesterase is a procedure open to 
criticism. Therefore, to confirm the suggested alterations 
occurring in the preleukemic period, the multiple forms of 
phosphodiesterase should be chromatographically separated
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and kinetically characterized from young and old AKR, 
C576J and a number of other mouse strains. The 
present observations, should they be confirmed by 
the experiments outlined above, would be interesting 
as it has been suggested that the activities of the 
multiple forms can be selectively modified by drugs 
(Weiss et al., 1974; Weiss, 1975; Weiss and Hait,
1977; Hait and Weiss, 1979). Such selective modifica­
tion of enzyme forms, if applicable to the in vivo 
situation, might be useful in determining whether 
the alterations in cyclic nucleotide phosphodiesterase 
activities have a functional role in the ultimate 
development of the lymphoma.
The differences in cyclic nucleotide 
phosphodiesterase activities and cyclic nucleotide 
concentrations between paired thymuses from the same 
animals were presented in Chapters Six and Seven. The 
observations suggest that during the preleukemic period 
of lymphoma development the metabolism of cyclic 
nucleotides is regulated differently in the two organs. 
This may be of functional significance, especially when 
the unilateral nature of the lymphoma development is 
taken into consideration. It should be noted that had 
the two thymuses been regarded simply as 'the thymus' 
then these observations would not have been apparent.
It was stressed in Section 2.4 that the study 
of cyclic nucleotide dependent protein kinase enzymes 
is of paramount importance to any investigation relating 
to the metabolism of cyclic nucleotides. Unfortunately,
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the appropriate techniques to study the activities 
and isoenzyme distribution were not available in 
our laboratory during the course of these experiments.
As it has been suggested that cyclic nucleotide 
metabolism may be differentially regulated in the 
two thymuses during the preleukemic period some 
potentially interesting experiments relating to the 
activities of the dependent protein kinases can be 
discussed. Although one is constantly faced with the 
problem of the limited amounts of tissue available, 
especially in the preleukemic animals, the two organs 
could be separated and assayed as independent entities 
for cyclic nucleotide dependent protein kinase activities. 
It would be of particular interest to see if the same 
substrates are available for phosphorylation in the 
two organs in the preleukemic period. Theoretically, 
this could be approached by separating the two organs and 
preparing single cell suspensions. The cells could be 
preincubated with [32P]Pi to allow incorporation of 
the label into the cellular pools of ATP. The proteins 
phosphorylated under these 'basal' conditions could be 
assessed by one- and two-dimensional polyacrylamide gel 
electrophoresis and subsequent autoradiography. This 
experiment could be repeated with cyclic AMP production 
in the cells preincubated with [32P]Pi being stimulated 
by the addition of appropriate agonists, e.g. PGE1, 
isoproterenol, etc. It would be interesting to see if 
cyclic AMP production, via activation of cyclic AMP-PK, 
stimulated the incorporation of the label into the same
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proteins in the two thymuses. These sorts of experiments 
could be repeated with established thymic lymphomas and 
the 'normal' uninvolved organs from the same animals to 
assess whether the enzymes function similarly in the 
neoplastic and 'normal' thymocytes and also if the same 
substrates are available for phosphorylation. This kind 
of approach has been applied to rat thymocytes by 
Wettenhall and Howlett (1979). The experiments outlined 
above would be very demanding technically and it would 
seem that the limited numbers of cells available would 
be inadequate for such manipulations. However, the 
future development of suitable 'micro'-techniques may 
conceivably allow such studies. It is suggested, 
therefore, that the AKR thymic lymphoma, characterized 
by the unilateral pathogenesis, lends itself to some 
interesting experimental approaches related to cyclic 
nucleotide dependent protein kinase enzymes.
Zick et al. (1979) have reported that cyclic
AMP-PK in murine thymocytes is predominantly of the 
Type I form, with the majority of the enzyme activity 
(>85%) being associated with the cytosolic fraction of 
the cell. As discussed previously the thymus has been 
shown, on the basis of size, to consist of at least 
three types of thymocytes. The large and medium cells 
are actively proliferating whilst the majority of the 
small thymocytes are quiescent. It would be of interest 
to separate the different cell populations to assess the 
cyclic AMP-PK isoenzyme ratio. As discussed in Section 
3.5, Russell (1978) has suggested that Type I cyclic
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AMP-PK dominance is associated with cells that are 
actively proliferating whilst Type II cyclic AMP-PK 
may be associated with more differentiated cellular 
functions. As noted in Section 3.5 this hypothesis 
does not appear to be universally applicable (DeRubertis 
and Craven, 1980b). The hypothesis could be tested by 
analysing the isoenzyme ratio in proliferating and 
quiescent thymocytes. Once again, cell numbers may 
prove to be a limiting factor as the medium and large 
thymocytes only constitute some 10-11% of the total cell 
population. However, for these experiments the thymuses 
from several young mice could be pooled to obtain 
satisfactory cell numbers.
In order to develop a hypothesis in which cyclic 
nucleotide metabolism may have a functional role in the 
pathogenesis of the tumour it is necessary to introduce 
the concept of thymic hormones and also to discuss the 
intrathymic differentiation of thymocytes and the 
possible roles of cyclic nucleotides in these differen­
tiation pathways. It is not possible here to give an 
adequate appraisal of the huge amount of work that has 
led to the establishment of the endocrine function of 
the thymus epithelium. Several reviews on the roles of 
thymic factors in immunity are available (Friedman,
1975; Bach and Carnaud, 1976; Bach, 1977; Bach et al., 
1979; Low et al., 1979). A number of peptides have been 
isolated from thymic extracts, and some have been 
characterized and eventually sequenced and synthesised. 
These include: a series of peptides isolated by
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Goldstein and coworkers (see Low et al., 1979) from 
the so-called thymosin (fraction 5); thymopoietin I 
and II (Goldstein et al., 1975); thymic humoral 
factor (Trainin et al., 1975); and thymic factor (Bach 
et al. , 1975) . It has been shown that these factors 
share the capacity to induce T-cell differentiation 
antigens in vitro and in vivo, and are able to 
reconstitute cell-mediated immune responses in vivo 
in athymic mice, i.e. nude mice or thymectomized, 
irradiated, anti-theta treated, bone marrow-reconsti­
tuted mice (Bach and Carnaud, 1976; Haddon, 1977).
There is some evidence that indicates that cyclic 
nucleotides are the intracellular mediators for thymic 
hormone-induced T-cell differentiation. When reviewing 
the literature it becomes obvious that all shades of 
opinion are expressed, from the somewhat dogmatic 
statement of Scheid et al. (1975) who say, 'We found
that cyclic AMP is indeed the intracellular mediator 
for the differentiation of prothymocytes to thymocytes 
. . .' to the more conservative statement of Bach et al. 
(1979), 'The effect of thymic hormones on cyclic AMP and 
cyclic GMP remains a matter of controversy and 
speculation'. The work of Scheid et al. (1973, 1975)
made use of an induction assay developed by Komuro and 
Boyse (1973a,b) in which the differentiation of prothymo­
cytes to early thymocytes can be induced by thymic factors 
in vitro within two hours. The assay was based upon work 
which characterized cell surface markers, especially the 
cytotypic differentiation alloantigens of murine T-cells
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(e.g. TL, G, Ly). They found that exogenous cyclic AMP 
(1 mM) or dibutyryl cyclic AMP (0.1 mM) could substitute 
for thymosin (fraction 5) in inducing T-cell differen­
tiation in vitro. Agents capable of modifying endogenous 
cyclic AMP levels were shown to cause appropriate 
changes in the efficiency of induction. Thus, theophyl­
line (1 mM) enhanced induction by suboptimal concentra­
tions of thymic extracts and epinephrine and ß-adrenergic 
agonists effectively induced T-cell differentiation.
Direct measurements of endogenous cyclic AMP levels 
during the induction process were reported to show 
'rapid and appropriate elevations'. Results similar to 
those reported by Scheid et al. (1973, 1975) have also
been reported by Bach et al. (1973, 1975) and Bach and
Bach (1973), in that cyclic AMP substituted for thymic 
extracts in the induction of Q-antigen on Q-negative 
spleen rosette-forming cells from adult thymectomized 
mice. The more cautious appraisal of Bach et al. (1979)
stems from the fact that although, as they accept, 
cyclic AMP and agents that modify the intracellular 
levels of the nucleotide mimic the induction of markers 
achieved by thymic factors, it has proven difficult to 
reproducibly show that these factors, with the exception 
of thymic humoral factor (THF), stimulate cyclic AMP 
synthesis in lymphocyte populations. Bach et al. (1979)
suggest that this paradox may be related to the dilution 
of the thymic hormone 'target cells' among other lymphoid 
cells, thus making possible changes in cyclic AMP concen­
trations difficult to detect by conventional assay
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techniques. With regard to cyclic GMP, the concentra­
tions of this nucleotide have been reported to be 
elevated, apparently via a Ca2+-dependent mechanism, 
by thymosin (fraction 5) in murine thymocytes (Naylor 
et al.<, 1976 , 1979; Naylor and Goldstein, 1979). Thymo­
poietin has also been shown to stimulate cyclic GMP 
accumulation in peripheral, thymus-derived lymphocytes 
from mice (Sunshine et al., 1978).
As stated above, THF has been shown to stimulate 
cyclic AMP production in lymphocyte populations. Most 
of the work on this factor has been carried out by 
Trainin and coworkers (Kook and Trainin, 1974, 1975; 
Trainin et al., 1975) using as a bioassay system an 
in vitro model of the graft versus host reaction. Their 
observations can be summarized:
(1) Incubation of spleen cells from neonatally 
thymectomized or normal C576J mice in the 
presence of THF significantly increased 
adenylate cyclase activity. It was shown 
that THF was activating adenylate cyclase 
activity in thymus-derived, and not bone 
marrow-derived, spleen cells.
(2) THF stimulated the intracellular accumulation 
of cyclic AMP in thymocytes in a dose-dependent 
manner.
(3) Dibutyryl cyclic AMP, theophylline and poly (A:U)
(an agent shown to activate adenylate cyclase in 
mouse spleen cells) all substituted for THF in 
inducing spleen cells from neonatally thymectomized
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(NTx) mice to elicit a graft versus host 
reaction in vitro.
(4) Prostaglandin E2 was shown to stimulate cyclic 
AMP accumulation in thymocytes. Flufenamic acid 
inhibited this prostaglandin E2-induced accumu­
lation of cyclic AMP. Preincubation with 
prostaglandin E2 induced immunocompetence in 
spleen cells from NTx mice. Flufenamic acid 
prevented the induction of immunological 
competence by prostaglandin E2.
(5) Cycloheximide prevented the induction of 
immunocompetence in spleen cells from NTx mice 
by THF, suggesting protein synthesis to be 
involved in the induction process. Cycloheximide 
had no effect on the THF-induced activation of 
adenylate cyclase. THF was observed to strongly 
suppress the incorporation of [3H]-thymidine 
into DNA of both thymocytes and spleen cells 
from NTx or intact mice.
Following on from point (5) above, Zick et al. 
(1978, 1979) have shown that incubation of intact 
thymocytes with THF rapidly activates cyclic AMP-PK 
(the activity ratio with or without THF was 0.81 and 
0.38 respectively). Wettenhall and Howlett (1979), using 
rat thymocytes, have shown that concanavalin A, 
prostaglandin E 1 or dibutyryl cyclic AMP selectively 
enhanced the 32P-labelling of a single protein of 40S 
ribosomal subunits. Concomitant with increases in 32P- 
labelling were increases in the rate of incorporation
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of [3H]-phenylalanine into protein, indicating that 
the phosphorylation of this protein may serve to 
regulate thymocyte protein synthesis. It could be 
suggested, therefore, that THF induces T-cell differ­
entiation by activating adenylate cyclase and 
therefore increasing intracellular cyclic AMP concen­
trations. Activation of cyclic AMP-PK and subsequent 
enhanced phosphorylation of a specific ribosomal 
protein may then stimulate thymocyte protein synthesis.
As Haddon (1977) notes, the events involved in 
the intrathymic evolution of the mature T-lymphocyte 
from the prothymocyte are ill understood. The immature 
cortical lymphocyte is a cell with a high rate of 
proliferation, while the more mature medullary lympho­
cyte has a low rate of proliferation. Using the infor­
mation discussed above, it is possible to speculate 
that the failure of the thymus epithelial cells to 
produce a 'thymus factor' that induces the prothymo­
cytes to differentiate could result in the accumulation 
of a population of cells whose proliferative activity 
remains unimpaired but whose normal differentiation is 
blocked. Clearly, in view of the unilateral nature of 
the thymic lymphoma development, the failure of the 
epithelium to produce such a factor would have to be 
limited to one organ only. Alternatively, some 
alteration in the prothymocytes may result in the 
failure of these cells to respond normally to 'factors' 
produced by the thymus epithelium. This unresponsiveness, 
assuming a role for cyclic AMP in the intrathymic
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differentiation pathways, could be due to the lack 
of a specific receptor on the cell surface, or an 
uncoupling of the receptor from adenylate cyclase. 
There could possibly be abnormalities in the cyclic 
nucleotide-dependent protein kinases, or in the 
expression of their target substrates within the 
cell. It could be suggested that the accumulation 
of cells whose normal differentiation pathway is 
blocked represents a population more susceptible to 
oncogenic transformation by the Gross virus.
Metcalf (1962) , in fact, has suggested that the main 
target cells for the oncogenic effect of the virus 
are large lymphoblastoid cells seen to accumulate in 
the outer thymic cortex just prior to the onset of 
leukemia (Nakamura and Metcalf, 1961).
The work of Fournier and Potworowski (1979) 
is relevant to the speculation that the thymus 
epithelial cells may fail to produce a factor that 
induces normal intrathymic differentiation. They have 
identified two thymic stromal fractions. The first, 
named insoluble thymic fraction (ITF), contains an 
antigenically specific moiety and is localized in 
the perivascular basement membranes of the medulla. 
Injection of ITF into mice provokes an accumulation 
of large lymphoblastoid cells in the outer cortex of 
the thymus, reported to be due to an increased homing 
of cells originating from the bone marrow. The second 
fraction, soluble thymic fraction (STF), has a 
molecular weight of 3,000 daltons, induces
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corticoresistance in thymocytes and, interestingly, 
is reported to have properties similar to those of 
Trainin's THF. The molecular weight of THF is reported 
to be approximately 3,000 daltons from Sephadex G-25 
data. Fournier and Potworowski reasoned that injecting 
AKR mice with ITF during the preleukemic period may 
accelerate the development of the disease by causing 
an accumulation of lymphoblastoid cells, and hence 
accelerating experimentally the situation which occurs 
spontaneously (Nakumura and Metcalf, 1961). Conversely, 
injections of STF may counteract the spontaneous 
accumulation of these cells by promoting their 
differentiation. It was shown that ITF injection 
caused a significant acceleration of death by leukemia 
and that STF significantly delayed the onset of the 
disease. To examine the possibility that a spontaneous 
disturbance of the ITF/STF ratio might be associated 
with the triggering of the onset of the disease, frozen 
sections of thymuses were examined by immunofluorescence 
with anti-ITF and anti-STF antibodies. Preleukemic mice, 
up to 6 months of age, and leukemic mice showed strong 
positive fluorescence, when stained with anti-ITF, on 
the perivascular membranes in the thymic medulla. The 
cytoplasmic staining of reticuloepithelial cells with 
anti-STF remained strong during the preleukemic period, 
up to an age of six months, and yet no staining could 
be found in the thymuses of leukemic mice. Fournier and 
Potworowski (1979) concluded, 'Thus, both in the 
uninjected and in the ITF-injected groups, the ITF/STF
286
equilibrium is disturbed in favour of ITF, either by 
the supply of additional ITF through injections in 
the latter group or by lack of STF in the former group.
One way or the other, T-cell differentiation is either 
blocked or slowed down'. Clearly, for this explanation 
to be valid the time of STF disappearance would have 
to precede, rather than coincide with, the onset of 
leukemia and would have to be localized to only one of 
the two thymuses to accommodate the unilateral patho­
genesis. It would be of great interest, in relation to 
the hypothesis presented above, to establish whether 
the STF of Fournier and Potworowski is in fact 
identical to Trainin's THF. Experiments should be 
conducted to see if STF is capable of activating 
adenylate cyclase, stimulating cyclic AMP accumulation 
and subsequently activating cyclic AMP-PK in thymocytes.
Therefore, it is suggested that the significantly 
lower cyclic AMP concentrations observed in established 
thymic lymphomas may be related to the failure of 
thymus epithelial cells to produce a factor that 
controls the intrathymic differentiation of prothymocytes 
by cyclic AMP-dependent mechanisms.
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APPENDIX I
EXPERIMENTAL ANIMALS
C576J mice were obtained from the Animal 
Breeding Establishment, The John Curtin School of 
Medical Research, The Australian National University.
AKR mice were obtained from The Jackson Laboratory,
Bar Harbor, Maine 04609, U.S.A. All mice were 
maintained in pathogen-free conditions in the J.C.S.M.R. 
animal houses and given access to a normal laboratory 
diet and water ad libitum.
APPENDIX I I
All reagents used were of analytical grade. 
Radionucleotides, as shown below, were obtained from 
The Radiochemical Centre, Amersham, U.K.
Adenosine 5'-[a-32P] triphosphate, Triethylammonium salt 
(approx. 40 Ci/mmol).
[2,8-3H] Adenosine 3,,5,-cyclic phosphate, Ammonium 
salt (approx. 40 Ci/mmol).
[8-3H] Guanosine 3',5'-cyclic phosphate, Ammonium salt 
(approx. 15 Ci/mmol).
[125I] supplied as sodium iodide (approx. 15 Ci125I/yg). 
Kontes Chromaflex Disposable Columns (Adenylate cyclase 
assay) were obtained from Kontes Glass Co., New Jersey,
U.S.A.
Dowex AG 50W-X4, 200-400 mesh, H+ form (Biorad).
Aluminium oxide 90 active, neutral for column chromato­
graphy (Merck).
Norit SA-3 activated carbon (for use in radioimmunoassays) 
was obtained from Amersfoort, The Netherlands.
A P P E N D I X  III
SOLUTIONS
(1) 'Buffer electrolyte': Adenylate Cyclase Assay
50 mM Tris, 30 mM KC1, 4.5 mM MgCl2* 7H20, 0.013% B.S.A. 
Adjust final pH to 7.8 (30°C) , 8.1 (room temp.),
7.55 (4 °C).
(2) 0.1 M Imidazole-HCl: Adenylate Cyclase Assay
Stock solution 1.5 M. Adjusted to pH 7.2 with cone.
HC1 (room temp.). Diluted 1/15 to give 0.1 M 
imidazole-HCl, pH 7.5.
(3) Phosphodiesterase Assay Buffer
10 mM Tris,. 1 mM MgCl2»6H20, 250 yM EGTA. Adjust 
final pH to 7.5.
(4) Radioimmunoassay Buffer
50 mM sodium acetate. Adjust to pH 5.0 using 
glacial acetic acid 0.1% B.S.A.
(5) Scintillation Fluid (bulk supply, J.C.S.M.R.)
1 part Triton X114, 2 parts Xylene, 0.5% 2,5-diphenyl-
oxazole (PPO).
